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Alkaline phosphatase (AP) is an endogenous enzyme present in many organs of 
the human body. The intestine, liver and kidney and also placenta are all organs in 
which AP is especially abundantly present. However, since AP is also expressed in 
blood cells such as neutrophils and vascular cells like endothelial cells, the enzyme 
in fact is active everywhere in the human body. In addition, AP is also present in 
bone tissue and plays a crucial role in the formation of bone material (1). Another 
and more recently recognized function of AP is its role as a lipopoly-
saccharide(LPS)-detoxifying enzyme. This function of AP was first established by 
Poelstra et al in 1997 (2; 3). 
In diseases associated with elevated serum LPS levels, like sepsis, liver diseases 
like fibrosis, cholestasis, hepatitis B & C and obstructive jaundice as well as 
inflammatory bowel diseases like Crohn’s disease (CD) and ulcerative colitis (UC), 
AP levels are usually changed compared to the normal situation. AP levels in 
serum and/or tissues are elevated or decreased. Yet, the mechanism for its 
regulation and the cause of the abnormal levels are in many cases unclear. Since 
abnormal AP levels are seen in most, if not all, LPS-associated diseases and AP is 
capable of detoxifying LPS, the question arises how AP tissue expression is 
regulated and whether AP might be a natural part of the immune system by 
serving as defense system against LPS-bearing Gramnegative bacteria. If it has a 
protective role, exogenous administration of AP or upregulation of endogenous AP 
activity during these diseases, in which LPS is an important pathogenic factor, 
could exert beneficial effects. 
 
The work described in this thesis can grossly be divided into two themes. The first 
theme deals with the regulation of endogenous liver AP (Ch. 3 and 4) and the 
second theme focuses on the possible application of exogenous AP in LPS-












Figure 1: Structure of the enzyme alkaline phosphatase. The two monomers are shown in 
blue (left) and green (right). The two metal binding domains are shown in yellow, the crown 
domain in brown and the location of both active sites is indicated. From Le Du, 2001 (a full 
color version of this figure can be found on page 169). 
 
Chapter 3 contains a report on the LPS-dephosphorylating activity in the rat liver. 
Although it is known that the liver is the major organ in the body that removes LPS 
from the circulation, very little is known about the capability of the liver itself to 
dephosphorylate LPS. We investigated the LPS-dephosphorylating activity of 
normal and fibrotic rat livers histochemically using several serotypes of LPS. Liver 
fibrosis was shown to be associated with altered AP levels and altered LPS 
responsiveness. Furthermore, we explored the effect of LPS on AP levels in rat 
livers in vivo and examined the effects of administration of intestinal AP to rats 
with LPS-induced sepsis. 
 
In the experiments described in chapter 4, we studied the effect of LPS on liver AP 
expression in liver cell lines, liver slices and in vivo in rats. The liver cell lines 
HepG2 and McA-Rh7777 were incubated with LPS and the well-known AP-
inducers retinoic acid and sodium butyrate. Also freshly prepared liver slices were 
Active site 
Active site 
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stimulated with LPS and the effects on AP expression were examined. In addition, 
expression levels of several cytokines were measured to gain more insight in the 
possible regulation of liver AP expression. Finally, liver AP expression was 
examined in vivo at several timepoints after LPS administration in rats. 
Chapter 5 describes the effects of 2 AP isoenzymes, placental AP and intestinal AP, 
on sepsis in mice. In addition, in this chapter we also introduced a novel assay for 
the detection of LPS. In this new assay, the dicationic molecule pentamidine is 
used, which fluoresces upon binding to LPS via its diphosphorylated lipid A part, 
but not with the monophosphorylated lipid A part. 
The possible role of intestinal AP (iAP) as a therapeutic enzyme in inflammatory 
bowel disease (IBD) has been examined in the final research chapter, chapter 6. 
Effects of iAP on sepsis were described in several models of sepsis in mice (4; 5) 
and pigs (6) while clinical trials in humans are ongoing. So far, there are no reports 
about the use of AP in IBD, although several lines of research indicate a role for 
LPS in this disease (7). We now assessed the effect of iAP on LPS-stimulated 
human biopsies of healthy persons and patients suffering from CD or UC. 
Moreover, we studied the effect of oral administration of iAP in tablet form on the 
progression of dextran sodium sulphate-induced colitis in rats. 
 
In summary, the studies described in this thesis examined factors that regulate AP 
activity in vivo (Ch. 3 and 4) and the potential applicability of exogenous AP in LPS 
mediated diseases like sepsis (Ch. 3 and 5) as well as inflammatory bowel disease 
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Lipopolysaccharide (LPS) is a toxic compound and a component of the cell wall of 
Gramnegative bacteria. LPS is an important pathogenic factor in sepsis. Its role in 
other diseases like liver fibrosis, cholestasis, hepatitis B & C, obstructive jaundice 
and inflammatory bowel disease (1-5) is now increasingly recognized.  
Although LPS plays an important role in all these diseases, its dominant role in 
Gramnegative sepsis is most often studied and generally known. Sepsis can occur 
when LPS levels in the blood become elevated, for instance due to a decreased LPS 
clearance in the liver or infiltration of LPS into the circulation across the intestinal 
wall. Elevated serum LPS levels can lead to a systemic inflammation and a massive 
activation of the immune system. This in turn will lead to the production of high 
levels of cytokines, lipid mediators and reactive oxygen species. In addition, blood 
coagulation is abnormal in sepsis and blood clotting in small blood vessels may 
lead to multiple organ failure and even death if vital organs are affected. 
In all LPS-mediated diseases, many different mediators, especially cytokines, are 
involved. Most therapies against these diseases are therefore based on eliminating 
particular cytokines and thereby attempting to shut down the inflammatory 
response. But as there are so many processes and mediators involved, in particular 
during sepsis, elimination of one mediator is unlikely to be sufficient.    
 
The aim of this chapter is to give an overview of the diseases in which LPS is 
thought to play an important role, in particular in the onset or progression of the 
disease. The role of LPS in these processes will be described as well as some of the 
therapies that are currently used for these disorders. In addition, the potential role 
of the LPS-dephosphorylating enzyme alkaline phosphatase (AP), as a new 
therapeutic agent in LPS-mediated diseases, will be discussed.  
Lipopolysaccharide 
Lipopolysaccharide (LPS) or endotoxin is a major component of the cell-wall of 
Gramnegative bacteria. It covers about 30 to 40 % of the bacterial cell surface. LPS 
is an amphiphilic molecule composed of a prominent sugar chain and several fatty 
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acids. Each strain of bacteria shows a somewhat different composition of the LPS 
molecule, but the gross structure of LPS molecules is quite similar in the majority 
of Gramnegative bacteria. Each molecule can be divided in a lipid A part, an inner 
core, an outer core and a long polysaccharide chain (Fig. 1). The hydrophilic 
polysaccharide chain contains many heptoses and anionic KDO (2-keto-3-deoxy-
octonate) sugars. The KDO-sugars link the hydrophilic polysaccharide chain to a 
hydrophobic lipid portion, lipid A, which anchors the LPS molecule into the 
bacterial outer membrane. The lipid A part is the most conserved part of the LPS 
molecule and is generally composed of two glucosamines to which two phosphate 
molecules and four to six fatty acids are bound (6). The lipid A moiety and 
particular the two phosphate groups in this part of the LPS molecule largely 
determine its toxicity (7; 8).  
 
 
Figure 1: Schematic representation of the structure of LPS (picture from 
http://glycoforum.gr.jp/science/word/immunity/IS-A01E.html). A full color version of this 
figure can be found on page 169. 
 
In vivo, multiple molecules are involved in the activation of cells by LPS. In order 
to activate cells, LPS first binds to the LPS-binding protein (LBP) in plasma. LBP is 
a 60-kDa acute phase protein that is mainly produced by hepatocytes in the liver 
but also in lower amounts by respiratory type II epithelial cells in the lung (9). 
Normal serum LBP levels in humans vary between 2 and 20 µg/ml (9-12), but LBP 
levels rise quickly to 100-200 µg/ml (12) during an acute phase response for 
instance caused by an inflammation.  
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After binding to LBP, the LPS-LBP complex binds to CD14, a 55-kDa glycoprotein. 
There are two forms of the CD14 molecule, a membrane-bound form and a non-
membrane bound form that is present in serum. The membrane-bound form of the 
CD14 receptor is mainly expressed by macrophages, monocytes and neutrophils 
(13; 14) and is attached to the membrane via a glycosyl-phosphatidyl inositol (GPI) 
anchor. Activation of cells that do not express membrane-bound CD14, e.g. 
endothelial cells,  epithelial cells, dendritic cells, fibroblasts, smooth muscle cells 
and vascular endothelium (15; 16), can occur via soluble CD14 (sCD14) present in 
serum. sCD14 is found in the serum of healthy individuals, but similar to LBP, 
levels rise quickly during a massive systemic inflammatory response like sepsis 
(17). Together, LPS, LBP and sCD14 form a complex. For a long time, people were 
puzzled by how this LPS-LBP-CD14 complex was able to initiate intracellular 
signals as CD14 does not have an intracellular signal transduction moiety.  
 
A few years ago, a family of receptors was discovered that showed homology with 
Toll receptors in Drosophila (18). This receptor family was called the toll-like 
receptor family and in human currently this receptor family consists of 10 
members (19), which have a variety of functions in innate immunity. The toll-like 
receptors (TLR) recognize pathogen-associated molecular patterns, which allows 
the immune system to sense molecules that are present in many pathogens. One 
member of the toll-like receptor family, the toll-like receptor 4 (TLR4), appeared to 
be the LPS-receptor (20). This TLR4 forms a LPS-signaling complex with another 
molecule that also appeared to be essential for LPS signaling, the myeloid 
differentiation-2-protein (MD-2) (21-23). The intracellular part of the toll-like 
receptor is responsible for the many intracellular signaling events after binding of 
the LPS-LBP-CD14 complex to the TLR4-MD2 complex. Mice bearing mutations in 
the TLR4 receptor (24) or MD-2 (25; 26) appeared to be hyporesponsive to LPS, 
thereby confirming the crucial role of the TLR4 and MD-2 in LPS-signaling.   
 
After binding of the LPS-LBP-CD14 complex to the TLR4-MD-2 complex, 
intracellular signaling is triggered. Several intracellular pathways are activated 
(27), for instance the NFκB, the AP-1, the IRF3 and IRF5 and the p38-MAPK 
pathways (15; 19).  





Figure 2: Binding of Gramnegative and Grampositive bacteria to cells and intracellular 
pathways activated by LPS and MDP. Figure from Bendtzen (Institute for Inflammation 
Research, Rigshospitalet Univ Hosp, Copenhagen), 2004. LPS, lipopolysaccharide; LBP, LPS-
binding protein; PG, peptidoglycan; MDP, muramyl dipeptide; TLR4, toll-like receptor 4; 
MD-2, myeloid differentiation protein 2; LRR, leucine-rich repeat; TIR, Toll/IL-1 receptor 
homology domain; IRAK, IL-1 receptor-associated kinase; TRAF, TNF receptor-associated 
factor; NFkappaB, nuclear factor kappa B; IkappaB, inhibitory kappa B proteins. 
 
All these pathways lead to the production of many cytokines and effector-
molecules. Upon LPS stimulation, macrophages start producing high amounts of 
pro-inflammatory cytokines such as Il-1, TNFα and IL-6 but also IL-12, IL-15 and 
IL-18 (15; 28). The release of pro-inflammatory cytokines in turn triggers other 
events like production of more cytokines, lipid mediators (prostaglandins, 
leukotrienes and platelet activating factor), reactive oxygen species like superoxide 
anion (O2-), the hydroxide radical (.OH) and nitric oxide (NO) and upregulation of 
adhesion molecules, enabling neutrophils to migrate into tissues. These mediators 
and adhesion molecules are mainly produced by macrophages but also neutrophils 
and endothelial cells contribute to their rapid rise in inflamed tissue.  
TNFα appears to be a crucial cytokine which is not only produced by macro-
phages, but also serves as a potent activator of macrophages that are not yet 
activated. Upon activation, all these macrophages start to produce IL-1β and IL-6, 
Cytokines, Lipid  mediators 
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which promotes coagulation in small blood vessels. Downregulation of three 
endogenous anticoagulant proteins, i.e. antithrombin, protein C and tissue factor 
inhibitor, further contributes to the pro-coagulant state of sepsis (15). Disturbed 
coagulation is one of the major characteristics of sepsis and may lead to 
disseminated intravascular coagulation (DIC), multiple organ failure due to 
hypoperfusion and ischemia and eventually death when the function of crucial 
organs has been largely violated. 
Besides cytokines, also lipid mediators are released by macrophages upon LPS 
stimulation. Lipid mediators like platelet activating factor (PAF) and several 
products of the cyclooxygenase and lipooxygenase pathways of arachidonic acid 
metabolism, like prostaglandin E2, thromboxane A2 and leukotriene C4, are 
formed (28). These factors are responsible for the activation of vascular 
endothelium and regulation of the vascular tone and high levels may lead to 
vascular damage (15). 
Finally, reactive oxygen species (ROS) are produced by macrophages upon LPS 
stimulation. Low concentrations of ROS are beneficial and enhance the 
antimicrobial killing capacity of macrophages, on the other hand, high 
concentrations of ROS cause tissue damage and high levels of NO are associated 
with vasodilatation and hypotension (29).  
Together, an excess of cytokines, protease release and ROS-production in tissues, 
perturbed coagulation, vasodilatation and hypotension all contribute to the 
development of multiple organ failure (Fig. 3) after systemic activation of the 
immune system by LPS in the circulation. Obviously, these events can also occur 
locally as part of the normal defense system. However, the systemic activation of 
all these events may result in a life-threatening disease. 





Figure 3: The sepsis cascade: from LPS-binding towards fulminated sepsis. Scheme from 
Cohen, Nature, 2002 (15). 
Role of LPS in disease 
Systemic diseases 
As outlined above, systemic LPS can elicit a systemic inflammatory response 
syndrome (SIRS), which is characterized by fever, diffuse intravascular 
coagulation, shock, multiple organ failure and eventually death. At present, sepsis 
is still the most important cause of death in intensive care units and the 10th cause 
of death overall in the United States, accounting for about 215.000 deaths a year in 
this country alone (30). Common causes of elevated LPS levels in the blood are 
open wounds i.e. in the case of burns or trauma’s, chronic inflammation of the 
intestines like in Crohn’s disease and ulcerative colitis, the use of antibiotics, a 
decreased liver function and abdominal surgery.  
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Normally LPS levels in humans are very low, ranging between 4 and 10 pg/ml (31-
33). The main organ responsible for keeping the LPS concentration at a low level is 
the liver. LPS is removed from the circulation mainly by Kupffer cells (34) and 
likely also partly by endothelial cells as binding of LPS to scavenger receptors on 
Kupffer cells and endothelial cells was reported (35). The internalized LPS is 
modified by these cells and subsequently released from them and exposed to 
hepatocytes that take up the compound and secrete the modified LPS into the bile 
(36). However, apart from this, hepatocytes themselves also directly remove LPS 
from the circulation. This is mostly done by endocytosis of chylomicrons and 
lipoproteins such as low density lipoproteins (LDL), high density lipoproteins 
(HDL) and very low density lipoproteins (VLDL), that are all capable of binding 
LPS (See references in Rensen et al (37)). If the LPS-removing capacity of the liver is 
reduced and an excess of LPS cannot be removed from the portal circulation, the 
levels in the general blood circulation rise and a systemic inflammatory reaction 
may occur. People with a progressive liver disease like fibrosis thus have an 
increased chance of developing elevated endotoxin levels in the blood due to a 
decreasing detoxifying capacity of the liver. 
IBD   
Inflammatory Bowel Disease (IBD) is a general name for diseases that are due to 
inflammation within the intestinal wall. In the Western world, approximately 3 
million people are suffering from IBD (38), making it an important chronic disease. 
The 2 most well-known examples of IBD are Crohn’s disease (CD) and ulcerative 
colitis (UC).  
CD usually affects the lower part of the small intestine, i.e. the part of the ileum 
closest to the colon, but can in principle affect any part of the gastro-intestinal tract. 
In contrast to CD, UC is limited to the colon and is most often located in the 
descending part of the colon and in the rectum. Another difference between CD 
and UC is that CD affects all layers of the intestine whereas UC only affects the 
intestinal lining. Common symptoms of IBD are abdominal pain, diarrhea, 
sometimes fatigue and weight loss. 
It is believed that the inflammation of the damaged gut is the result of an 
inappropriate ongoing activation of the mucosal immune system triggered by 
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components of the normal luminal flora (39). When the sub-epithelial layers of the 
intestinal wall are exposed to LPS due to damage, macrophages residing in these 
layers start to produce cytokines and chemoattractants (40), leading to the 
migration of high amounts of neutrophils to the site of damage and local 
activation. Production of high amounts of ROS by accumulated neutrophils will 
evoke local damage and further enhance inflammation, which sometimes leads to 
systemic effects. During relapses of CD and UC, some patients are diagnosed with 
elevated serum levels of LPS (3-5) and cytokines like TNFα, IL-1β, IL-6 and IL-17 
(41; 42). Chronic inflammation may result in further damage to the intestinal 
barrier and an increased permeability of the mucosa, enabling LPS to leak across 
the intestinal membrane into the circulation. For CD even bacterial translocation 
across the intestinal barrier has been reported (43; 44). 
Despite their high prevalence, the etiology of CD and UC is still unclear. Due to 
many epidemiological studies it has become clear that genetic predisposition plays 
an important role in the susceptibility of people to develop these chronic 
inflammatory diseases. Some genes are now linked to this predisposition.  
Mutations in the caspase recruitment domain (CARD15) gene (See figure 2), also 
called nucleotide-binding oligomerization domain (NOD2) gene, are associated 
with a higher susceptibility to Crohn’s disease (45-48). The exact function of the 
NOD2 gene, which is present in macrophages (49), epithelial cells (50), Paneth cells 
(51), granulocytes and dendritic cells (52), is still not fully elucidated. At first it was 
thought that the NOD2 might function as an intracellular LPS receptor, but recent 
work of Inohara et al and Girardin provided evidence that NOD2 functions as an 
intracellular sensor of bacterial peptidoglycan. Not LPS but muramyl dipeptide 
(MDP, see figure 2), which is a component of peptidoglycan (a membrane 
compound of many bacteria), appears to be the compound that is recognized by 
NOD2 (53; 54).  
Also certain mutations in the “LPS-receptor”, i.e. the toll-like receptor 4, are 
associated with a higher susceptibility for IBD. The Asp299Gly TLR4 
polymorphism for instance is detected twice as much in CD patients compared to 
healthy controls (55). Besides mutations in the TLR4, which seem to predispose for 
IBD, also the altered expression of the TLR4 in inflamed intestinal tissue most 
likely contributes to the pathogenesis of diseases like CD and UC. Recent studies 
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have shown that the expression of the TLR4 is upregulated in inflamed intestinal 
tissue (56). This might elicit a response on LPS, which is abundantly present in the 
intestinal lumen. 
Finally, mutations in the CD14 receptor are found to occur significantly more often 
in CD patients compared to controls (57). 
The discovery that mutations in receptors involved in LPS and peptidoglycan 
signaling, e.g. CD14, TLR4 and NOD2, seem to predispose for IBD, strongly 
emphasizes that an aberrant detection of bacterial products in the intestine is a 
very important factor in the development of IBD. It might result in a chronic 




Liver fibrosis is a disease which can be the result of many underlying different 
diseases and disorders like cholestasis, chronic viral infections (hepatitis B and C), 
parasitic disease e.g. schistomiasis, metabolic disorders (e.g. lipid and glycogen 
storage disorders, Wilson’s disease and hemochromatosis), cancer growth, 
immune deficiencies (autoimmune diseases like primary sclerosing cholangitis and 
primary biliairy sclerosis), persistent liver inflammation (sarcoidosis) and 
environmental chemicals, e.g. alcohol (58; 59). Alcohol abuse is a well-known cause 
of liver fibrosis by inducing steatohepatitis which will ultimately result in 
hepatocyte damage and scar tissue formation. In Western society, today also 
obesity, insulin resistance and hyperlipidemia are important risk factors for 
developing liver fibrosis as a result of non-alcoholic steato-hepatitis (NASH) (60). 
NASH is regarded as a typical welfare disease and as more and more people 
become obese or diabetic, it can be expected that the number of people suffering 
from NASH will increase in the coming years. 
 
Liver fibrosis is a chronic disease that is characterized by excessive production of 
extra-cellular matrix (ECM). Healthy liver cells are gradually replaced by ECM, 
which results in a continuous decrease of liver function. Hepatic stellate cells 
(HSC) are the most important cells in the fibrotic process as these cells are the main 
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producers of the ECM components. The development of liver fibrosis may take 15 
to 20 years before it reaches the end-stage of liver failure, cirrhosis. Patients with 
liver cirrhosis are vulnerable for infections and Gramnegative sepsis may occur in 
these patients. One reason is the decreased capacity of the liver to remove LPS 
from the circulation. Another reason is the increased intestinal permeability, in 
particular occurring in patients in which the fibrosis is due to alcohol abuse (61). 
Alcohol causes mucosal injury in the upper part of the gastrointestinal tract 
resulting in an increased intestinal permeability and increased endotoxin levels in 
the portal system (62; 63). In addition, excessive amounts of alcohol also result in a 
decreased intestinal motility, resulting in bacterial overgrowth in the gut of 
Gramnegative bacteria (59). The increased intestinal permeability and bacterial 
overgrowth may result in further LPS leakage (64; 65) or bacterial translocation. 
The latter has been demonstrated in cirrhotic rats (66) and cirrhotic patients (67; 
68). LPS leakage and bacterial translocation both contribute to elevated portal 
blood levels of LPS. The excessive amount of gut-derived endotoxin will lead to 
the activation of Kupffer cells in the liver and thus to the onset of an inflammatory 
reaction in the liver and aggravation of the fibrotic process (63). Moreover, several 
reports have described that an enhanced sensitivity of the liver to LPS caused by 
increased expression of CD14 on Kupffer cells, also serves as an important 
contributor to the inflammatory reaction in the liver (69-71). The fact that CD14-
deficient mice showed only minimal pathological changes upon chronic alcohol 
exposure when compared with wild-type mice, further emphasizes the importance 
of CD14 in alcohol-induced liver injury (72).  
 
Recently, several studies have reported that HSC might contribute in another way 
to the progression of liver fibrosis. HSC are well-known as producers of ECM in 
fibrosis, but current reports showed that HSC are also capable of releasing pro-
inflammatory cytokines, thereby contributing to the inflammatory component of 
fibrosis. In addition, Brun et al demonstrated that murine HSC expressed receptors 
for bacterial endotoxin and that HSC develop a strong pro-inflammatory 
phenotype upon LPS stimulation (73). These results confirm an earlier study of 
Paik et al in which the presence of molecules participating in LPS-signaling, e.g. 
CD14, TLR4 and MD-2, were demonstrated on activated human HSC (74). In 
 Chapter 2 
 
18 
addition, they also showed that LPS stimulation of these activated HSC resulted in 
activation of the NF-κB pathway.  
Involvement of LPS-signaling molecules in the progression of the process of 
fibrogenesis was also demonstrated by Isayama et al. They showed in a murine 
model of fibrosis caused by experimental cholestasis that LBP- and CD14-knock-
out mice showed less fibrosis and liver damage (75).  
Hepatitis B and C and alcoholic hepatitis 
Viral infections with hepatitis B and C and alcoholic hepatitis are three of the most 
well-known causes of liver fibrosis. In 2000, it was estimated by the World Health 
Organization that world-wide approximately 350 and 170 million people were 
infected with hepatitis B and C respectively. Numbers of patients suffering from 
alcoholic liver disease are not clear as a majority of these patients experiences no 
signs of disease.  
As the liver is the major LPS-removing organ in the body and as the liver function 
is impaired during hepatitis B and C and alcoholic hepatitis, endotoxemia may 
occur in patients suffering from these diseases (1; 2; 31; 76; 77). Lin et al 
demonstrated that chronic hepatitis patients did not have significantly elevated 
endotoxin levels in the blood. Yet, very significant elevations of endotoxin levels 
could be detected in chronic hepatitis patients with an acute exacerbation of the 
disease (77). A decreased phagocytotic capacity of polymorphonucleocytes and 
Kupffer cells, which are the major cells responsible for removing LPS and whole 
bacteria from the circulation, and a reduced antibacterial activity of T-cells (78) 
contribute to the development of endotoxemia during viral hepatitis. An increased 
intestinal permeability may further contribute to elevated LPS levels in alcoholic 
liver disease (61; 63). The effects of elevated LPS levels during hepatitis may be 
further enhanced by the increased levels of sCD14 in chronic hepatitis B (79) and C 
patients (78; 79). In addition, sCD14 and C-reactive protein levels were higher in 
patients with cirrhotic livers than in patients with non-cirrhotic livers (79). In 
patients suffering from alcoholic hepatitis, also elevated levels of LPS-binding 
protein (LBP) were detected in the acute phase of the disease (31).  




Obstructive jaundice is a liver disease in which the bile flow into the intestine has 
been decreased or stopped due to obstruction of bile duct(s). Obstructive jaundice 
is characterized by a high post-operative morbidity of around 10% (80). A common 
post-operative complication of obstructive jaundice is renal failure, which is often 
associated with portal and/or systemic endotoxemia (80).  Also in the pre-operative 
state of obstructive jaundice, portal and systemic endotoxemia are thought to be an 
important factor in the pathophysiology of the disease (81; 82). Clinical studies 
revealed that elevated serum levels of LPS in obstructive jaundice may have 
several causes. First, it has been shown that during obstructive jaundice, the 
capacity of the reticuloendothelial system (RES) of the liver to remove LPS or 
whole bacteria from the circulation (83; 84) has been decreased. Second, enhanced 
absorption of endotoxin from the intestinal lumen due to a decreased or abrogated 
gastrointestinal bile flow has been reported (85). In addition, also increased 
intestinal permeability during cholestasis has been mentioned as a reason for 
elevated serum LPS levels (82; 86; 87) and bacterial translocation. Oral 
administration of bile acids reduced this increase in endotoxin absorption (80; 85; 
88) and bacterial translocation (88), thus emphasizing the importance of bile flow 
in preventing endotoxin absorption.  
Available therapies 
Sepsis 
There are many experimental anti-sepsis therapies, most of which are not very 
successful in patients or only effective in animal models. As sepsis is a very 
complex disease in which many mediators and pathways are involved, elimination 
of one mediator or inhibition of a single pathway seems often insufficient. 
Cytokines and especially TNFα and IL-1 play an important role in the onset of 
sepsis and the development of septic shock. High levels of these cytokines are 
associated with increased mortality (89). Several clinical trails have therefore been 
performed with anti-inflammatory agents like anti-TNF antibodies, IL-1 receptor 
antagonists and soluble TNF receptors, but also with antibradykinin agents, 
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platelet activating factor acetylhydrolases and antiprostaglandin agents (90). 
However, only very small improvements have been seen and sometimes even 
adverse effects were found, as shown by Fisher et al in a study with a soluble TNF 
receptor (91).  
Besides the production of cytokines, sepsis also leads to activation of the 
coagulation cascade. Endothelial cells activated by pro-inflammatory cytokines like 
TNFα, IL-1 and IL-6, start releasing tissue factor, leading to the activation of factor 
VII and thus initiation of the coagulation cascade and the formation of thrombin. 
This may lead to blood clotting in small blood vessels and occlusion of these 
vessels resulting in disseminated intravascular coagulation (DIC). The result of 
DIC is organ dysfunction which may eventually lead to multiple organ failure and 
death. Therapies aimed at the impaired coagulation cascade are anti-coagulant 
therapies like antithrombin III (AT-III), tissue factor pathway inhibitor and 
activated protein C (90). Activated protein C has, as part of the protein C pathway, 
also an important role in counterbalancing the fibrinolytic pathway and also seems 
to directly influence neutrophil activity. To date, only this activated protein C 
(Xigris) has shown to be a partly successful therapeutic strategy for sepsis by 
significantly, but modestly, improving survival, in certain groups of patients (92; 
93). 
 
The therapies mentioned so far, are mainly focused on eliminating mediators of the 
inflammatory cascade. Few therapies are directed against the initiator of the 
cascade, the LPS molecule itself. Some therapies with anti-endotoxin antibodies 
have been explored, but no significant effects were detected then (94; 95). 
Besides the already mentioned therapies, there are also new experimental therapies 
explored in clinical trails that are currently ongoing. In previous studies, we 
demonstrated that alkaline phosphatase (AP) is able to detoxify LPS by 
dephosphorylation (96-99). The applicability of this concept as a therapy is 
currently tested in two different clinical trials, each dealing with a different LPS-
mediated disease. In one trial, the effect of AP on the clinical outcome of septic 
patients is examined and in the second trial, the effect of AP on intestinal 
inflammation in ulcerative colitis is assessed. An overview of the various anti-
sepsis therapies that have been explored is given in table 1. 
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Table 1: Overview of clinically tested therapeutic compounds directed at different 
mediators of the sepsis-cascade. Based on information of amongst others Deans and 
Riedemann (90; 100). 
Target Therapeutic compound Reference 
   
Cytokines Anti-TNF monoclonal antibodies (101) 
 Soluble TNF receptors (91) 
 IL-1 receptor antagonist (102) 
   
Lipid mediators Platelet activating factor (PAF) receptor antagonists (103) 
 Platelet activating factor acetylhydrolase (PAF-AH) (104) 
 Cyclooxygenase inhibitor  (ibuprofen) (105) 
 Bradykinin receptor antagonist (106) 
 Thromboxane A2 inhibitor (107) 
 Thromboxane synthase inhibitor (108) 
   
Nitric oxide (NO) N(omega)-nitro-l-arginine methylester (L-NAME) (109) 
 N(G)-monomethyl-L-arginine (L-NMMA) (110) 
   
Lipopolysaccharide E5 murine anti-endotoxin antibody (94) 
 HA-1A human monoclonal antibody to endotoxin (95) 
 Bactericidal / Permeability increasing Protein (rBPI21) (111) 
   
Immune system Glucocorticoids (hydrocortisone and equivalents) (112; 113) 
 Intravenous Immunoglobulin (IVIG) (114) 
   
Coagulant compounds Activated protein C (APC) (92) 
 Tissue factor pathway inhibitor (TFPI) (115) 
 Antithrombin III (AT-III) (116; 117) 
   
CD14 Anti-CD14 monoclonal antibody (IC14) (118) 
   
  
Liver fibrosis 
Liver fibrosis is a disease as complex as sepsis. Both diseases have in common that 
no effective, curative therapy has been found to date. Despite many clinical trials 
that have been performed, liver fibrosis still cannot be reversed, leaving only liver 
transplantation as the final option for fibrotic patients. The fact that liver fibrosis 
can be the result of liver injury with very different etiologies, makes the 
development of therapeutics more complicated. 
As the hepatic stellate cell (HSC) plays a central role in the progression of liver 
fibrosis, most experimental therapies for liver fibrosis are directed at the HSC. If 
HSC become activated, they transform from a quiescent vitamin A storing cell into 
a proliferative, fibrogenic and contractile myofibroblast, which starts to produce 
extra-cellular matrix (ECM) components. Many therapies are directed at interfering 
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at different pathways of this process: avoiding activation of quiescent HSC, 
downregulation of the activation of HSC, neutralizing proliferative, fibrogenic, 
contractile and/or pro-inflammatory responses of stellate cells, promotion of 
apoptosis of activated HSC or increasing the degradation of the produced ECM 
(58). 
Avoiding HSC-activation might be achieved by anti-inflammatory agents, like 
corticosteroids, that prevent Kupffer cells from producing profibrogenic cytokines 
like TGFβ and TNFα and other mitogenic compounds like platelet derived growth 
factor (PDGF). In avoiding HSC-activation, anti-LPS therapies might come in view 
as recent studies have indicated that LPS can directly activate HSC (74). The 
increased leakage and reduced removal of LPS from the circulation during fibrosis, 
may indicate an important role for LPS and hence for anti-LPS drugs during 
fibrosis. As LPS is one of the most potent activators of Kupffer cells, preventing 
LPS from reaching the Kupffer cell might also help avoiding HSC activation. 
Hepatitis B and C 
Liver fibrosis induced by Hepatitis B and C may be inhibited by removal of the 
inciting stimulus. In recent years, many successes have been obtained in this area. 
Since 1999, the standard therapy for hepatitis C has been a combined therapy of 
interferon-alpha 2a (Roferon-A) and ribavirin (119), a nucleoside analog that 
inhibits the replication of many RNA and DNA viruses. In recent years, the 
standard therapy for hepatitis C is a combination therapy consisting of pegylated 
interferons, like pegylated interferon-α-2a (Pegasys) or peginterferon-α-2b 
(Pegintron), combined with ribavirin (119), which enhances the effect of the 
pegylated interferons (120). 
Today, several antiviral orally-administered nucleoside analogs like lamivudine, 
adefovir, dipivoxil and entecavir are used in the treatment of hepatitis B. In 
addition, new antiviral nucleoside analogs like telbuvidine, tenofovir and 
emtricitabine are currently clinically tested (121). The most successful treatment for 
chronic hepatitis B though, is treatment with pegylated interferon-α-2a (Pegasys) 
without a nucleoside analog. Pegylated interferon-α-2b is in clinical development 
for treatment of hepatitis B (121). Despite the fact that elevated serum levels of LBP 
and sCD14 have been reported during hepatitis and endotoxemia occasionally 
 General Introduction 
 
23 
occurs in hepatitis patients, suggesting a role for LPS in the disease, no anti-LPS 
strategies are being explored for these diseases now. 
Inflammatory Bowel Disease 
Several therapies are used for the treatment of inflammatory bowel diseases (IBD). 
The chosen therapy depends on the localization, the severity and the nature of the 
disease. Mild to moderate disease activity is often treated with 5-aminosalicylic 
acid compounds like sulfalazine, olsalazine and mesalamine (122). 5-aminosalicylic 
acid is a topically active anti-inflammatory compound that reduces the 
inflammation in the intestinal mucosa. As bacteria are thought to play an 
important role in IBD, antibiotics are also examined as therapeutics in IBD. Most 
research about the use of antibiotics is performed in patients suffering from 
Crohn’s disease (CD) (123). Antibiotics like metronizadol have shown to be quite 
effective in CD affecting the perianal part of the colon. Also ciprofloxacin has been 
reported to have beneficial effects in CD. Patients who are suffering from more 
severe symptoms or patients not responding to 5-aminosalicylic acid compounds 
are often treated with corticosteroids like prednisone or hydrocortisone. Although 
corticosteroids are already used for a long time in IBD-treatment protocols, these 
compounds unfortunately sometimes cause side effects, which can make them 
inappropriate for chronic treatment. Possible side-effects are acne, severe mood 
changes, adrenal insufficiency, hypertension, bone loss and visual changes (124). If 
corticosteroid treatment does not ameliorate the disease or if too many side-effects 
are encountered, other immunosuppressants may be used. Common 
immunosuppressants used in IBD are azathioprine, 6-mercaptopurine, 
cyclosporine and methotrexate.  
 
Besides these more or less established therapies, also several new therapies have 
been developed recently, amongst them a variety of cytokine-based therapeutics 
(125). One of these therapeutics is infliximab (Remicade). Infliximab, an antibody 
composed of human and mouse components that binds and neutralizes TNFα, was 
originally developed as an anti-sepsis agent. Unfortunately, infliximab did not 
improve clinical outcome in trials with septic patients (126), but in contrast to this 
lack of beneficial effects in sepsis, infliximab proved to be quite beneficial in other 
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diseases in which high TNFα levels play an important role, like rheumatoid 
arthritis (127) and CD (128; 129). Ever since, infliximab has shown to have 
significant beneficial effects in many patients. Another cytokine which was thought 
to play an important role in inflammatory bowel disease is interleukin-10 (IL-10). 
IL-10 is an anti-inflammatory cytokine which inhibits several functions of 
macrophages, monocytes and dendritic cells (130). The thought that interleukin-10 
might play an important role in IBD arose after the discovery that IL-10 knock-out 
mice developed spontaneously chronic enterocolitis (131). Patient trials though did 
not show the effects that were expected, which might be due to the complex 
pleiotropic functions of IL-10, exerting both anti- and pro-inflammatory effects (See 
references in Stokkers et al) (125).  
 
Another compound that has been tested for its potential use as a therapeutic 
compound in IBD is the short-chain fatty acid butyrate. Butyrate is produced in 
large amounts in the colon when dietary saccharides that escaped enzymatic 
breakdown in the small intestine, are fermented by anaerobic bacteria in the colon. 
Products of this fermentation process are mainly short-chain fatty acids (SCFA), of 
which butyrate is the most interesting one regarding its effects on the colon. In the 
colon, butyrate serves as the primary energy source for colonic epithelium but also 
regulates epithelial cell proliferation and differentiation in the colonic crypts. 
Moreover, butyrate displayed anti-inflammatory effects (132), which led to the 
hypothesis that butyrate might be beneficial during ulcerative colitis (UC) (133). 
The mechanism behind the anti-inflammatory effects of butyrate are not fully 
elucidated yet, but Segain et al demonstrated in human biopsies and human lamina 
propria mononuclear cells that butyrate inhibited NFκB activation, which resulted 
in a lower production of inflammatory cytokines like TNFα, IL-6 and IL-1β (134). 
In addition, Luhrs et al, showed that butyrate ameliorates inflammation in UC by 
inhibiting the IκB mediated translocation of NFκB to the nucleus in lamina propria 
macrophages (135). So far, evidence from clinical trials using butyrate in UC is still 
limited to a few studies (135-137). The studies are hampered by the fact that when 
using enemas, the disease has to be located distal to the splenic flexure (133). New 
oral formulations of butyrate might help to overcome this problem in the future.  




Alkaline phosphatase (AP) is an endogenous enzyme present in several organs, for 
instance liver, lung, kidney, intestine and placenta. AP is a 120 kDa dimeric 
orthophosphoric monoester phosphohydrolase that hydrolyzes many substrates at 
a high pH. It is a membrane-bound enzyme, which is linked to the cell membrane 
by a glycosylphosphatidylinositol anchor enabling the enzyme to fulfill its function 
outside the cell. 
There are several isoenzymes of AP: the liver/bone/kidney (LBK), the intestinal, the 
placental and the placental-like or germ-cell isoenzymes. The intestinal and 
placental isoenzymes are so-called organ-specific enzymes and are in healthy 
persons only expressed in intestinal and placental tissue. In contrast, the LBK-
isoenzyme, also called tissue non-specific alkaline phosphatase, is not only 
expressed in liver, bone and kidney tissue but also in neutrophils (138; 139), 
endothelial cells and fibroblasts and consequently in nearly all organs of the body. 
The isoenzymes of AP share structural homology (140), especially the intestinal, 
placental and germ-cell AP, which are clustered on the long-arm of chromosome 2, 
which are up to 90 to 98% homologous (141). The other isoenzyme, the 
liver/bone/kidney isoenzyme, is located on chromosome 1 and is only 50% 
homologous to the other three isoenzymes (141). In contrast to humans, rats 
display two isoenzymes of the intestinal alkaline phosphatase (142).  
 
For a long time, the only known physiological function of AP was a role in bone 
formation (143; 144). This role has already been described in 1923 by Robison. In 
his study in which he describes his theory of calcification, he mentioned “a bone 
enzyme” with a pH optimum of 9. At a later stage this enzyme was called AP. In 
addition, he described in this study that the function of the “bone-enzyme” is 
liberating phosphates from organic phosphates. The liberated phosphates 
subsequently form an insoluble precipitate with calcium ions and hence bone 
material is formed. Since then, AP has been used as a marker for bone formation by 
osteoblasts, the bone forming cells. But as it is present in large amounts in other 
organs, particularly in the intestine and brush border of renal tubules, already in 
1947 Lorch anticipated that it was likely that the enzyme had another physiological 
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function (145). This completely other function was discovered in 1997 by Poelstra et 
al, who demonstrated that the enzyme AP was able to dephosphorylate and 
detoxify LPS (97; 98). Removal of one of the 2 phosphates of the lipid A part of LPS 
resulted in a non-toxic lipid A moiety (96-98). These findings were extended and 
confirmed by studies of Bentala et al, Verweij et al and Beumer et al (96; 99; 146). 
Dephosphorylation of LPS by AP seems relevant in several tissues with high AP 
activity, e.g. the small intestine and the liver. 
 
Several diseases may lead to an altered expression of AP isoenzymes. For instance, 
placental alkaline phosphatase (plAP) has been detected in various types of cancer, 
e.g. testis, ovary, pancreas, colon, lymph tissue, stomach and bladder cancer (147), 
and is used as a tumor marker. It can be expected that the enzyme has other 
functions in these tissues, but this remains to be elucidated.  
 
Until now, data about the regulation of endogenous AP expression are scarce. 
Several AP-inducing agents are known, for instance sodium butyrate (148-151), 
retinoic acid (152; 153) and IL-6 (154).  
Sodium butyrate, as mentioned earlier, is a short-chain fatty acid that is produced 
in large amounts by colonic bacteria. It is known as a strong inducer of placental-
like or germ-cell alkaline phosphatase, which is often present in tumors (155). As 
described in paragraph 2.3, butyrate also ameliorates symptoms of ulcerative 
colitis. Studies of Chakravortty et al and Wu et al (156; 157) demonstrated that this  
is associated with inhibition of IκB-degradation, which prevents NFκB-
translocation to the nucleus and thereby activation of several genes, e.g. iNOS, 
TNFα and IL-8. In contrast, Ogawa et al did not find any effect of butyrate on IκB-
degradation and NFκB-activation in human intestinal microvascular endothelial 
cells (132). Although it is known that butyrate induces germ-cell AP and AP is 
abundantly present in the intestine, no studies have reported whether butyrate 
might also induce intestinal AP. 
Vitamin A or retinoic acid is another compound capable of increasing AP 
expression in a variety of cell lines, e.g. cultured human oral cancer cells (158), 
murine preosteoblastic cells (159), human ovarian carcinoma 3AO cells (160), 
intestinal Caco-2 cells (161) and rat small intestinal epithelial crypt IEC-6 cells 
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(152). Moreover, retinoic acid is known as a key regulator in the process of bone 
formation and LBK-AP is the most important enzyme involved in this process. 
Orimo et al demonstrated that retinoic acid regulates AP expression via a retinoic 
acid responsive element in the promoter region of the AP gene (162). Interestingly, 
HSC release their vitamin A upon activation during the fibrogenic process. 
Despite the fact that there are quite a few AP-inducers, a final common pathway 
for all these inducers to enhance AP activity is not known yet. 
 
AP expression during disease 
Sepsis 
Several recent papers, of amongst others our group, have reported about the 
beneficial effect of administration of AP during sepsis (96; 99; 146; 163; 164). 
Administration of high amounts of AP increases the LPS-dephosphorylating 
capacity. As administration of “extra” AP results in a protective effect during 
sepsis, one could anticipate that probably endogenous AP levels have also changed 
during sepsis. This hypothesis is confirmed by several studies in which elevated 
AP levels during sepsis (165; 166) and bacteraemia (167) have been found. 
Nevertheless, elevated AP levels due to hepatic complications accompanying 
sepsis are more often reported. Sepsis also can affect the liver function and 
common hepatic complications occurring during sepsis are for instance cholestasis 
and jaundice (168-170).   
Liver fibrosis 
In normal human and rat livers, AP activity is only found at the hepatocyte 
canalicular membrane. In cholestatic livers, this activity profoundly changes. In 
rats subjected to bile duct ligation, AP activity was found not only at the 
canalicular membrane but also at the sinusoidal membrane of hepatocytes (171). 
An identical change in pattern of AP activity in the liver was found in human 
cholestatic livers. Livers of patients suffering from primary biliary cholangitis 
(PBC) displayed AP activity at both the canalicular and sinusoidal membrane 
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(172). Furthermore, they also reported high AP activity in the cytoplasm of bile 
duct epithelial cells (172). 
In addition, cholestatic liver diseases like PBC and primary sclerosing cholangitis 
(PSC) are also accompanied by significant changes in serum AP levels (172; 173). In 
fact, serum AP levels are used as a marker to assess disease activity. In contrast to 
cholestatic liver diseases, hepatitis C patients did not show any change in hepatic 
AP expression compared to control livers (172). 
Inflammatory bowel disease  
AP is normally expressed in high amounts by the epithelial cells of the small 
intestine and in small amounts by epithelial cells of the colon. If the gut epithelial 
layer is damaged, LPS from the bacteria colonizing the gut cannot be detoxified by 
AP and a subsequent exposure of sub-epithelial cell layers to this LPS may initiate 
a local inflammation. Damage to the AP-bearing epithelial layer of the intestine 
thus may be an important factor in the perpetuation of the inflammatory process in 
IBD. 
Chronic inflammatory bowel diseases in some cases also lead to changes in serum 
AP levels. A common complication of inflammatory bowel diseases, and especially 
ulcerative colitis, is PSC. PSC ultimately results in biliary cirrhosis and is 
characterized by elevated serum AP levels (173). 
Other diseases 
Besides the diseases already mentioned in this paragraph, there are several other 
diseases displaying aberrant AP levels in tissue and / or serum.   
Several bone diseases are characterized by very high AP levels, so called 
hyperphosphatasia or very low AP levels called hypophosphatasia. Examples of 
diseases which are accompanied by hyperphosphatasia are Paget’s disease and 
hereditary hyperphosphatasia. Hereditary hypophosphatasia has also been 
described and it is known that the low serum AP levels which are characteristic for 
this disease, are caused by a structural abnormality in the tissue non-specific AP 
enzyme, which is due to mutations in the gene (174; 175). Besides for bone 
diseases, AP levels are also used as a marker for rheumatoid arthritis. One of the 
hallmarks of rheumatoid arthritis are elevated AP levels in serum (176). 
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Besides bone diseases, also some tumors express abnormal levels of the enzyme 
AP. Especially elevated levels of placental alkaline phosphatase are measured in 
tumors of different origin (147). The cause of the AP elevations in these diseases 
may be the enhanced inflammatory activity leading to release of AP from 
neutrophils, enhanced activity of fibroblasts or osteoblasts that release AP, or 
aberrant transcription of embryonic genes in tumors. 
 
This thesis 
This chapter has given an overview of what is known about AP and LPS-mediated 
diseases, with a special focus on sepsis, IBD and liver fibrosis. In addition, the 
possible role of endogenous and exogenous AP in these diseases has been 
described. Sepsis, IBD and liver fibrosis are examples of three well-known diseases 
in which LPS plays an important role in the onset or progression. Of note, as 
shown in the previous paragraph, AP levels deviate from standard values in a lot 
more diseases. Yet, not much is known about the mechanism behind the 
endogenous regulation of AP activity. More knowledge about this process may 
lead to new possibilities for therapeutic interventions in LPS-mediated diseases. 
We therefore explored the factors that regulate endogenous AP activity (chapters 3 
and 4). 
To date, the only LPS-mediated disease in which AP had shown a significant 
therapeutic effect is sepsis. In mice, rats, pigs and sheep, significant effects of AP 
on survival and several inflammatory parameters were found (96; 99; 146; 163). So 
far, this concept has only been tested in sepsis, but in other diseases in which an 
excess of LPS is initiating inflammatory processes, administration of AP might also 
result in beneficial effects. For that reason, the second research topic of this thesis 
was elaborating the knowledge on the therapeutic effects of AP in sepsis (chapters 
3 and 5) and examining its applicability in another disease in which LPS plays a 
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Gut-derived lipopolysaccharide (LPS) plays a role in the pathogenesis of liver 
diseases like fibrosis. The enzyme alkaline phosphatase (AP) is present in, amongst 
others, the intestinal wall and the liver and was previously shown to 
dephosphorylate LPS. Therefore, we investigated the effect of LPS on hepatic AP 
expression and the effect of AP on LPS-induced hepatocyte responses.  
LPS-dephosphorylating activity was expressed at the hepatocyte canalicular 
membrane in normal and fibrotic animals. In addition to this, fibrotic animals also 
displayed high LPS-dephosphorylating activity around bile ducts. The enzyme 
was shown to dephosphorylate LPS from several bacterial species. LPS itself 
rapidly enhanced the intrahepatic mRNA levels for this enzyme within 2 hr by a 
factor 7. 
Furthermore, in vitro and in vivo studies showed that exogenous intestinal AP 
quickly bound to the asialoglycoprotein receptor on hepatocytes. This intestinal 
isoform significantly attenuated LPS-induced hepatic TNFα and nitric oxide (NOx) 
responses in vitro. The enzyme also reduced LPS-induced hepatic glycogenolysis in 
vivo. This study shows that LPS enhances AP expression in hepatocytes and that 
intestinal AP is rapidly taken up by these same cells, leading to an attenuation of 
LPS-induced responses in vivo. Gut-derived LPS-dephosphorylating activity or 
enzyme upregulation within hepatocytes by LPS may therefore be a protective 








Lipopolysaccharide (LPS) or endotoxin is a highly toxic molecule derived from the 
outer membrane of Gramnegative bacteria. The toxic part of LPS is located in the 
lipid A part of the molecule, which is the most well conserved moiety among LPS 
serotypes from a variety of Gramnegative bacteria. Two phosphate groups coupled 
to two glucosamines in the lipid A part largely determine the toxicity of LPS (17; 
39). Removal of a single phosphate group results in the formation of a non-toxic 
monophosphoryl lipid A (MPLA) moiety (6; 24; 46).  
Systemic LPS can elicit a systemic inflammatory response syndrome (SIRS) 
characterized by fever, diffuse intravascular coagulation, shock, multiple organ 
failure and eventually death (2; 16). At present, sepsis is still the most important 
cause of death in intensive care units (25) and the 10th cause of death overall in the 
United States (5), accounting for about 215.000 deaths a year (4). Elevated LPS 
levels in the blood may be the result of a serious bacterial infection, an impaired 
host-defence system or damage to barriers like the skin or the intestine or 
alternatively from a reduced capacity of the liver to remove LPS from the blood. 
Several diseases are now associated with bacterial translocation from the gut 
(Silverman et al, 2003, report at www.xoma.com/pdf/kpmgendo.pdf) e.g.: trauma, 
hemorrhagic shock, burn injuries, inflammatory bowel disease, cardiovascular and 
liver surgeries, acute pancreatitis and necrotizing enterocolitis. Impaired clearance 
of LPS by the liver is usually observed during liver diseases like cirrhosis and 
hepatitis B and C (22; 43). These diseases demonstrate the importance of an intact 
liver and intestinal wall to prevent LPS-induced diseases.  
The liver is the major LPS-removing organ. The majority of systemic LPS is 
removed from the bloodstream by Kupffer cells and likely also endothelial cells. 
Kupffer cells modify the endocytosed LPS (48) and somehow pass it on to the 
hepatocytes that subsequently excrete these products into the bile (18). Part of the 
LPS though, is removed from the circulation directly by the hepatocytes (40). 
Direct uptake of LPS by hepatocytes is significantly enhanced by binding of LPS to 
proteins such as apoE (38) and particles like chylomicrons (12; 13), VLDL, LDL (11) 
and HDL (11).  
 Chapter 3 
 
50 
In 1993, Poelstra et al (6; 33; 34) were the first to postulate a role of the endogenous 
enzyme alkaline phosphatase (AP) in LPS detoxification. This enzyme appeared to 
be able to remove phosphate groups from LPS, thus attenuating the toxicity of this 
molecule. Until then, the only physiological role for AP that was identified was a 
role in bone formation (36).  
As the enzyme is present within the liver, and in fact is upregulated during several 
liver diseases, we now addressed the question whether this enzyme plays a role in 
the protection of the liver against LPS. Cholestasis and sepsis are characterized by 
both elevated serum AP and LPS levels (23; 49). Commonly, these elevated AP 
levels are regarded as a reflection of liver damage. In view of the LPS-detoxifying 
activity of AP, we now tested whether these elevated AP levels may be an adaptive 
physiological response upon LPS. To answer this question, we examined the LPS-
dephosphorylating activity of the liver and measured intrahepatic changes in this 
activity after LPS administration and after induction of fibrosis both at the enzyme 
and RNA level.  
In addition, AP activity is also high on the membranes of enterocytes lining the gut 
and this intestinal enzyme is also present as a soluble enzyme in plasma from 
where it is rapidly taken up by hepatocytes (3; 7; 26). This expression pattern and 
pharmacokinetic profile might be indicative for a hepatoprotective role. Therefore, 
we also tested whether exogenous intestinal AP (iAP) might protect hepatocytes 
from LPS-induced damage. Our data show that intestinal AP is likely to be 
targeted to hepatocytes and support the hypothesis that this enzyme is part of the 
endogenous defence system against LPS. 
  
Materials & Methods 
Chemicals  
Highly purified calf intestinal alkaline phosphatase (ciAP, specific activity 2530 
U/mg) was obtained from AM-Pharma (Bunnik, The Netherlands). 
Lipopolysaccharide (LPS) from Escherichia Coli, Serotype O55:B5, obtained from 
Sigma (Sigma Co., St Louis, USA), was used in all in vitro and in vivo studies. All 
other chemicals were of analytical grade.  




Male Wistar rats (Harlan, Zeist, The Netherlands) were housed under standard 
laboratory conditions; a regular light/dark cycle and laboratory chow and acidified 
water ad lib. All animal experiments were approved by the Local Committee on 
Animal Experimentation.  
 
Enzymehistochemistry 
LPS-dephosphorylating activity of endogenous AP in rat livers was examined by 
incubating cryostat sections (5 µm) with LPS as a substrate according to Wachstein 
and Meisel (27). Briefly, sections were fixed in 4% formalin-macrodex and 
subsequently incubated for 120 min. in Tris/HCl buffer pH 7.6 containing LPS 
(final conc. 3.2 mg/ml), MgSO4 (final conc. 0.01 M) and Pb(NO3)2 (final conc. 0.06% 
w/v) at 37°C. A lead phosphate precipitate will be formed at the site of enzyme 
activity, which is converted by incubation with Na2S to a lead sulphate precipitate, 
which appears as a dark brown staining. Specificity of this staining has previously 
been demonstrated by inhibition of AP activity using levamisole (34) and L-
phenylalanine (47). LPS was omitted in control incubations.   
 
Immunohistochemical staining of the CD14 receptor  
Acetone-fixed cryostat sections (5 µm) of BDL3 rat liver, lung, kidney and small 
intestine were prepared and subsequently incubated with a rabbit polyclonal 
antibody against the CD14 receptor (cat.no. sc-9150, Santa Cruz, Biotechnology, 
Inc.), or PBS (control sections). After inhibition of endogenous peroxidase (0.25% 
H2O2), sections were incubated with GARPO (goat anti-rabbit IgG conjugated with 
horseradish peroxidase). Peroxidase activity was visualized with 3-amino-9-
ethylcarbazole (AEC) according to standard methods. Finally, sections were 
counterstained with haematoxylin. 
 
Immunohistochemical staining of collagen III  
This staining was performed as described for the CD14 receptor staining. A goat 
polyclonal antibody against collagen III (cat.no. 1330-01, Southern Biotechnology 
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Associates, Inc., Birmingham, USA) was used and RAGPO (rabbit anti-goat IgG 
conjugated with horseradish peroxidase) was used as a secondary antibody. 
 
In vivo experiments  
Experiments were carried out in normal rats and in rats with established liver 
fibrosis 3 weeks after bile duct ligation (BDL3). The rats were divided into three 
groups. Control animals received saline i.v. at t = 0 whereas others received 1 
mg/kg LPS i.v. at t = 0. Part of the animals were treated with 100 U or 1000 U ciAP 
i.v. 1 min. prior to the LPS injection. After 2 hr, the rats were sacrificed under 
O2/N2O/forene (Isoflurane, Abbott Laboratories Ltd, Queensborough, Kent, UK) 
anaesthesia. Livers were taken out, partly frozen in isopentane and stored at –80°C 
for immunohistochemical staining and partly snap-frozen in liquid nitrogen for 
RNA isolation. Blood was collected to measure liver enzymes. If indicated, 
kidneys, lungs and intestines were taken out and handled as described above for 
the liver. 
 
Slice experiments  
BDL3 rats were sacrificed under O2/N2O/forene anaesthesia and livers were taken 
out and stored in University of Wisconsin organ preservation solution (UW) until 
slice preparation. Precision-cut liver slices (10-14 mg) were prepared as described 
previously (29) and stored in UW on ice until incubation. Slices were incubated 
individually at 37°C in 6-well plates (Greiner, Alphen a/d Rijn, The Netherlands) in 
3.2 ml Williams’ medium E supplemented with Glutamax I (Gibco BRL, Paisley, 
Scotland), 50 mg/ml gentamicin (Gibco BRL) and saturated with 95% O2 / 5% CO2. 
Slices were incubated for 24 hr with or without 10 µg/ml LPS. Slices incubated with 
LPS were incubated with or without ciAP (1.56 or 15.6 U/ml). Medium of the slices 
was stored at -20°C until NOx measurement or at -80°C until TNFα measurement. 
Also, slices were embedded in Tissue-Tek and stored at -80°C until the 
preparation of cryostat sections. 
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Real-time quantitative PCR analysis  
RNA was isolated from rat liver pieces using the QIAGEN RNeasy Mini Kit. 
Quality of the RNA was checked on a 2% agarose gel and the RNA concentration 
was determined with a ribogreen assay. The Reverse Transcription System from 
Promega was used to convert 1.6 µg of RNA into complementary DNA (cDNA). 
Reverse transcriptase PCR was performed for 10’ at 25°C, 60’ at 45°C and 5’ at 
95°C, using olido-dT (0.633 µg per reaction) primers. Then 1.25 µl of cDNA was 
amplified by quantitative real-time PCR using the SYBR Green PCR Master Mix 
from Applied Biosystems. PCR reactions were carried out in a ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems) in a volume of 21.25 µl. Genes of 
interest were amplified using the following primers: glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (forward primer 5’-CCATCACCATCTTCCAGGAG-3’; 
reverse 5’-CCTGCTTCACCACCTTCTTG-3’), liver/bone/kidney AP (forward 
primer 5’-GCAAGGACATCGCCTATCAG-3’; reverse 5’-
AGTTCAGTGCGGTTCCAGAC-3’) and glutamate-pyruvate-transaminase (GPT) 
(forward primer 5’-TGTGCCTCCTGGAAGAGACT-3’; reverse 5’-
TGTTGCGTCAGAGACTGTCC-3’). GAPDH was used as a housekeeping gene and 
levels of AP and GPT were normalized to GAPDH levels. Data obtained were 
analyzed using the comparative threshold cycle (CT) method as described in the 
User Bulletin #2 of the ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems). Data are expressed as fold induction or repression of the gene of 
interest compared to the control condition as calculated by the formula 2-∆∆CT.  
 
NOx assay  
Nitrite and nitrate (indicated as NOx) production by rat liver slices was assayed by 
determining the NOx levels in the media of slices. This assay was performed 
according to Bentala et al (6). 
 
TNFα assay 
TNFα levels in rat serum and in media of liver slices were determined using a 
sandwich ELISA according to Bentala et al (6). 96-wells ELISA plates were coated 
overnight with a monoclonal anti-rat TNFα capturing antibody (R&D Systems). 
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Sera from rats were diluted 2 or 5 times prior to transferring them to the plate 
whereas samples from the incubation media of rat liver slices were measured 
undiluted. Recombinant-rat TNFα (R&D Systems) was used to prepare a TNFα 
standard curve. Biotinylated rabbit anti-mouse/rat TNFα (R&D Systems) was used 
as a detection antibody according to standard methods. 
 
PAS staining  
The glycogen content of hepatocytes was visualized by a PAS staining. Briefly, 
cryostat sections (5 µm) were fixed in 4% v/v formalin in methanol, subsequently 
incubated in 1% periodic acid, washed, incubated in Schiff’s reagens, washed with 
tap water and counterstained with haematoxylin. The hepatic glycogen content 
appears as a purple staining. 
 
Clearance of iAP and uptake by hepatocytes  
Uptake of exogenous AP by hepatocytes was studied in rats in vitro and in vivo. In 
vivo, 3 rats received 100 U calf intestinal AP i.v. and 3 rats received 10 mg 
asialofetuin (AsF) i.v. 1 min. prior to the ciAP injection. Blood samples were taken 
at t = 0, 1, 2, 5, 10, 20, 30 and 60 min. after ciAP administration. Serum AP-activity 
was measured at pH 9.8 using para-nitrophenyl-phosphate (pNPP) as a substrate 
according to standard methods (9). Pharmacokinetic parameters were assessed 
with the computer program MultiFit (Dr. J.H. Proost, Groningen, The 
Netherlands). 
In vitro, precision-cut rat liver slices were incubated, as described above, for 2 hr 
with 15.6 U/ml ciAP alone or with 15.6 U/ml ciAP plus 0.5 mg/ml AsF and 5 µm 
cryostat sections were stained for AP activity using β-glycerophosphate as a 
substrate according to the method of Gomorri (21).  
 
Statistics 
Results are expressed as the mean ± SD of at least three separate experiments. Data 
were analyzed using a two-sided Student’s t-test and considered significant at p< 
0.05. 




LPS dephosphorylation in rat liver 
Since the liver is the major LPS-removing organ of the body, we first tested 
whether the liver itself is capable of dephosphorylating, and thus detoxifying, LPS 
by means of its endogenous AP activity. The LPS-dephosphorylating activity of rat 
livers was examined in 5 µm cryostat sections using an enzymehistochemical 
staining method at pH 7.6 with LPS as a substrate and lead phosphate as the 
product. LPS-dephosphorylating activity was examined in normal as well as BDL3 
rat livers, which are known to have elevated AP levels. Figure 1 shows LPS 
dephosphorylation in cryostat sections of normal (Fig. 1A) and BDL3 (Fig. 1B & 
1C) rat livers. Control sections (Fig. 1D), which were incubated with vehicle 
instead of LPS, showed no staining at all. In normal rat livers, a clear dark brown 
staining, reflecting the dephosphorylating activity was found. Lead phosphate 
precipitates were located around hepatocytes, showing a clear canalicular staining 
pattern (8). In BDL3  rats, a similar staining pattern was found around hepatocytes, 
but in addition to this, a very strong staining around bile ducts was also seen (Fig. 
1C).  
 
Dephosphorylation of different LPS-serotypes by endogenous hepatic AP 
In order to investigate whether rat liver AP is capable of dephosphorylating LPS 
from several bacterial species, the enzymehistochemical staining was also carried 
out with LPS from five other bacterial species: next to wild-type E.Coli, we tested 
Salmonella typhimurium, Pseudomonas aeruginosa (serotype 10), Shigella flexneri 
(serotype 1A), Klebsiella pneumonia (Sigma Co., St Louis, USA) and Salmonella 
minnesota Re 595 (List Biological Laboratories Inc., Campbell, CA, USA). Light 
microscopical evaluation clearly showed that LPS from all bacterial species tested 
was dephosphorylated, albeit different staining intensities were found (Table 1). A 
semi-quantitative evaluation by two independent observers was performed by 
ranking the sections in order of increasing staining intensity. 





Figure 1: Staining for phosphatase activity in the rat liver using LPS as a substrate. Dark 
staining (arrows) indicates sites of LPS dephosphorylation (PbS precipitate). Figure 1 shows 
enzyme activity in representative sections of normal (A) and BDL3 (B & C) rat livers 
respectively. Figure D depicts a control rat liver section incubated without the substrate LPS 
(magnification 400*). Sections of normal and BDL3 rat livers were also stained for collagen 
III deposition to show that fibrosis had developed 3 weeks after bile duct ligation. The 
collagen III stained sections are shown as inserts in figures A and B (magnification 100*). 
The insert in figure C depicts a higher magnification of the bile duct epithelial (BDE) cells 
(magnification 1000*). The insert clearly shows that AP activity is present along the BDE 
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Table 1: Semiquantitative evaluation of LPS-dephosphorylating activity in rat liver sections 
using LPS from six different bacterial species in BDL3 rat liver sections. 
 
Bacterial source of LPS Intensity of LPS dephosphorylation 
E. Coli (serotype O55:B5) ++ 
Shigella flexneri (serotype 1A) +/- 
Salmonella typhimurium +++ 
Pseudomonas aeruginosa (serotype 10) ++++ 
Klebsiella pneumonia +++++ 
Salmonella minnesota Re 595 + 
  
 
Localization of the CD14 receptor and AP activity in rats 
Together with the toll-like receptor 4 and MD2, the CD14 receptor (CD14r) is part 
of the LPS-signaling system. As AP is present at sites were possible pathogens, e.g. 
Gramnegative bacteria, may enter the body (e.g. lung epithelium, intestine) or 
where LPS may accumulate (liver, kidney), it is interesting to see how AP activity 
is related to CD14r expression. To address this issue, an immunohistochemical 
staining of the CD14r was performed on cryostat sections of BDL3 rat livers, lungs, 
kidneys and intestines. This staining was compared to the staining of AP activity in 
these organs. 
In the kidney, we found a striking colocalisation of AP activity and CD14r 
expression. Both AP activity and CD14r were located at the brush borders in the 
renal tubuli (Fig. 2C and 2D). Also in lungs, livers and intestines, AP activity and 
CD14r expression were found although they did not completely colocalise. In 
lungs, the CD14r expression was detected at the apical side of the alveolar 
epithelial cells (Fig. 2E) whereas the AP activity was detected at the basal side of 
alveolar epithelial cells (Fig. 2F). In livers, CD14r expression was localized on bile-
duct epithelial cells (Fig. 2A), whereas AP activity was detected around the bile 
duct on fibroblast-like cells (Fig. 2B). In contrast, hepatocytes that showed AP 
activity along their membrane did not show any detectable CD14r expression.  









Figure 2: CD14r expression and 
AP activity in rat liver (A, B), 
kidney (C, D), lung (E, F) and 
small intestine (G, H). Figures A, 
C, E and G show the localization 
of the CD14r, indicated by the 
red staining, whereas figures B, 
D, F and H show AP activity, 
reflected by brown staining. 
Pictures show occasional staining 
for CD14r in all organs 
examined. Staining for AP 
activity is also seen in every 
organ. AP staining is frequently 
localized in the same areas as the 
CD14r staining (details see text). 
Figures I and J are negative 
controls (omission of the first 
antibody) of the two organs in 
which the CD14r staining was 
most intense, that is, the liver (I) 
and the kidney (J). Fig. D: 
a=artery (magnification 400*). A 
full color version of this figure 







Other studies however, do report a low CD14r expression in hepatocytes (44) while 
recent studies also indicate CD14r expression in activated human stellate cells 
(myofibroblasts) around the proliferative bile ducts (31). Within the small intestine, 
AP activity was found along the entire villus (Fig. 2H), whereas CD14r expression 
was only detected in the crypts and the lowest part of the villus (Fig. 2G). This 
corresponds with literature data (30). In the small intestine there is thus a 
colocalisation of AP activity and CD14r expression in the lower half of the villi at 
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the bottom of the crypts. In conclusion, AP and CD14r are localized in all organs 
tested, with a colocalisation in kidneys, livers and intestine. Within the lung, both 
are in close proximity of each other. An exception seems to be the arterial wall. In 
the tunica adventitia of blood vessels, high AP activity was found (Fig. 2D) but no 
CD14r expression was seen at all. 
 
AP activity after LPS administration in vivo 
From literature it is known that several diseases are associated with elevated AP 
levels as well as high LPS levels, e.g. cholestasis, sepsis and liver fibrosis. In order 
to test whether both events can be related to each other, rats received LPS (1 
mg/kg) or saline i.v. and the effect on AP activity in the blood and AP mRNA 
levels in livers was assayed. We studied mRNA levels 2 hr after injection of LPS to 
exclude a role for the many mediators that are produced several hours after an LPS 
challenge. After 2 hr, normal rats did not show a significant change in serum AP 
levels in response to LPS administration (Fig. 3A). In literature, increases of AP 
activity in serum after LPS administration were also reported in normal rats but in 
other conditions; e.g. at intervals longer than 2 hr after LPS injection and at higher 
LPS concentrations (19). Also the levels of other markers of liver damage (37), 
lactate dehydrogenase (LDH), glutamate-oxalacetate-transaminase (GOT), GPT 
and gamma-glutamyl transferase (γ-GT) did not show a significant elevation 2 hr 
after an LPS challenge (data not shown). In contrast, in serum of BDL3 rats, 
significant increases in serum markers were found at t = 2 hr (Fig. 3A). AP activity 
in serum rose from 414 ± 48 (saline-treated rats) to 541 ± 94 (LPS-treated rats; p < 
0.05). This paralleled an increase in serum levels of LDH (from 2674 ± 1581 to 5835 
± 2114), GOT (from 374 ± 116 to 1466 ± 483) and GPT (from 78 ± 15 to 134 ± 23).  
To examine whether the elevated AP levels are the result of release from damaged 
hepatocytes or de novo synthesis, we studied mRNA expression in these livers 
using real-time PCR. In both normal and BDL3 rats, a significant induction of AP 
mRNA could be detected 2 hr after LPS administration (Fig. 3B). Real-time PCR 
revealed a 7-fold induction of AP mRNA in normal livers of rats receiving LPS 
compared to control rats receiving saline. BDL3 rats showed almost the same 
result, but with a maximum fold of induction of 5.  




Figure 3: Serum AP levels and intrahepatic mRNA levels for AP and GPT in normal and 
BDL3 rats, 2 hours after administration of saline or LPS. A: serum AP levels, B: intrahepatic 
mRNA expression for AP, C: intrahepatic mRNA expression for GPT. It can be seen that LPS 
causes an elevation in serum AP levels in BDL3 rats, but not in normal rats. In contrast, 
mRNA levels for AP are significantly elevated in both normal and BDL3 livers at this 
timepoint. These elevated AP mRNA levels are not associated with increased intrahepatic 
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This increase could be mimicked in vitro by incubation of liver slices with LPS. In 
these slices there is no influx of neutrophils (that have high mRNA levels for AP) 
thus excluding a role for these cells as the source of this mRNA (data not shown). 
To assess whether this induction in mRNA levels for AP parallels the increase in 
markers reflecting liver damage, we also measured GPT mRNA levels. Figure 3B 
depicts the GPT mRNA levels and data clearly show that these mRNA levels 
remain constant (normal rats) or even slightly decrease (BLD3 rats). This means 
that although both serum GOT and serum AP are elevated after LPS in BDL3 rats, 
only in case of AP this is associated with an increase in mRNA for AP. Elevated AP 
and GPT levels in the blood observed after LPS-induced liver damage therefore 
seem to have a different physiological background. 
 
Uptake of intestinal AP by hepatocytes 
Intestinal AP (iAP) is a glycoprotein with terminal galactose groups that is 
produced by enterocytes. From literature it is known that iAP originating from 
dogs is taken up from the circulation by the asialoglycoprotein receptor (ASGP-R) 
on hepatocytes (7; 26). We also tested this in our system with our highly purified 
calf iAP (ciAP) preparations. To this end, we examined the plasma half-life of ciAP 
in serum and also tested the effect of asialofetuin (AsF), a well-known blocker of 
the ASGP-R, on plasma disappearance. Our results (Fig. 4A) clearly confirm the 
particular literature data. The plasma concentration versus time curve in rats that 
only received ciAP show a short distribution half-life of 2.8 min. and an 
elimination half-life of 39 min. Assessment of the effect of AsF on the 
pharmacokinetic profile shows that AsF can almost completely prevent ciAP 
clearance from the blood. These data demonstrate that the ASGP-R is most likely 
involved in the clearance of ciAP.  
We also examined binding and uptake of intestinal AP by hepatocytes in vitro. To 
show these events, rat liver slices were incubated with ciAP alone or with ciAP 
plus AsF and AP activity was detected by enzymehistochemistry (Fig. 4B). In slices 
incubated with ciAP alone, high AP activity was found in the cytoplasm of 
hepatocytes whereas in slices incubated with ciAP plus AsF no AP activity was 
detected at all. The absence of AP activity in hepatocytes treated with ciAP plus 
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Figure 4: A Serum AP activity after 
i.v. administration of 100 U ciAP, 
with or without prior administration 
of the ASGP-R blocker asialofetuin 
(AsF, 10 mg/rat). Serum AP activity 
was measured at pH 9.8 at different 
timepoints after ciAP administration; 
B AP activity in rat liver slices. Rat 
liver slices were incubated for 2 hr 
with 15.6 U/ml ciAP alone (upper 
picture) or with 15.6 U/ml ciAP plus 
0.5 mg/ml AsF (lower picture) and 
thereafter embedded in Tissue-Tek®. 
Cryostat sections were stained for AP 
activity at pH 9 using β-glycero-
phosphate as a substrate according to 
the method of Gomorri (21). Arrows 
indicate the presence of AP activity in 
hepatocytes. It can be seen that AsF 
blocks the uptake of ciAP in vivo and 







In vitro studies with intestinal AP 
To assess the effect of this exogenous iAP on hepatocytes in vitro, slices prepared 
from BDL3 rat livers were incubated with 10 µg/ml LPS for 24 hr with or without 
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in the medium was assayed. After stimulation of BDL3 liver slices with LPS, NOx 
levels in the medium rose from 5.4 ± 1.3 µM (control without LPS) to 114.4 ± 13.7 
µM at t = 24 hr after addition of LPS. Importantly, our data also show that NOx 
levels in the medium were significantly reduced when 1.56 and 15.6 U/ml ciAP 




































































Figure 5: NOx and TNFα levels in the medium of rat liver slices after incubation with LPS 
and ciAP. A NOx-levels in the medium of rat liver slices in response to LPS. BDL3 rat liver 
slices were incubated for 24 hr with 10 µg/ml LPS with or without 1.56 or 15.6 U/ml ciAP.  
B TNFα-levels in medium from BDL3 liver slices treated with LPS and incubated with or 
without ciAP. BDL3 rat liver slices were incubated for 24 hr with 10 µg/ml LPS with or 
without 1.56 or 15.6 U ciAP. TNFα and NOx production of liver slices under basal conditions 
was 46 ± 27 pg/ml resp. 5.4 ± 1.3 µM and after addition of LPS levels rose to 560 ± 108 pg/ml 
resp. 114.4 ± 13.7 µM. These amounts were set to 100% in each experiment. Each bar 
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In addition, we looked at the TNFα response in slices upon LPS. Also for these 
experiments, only slices from BDL3 rat livers were used, because these rats 
produced much higher amounts of TNFα in response to LPS. After incubation of 
slices with LPS, TNFα levels reached a maximal response at t = 24 hr and the level 
had risen from 46 ± 27 pg/ml (control without LPS) to 560 ± 108 pg/ml (data not 
shown). We observed (Fig. 5B) that slices incubated with ciAP displayed a 
significantly lower TNFα response upon LPS compared to slices incubated with 
LPS alone (p < 0.05). 
 
In vivo studies with intestinal AP 
We also tested the effect of LPS and ciAP on hepatocytes in vivo. Because of the 
early timepoint of sacrifice after the LPS challenge (t=2 hr), endogenous AP activity 
was not increased yet (data not shown) and only direct effects of LPS can be found. 
One of the earliest effects of LPS on the liver is stimulation of glycogenolysis (45). 
This glycogen degradation is an early event in hepatocytes responding to stress or 
illness. We therefore examined the glycogen content of hepatocytes in rat livers 
after LPS administration using a PAS staining. Figure 6 clearly shows that 2 hr 
after LPS administration, the glycogen content in hepatocytes is very strongly 
reduced in livers of rats that received LPS (Fig. 6B) compared to rats that received 
saline (Fig. 6A). All of the rats (n=9) treated with LPS showed a strong reduction in 
PAS staining throughout the whole liver (Fig. 6B). In contrast, all of the rats (n=6) 
treated with 1000 U ciAP after LPS clearly exhibited a partially retained PAS 
staining (Fig. 6C), whereas none of the control rats, rats receiving ciAP alone (n=3) 
or saline (n=8), displayed significant disappearance of PAS staining. 
 
 






Figure 6: Glycogen staining in hepatocytes as detected by a PAS staining on rat liver 
cryostat sections (a full color version of this figure can be found on page 171). Rats received 
saline (A, n = 9), LPS (B, 1 mg/kg, n = 9) or LPS (1 mg/kg) plus ciAP (1000 U) i.v. (C, n = 6). 
Note the reduced PAS-staining in LPS-treated rats (B) as compared to control (A), whereas 
PAS-staining was higher in rats that received LPS plus ciAP (C) as compared to untreated 
LPS-rats (B) (magnification 100*). 
 
Discussion  
Numerous papers have described AP activity in the liver and changes in this 
activity during diseases. Yet, this was not related to a possible physiological role 
for this enzyme. Until recently, the only known physiological function of AP was 
its role in bone formation (36), but obviously, the enzyme fulfils another function 
in the intestine, kidney, liver and along blood vessels. All of these organs are 
located at sites in close contact with the external environment and represent sites 
where pathogens, e.g. Gramnegative bacteria, may enter the body. The presence of 
AP at these locations as well as the simultaneous elevation of AP and LPS levels in 
the blood in several diseases combined with the observation that AP is able to 
dephosphorylate and detoxify LPS, led us to the idea that another physiological 
function of AP could be the detoxification of LPS (6; 33; 34). 
This study therefore was focused on the role of the liver-bone-kidney type of 
alkaline phosphatase (LBK-AP) in the liver and on the role of intestinal AP (iAP) in 
LPS dephosphorylation. We found that the liver by means of its AP is able to 
dephosphorylate LPS and that LPS in turn is able to induce LBK-AP mRNA levels. 
Whether this is a direct effect of LPS or mediated by other factors remains to be 
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elucidated, but the effect occurs very rapidly at a timepoint when most 
inflammatory mediators are not elevated yet.  
Within the liver, the LPS-dephosphorylating activity was present in hepatocytes 
but also in non-parenchymal cells, most likely fibroblasts and Kupffer cells (Fig. 1). 
In BDL rats, the non-parenchymal staining was mainly visible around the bile 
ducts and blood vessels. Localization of LPS-dephosphorylating activity 
corresponded with known AP localization in the liver and was inhibited by the 
LBK-AP inhibitor levamisole (34). It should be noted that this activity of the 
“alkaline” enzyme is detectable at pH 7.4. When AP activity was measured with 
conventional substrates (β-glycerophosphate) in the same concentration as LPS 
(approx. 160 µM) and at pH 7.4, no dephosphorylating activity was found at all, 
indicating that at pH 7.4 LPS is a better substrate for the enzyme than β-
glycerophosphate. We showed in the present study that LBK-AP was able to 
dephosphorylate LPS from different bacterial species albeit to a different extend 
(Table 1). This may be related to differences in chemical structure between the 
various LPS molecules that cause differences in solubility and micelle formation or 
to differences in molecular weight, resulting in differences in molarities of 
solutions with the different LPS molecules. The molecular weight of wild-type LPS 
molecules can not be determined accurately (32). 
LPS circulating in the plasma can activate LPS-responsive cells via LPS-binding 
protein (LBP). The LBP-LPS complex will bind to the CD14r (35), which is present 
in the membrane of amongst others, monocytes and macrophages (14). Cells 
lacking the membrane-bound CD14r, like endothelial cells, can be activated via a 
soluble CD14r, present in serum (15). The LBP-LPS-CD14r complex associates with 
the toll-like receptor 4 (TLR4) and myeloid differentiation protein-2 (MD-2), 
resulting in intracellular signaling (1; 42). Epithelial cells that do not express 
membrane-bound CD14r and MD-2 can be activated by soluble forms of both 
CD14r and MD-2 (15; 20; 35). As AP may be involved in LPS detoxification, a 
distribution pattern of these LPS-capturing molecules similar to AP was 
anticipated. In rat kidney, liver and small intestine, but not in the blood vessel 
wall, the CD14r colocalised with the LPS-dephosphorylating activity while in rat 
lung, CD14r expression and AP activity were detected in close proximity to each 
other. The present results support and extend another study that showed a 
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colocalisation of AP and CD14 in intracellular compartments in neutrophils (10) 
and is in line with the newly proposed function of the enzyme.  
We also studied the influence of LPS on the AP expression in the body and focused 
on the hepatic expression of the LBK-AP isoenzyme. Although AP induction by 
LPS in cardiac muscle has already been reported (28), we show for the first time 
that LPS directly induces AP mRNA levels in normal as well as BDL3 rat livers. 
The increment in hepatic mRNA levels likely precedes the rise in serum AP levels 
in normal rats (Fig. 3A & B). Other reports support this hypothesis by showing a 
rise in serum AP levels at later timepoints after LPS injection (19). Rats that 
underwent bile duct ligation are characterized by enhanced serum AP levels 
(Fig.3A) already at t = 2 hr and increased basal mRNA levels for AP compared to 
normal rats (data not shown). The reason for this increased basal AP expression 
and increased serum levels after BDL remains to be elucidated, but again, this 
might be a physiological response to the increased LPS levels that occur after BDL 
(23; 41).  
The next question we addressed was whether AP is able to protect the liver, and 
especially hepatocytes, from LPS-induced damage. This was examined in vitro in 
rat liver slices and in vivo in rats using exogenous calf intestinal AP (ciAP). We 
used exogenous intestinal AP to mimic the induction of endogenous AP on the 
plasma membrane of hepatocytes. From literature, it is known that intestinal AP 
rapidly binds to the asialoglycoprotein receptor (ASGP-R) present on hepatocytes 
(7; 26). We confirmed this by using a known blocker of the ASGP-R, asialofetuin, 
and studied its effects on the clearance of highly purified ciAP (Fig. 4). In addition, 
binding and uptake of intestinal AP by hepatocytes was confirmed in vitro in rat 
liver slices by enzymehistochemical staining for AP activity.  
The effect of ciAP on hepatocytes in vitro was assessed in BDL3 liver slices which 
contain all the resident liver cell types in their original phenotype and context, 
including the cell-cell contacts. TNFα and NOx are rapidly produced by hepatic 
cells in response to LPS and addition of ciAP to the medium significantly reduced 
both NOx and TNFα levels (Fig. 5A & B).  
Also in vivo, ciAP exhibited a protective effect. Our hypothesis that intestinal AP 
protects hepatocytes against LPS-induced damage was supported by a glycogen 
PAS staining on the rat livers. We explored the glycogen content of hepatocytes as 
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a parameter because it is strikingly influenced by LPS (45). On the basis of this 
parameter, our study clearly showed a protective effect of intestinal AP in all rats 
examined after a challenge with LPS. 
In conclusion, our results demonstrate that liver AP dephosphorylates LPS (Fig. 1 
and Table 1) and that the LPS-dephosphorylating activity in various organs 
colocalises with or is closely located near the CD14r (Fig. 2). Furthermore, LPS 
rapidly induces mRNA for AP in hepatocytes while at the same time intestinal AP 
is rapidly transferred from the intestine to hepatocytes (Fig. 4). The combined AP 
induction and AP-transfer from the small intestine to the liver likely reflects a 
physiological response to LPS. It is well-known that dephosphorylated LPS is non-
toxic (6; 24; 46). The hepatoprotective effect of AP is supported by a reduction of 
TNFα and NOx levels in vitro (Fig. 5) and a decreased glycogenolysis (Fig. 6) in 
hepatocytes in vivo induced by intestinal AP. Our study may provide new 
perspectives for a possible treatment of Gramnegative sepsis and illustrates the 
relevance of cross-talk between the liver and the intestine. 
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Alkaline phosphatase (AP) is an endogenous enzyme which is present in multiple 
organs in the body. AP is supposed to play a crucial role in bone formation and in 
the dephosphorylation of various substrates. One of these substrates is LPS, as has 
been reported previously by us. Despite these essential physiological functions and 
natural presence in various crucial organs, data about the regulation of 
endogenous AP activity during disease are scarce. We have recently shown that 
LPS itself induces AP mRNA in rat livers, which may represent an adaptive 
response. 
Therefore, in the present study, we further pursued this observation and aimed to 
explore the regulation of AP levels in the liver. In vitro, we stimulated the liver cell 
lines HepG2 and McA-Rh7777 as well as liver slices with LPS. Furthermore, we 
examined mRNA levels in rat livers, 2 and 24 hr after injection of LPS in vivo.  
Upon incubation with LPS, HepG2 as well as McA-Rh7777 cells did not show any 
change in AP activity. In contrast, liver slices showed a maximal AP mRNA 
elevation of about 25-fold after 4 hr. In these slices, mRNA levels for TNFα, IL-1β 
and IL-6 were also elevated upon incubation with LPS.  In vivo, liver AP mRNA 
was already 7 times elevated 2 hr after LPS injection and had returned to normal 
levels 24 hr after an LPS challenge. 
As liver cell lines, in contrast to liver slices, do not show elevated AP mRNA levels 
upon LPS stimulation, we hypothesized the involvement of pro-inflammatory 
cytokines in the regulation of AP mRNA levels. Indeed, incubation of rat liver 
slices with LPS clearly supports this hypothesis. The potential influence of these 
cytokines on AP expression in the liver might open possibilities to modify 








Several diseases, like cholestasis and liver fibrosis, are characterized by elevated 
serum alkaline phosphatase (AP) levels like. Until now, little is known about the 
possible mechanism behind these elevated AP levels during disease, although 
recent studies have shown that this enzyme may be an important part of the 
defense system (1-5). Various compounds are known for their ability to increase 
AP activity, e.g. the bacterial product sodium butyrate (SB), retinoic acid (RA), 
dexamethasone and interleukin-6 (IL-6).  SB induces the germ-cell AP isoenzyme 
(6), RA induces the liver/bone/kidney (LBK) AP isoenzyme (7-11) and 
dexamethasone induces both the placental AP and intestinal isoenzyme (6; 8; 12). 
IL-6 induced AP activity in calf pulmonary aortic cells but it has not been 
established which AP isoenzyme was affected in this study (13). Besides these 
compounds, also bile acids like cholate, chenodeoxycholate and ursodeoxycholate 
are known to induce liver AP activity (14). So far, common players in these 
different pathways of enzyme-induction such as a transcription factors, have not 
been described in literature. 
AP is an endogenous enzyme capable of dephosphorylating and detoxifying 
lipopolysaccharide (LPS) (4; 15-17). Previous research by our group has revealed 
recently that LPS itself is also capable of elevating liver AP mRNA levels (1). LPS, a 
toxic constituent of the cell wall of Gramnegative bacteria, is a key player in 
diseases like sepsis and inflammatory bowel disease. Also, during liver fibrosis 
elevated systemic LPS levels have been reported. Increased LPS levels in the 
bloodstream may result in systemic inflammation and massive cytokine 
production of e.g. TNFα, IL-1β and IL-6. As AP is able to dephosphorylate LPS and 
as LPS itself is capable of elevating AP mRNA levels, it is of great interest to study 
the mechanism behind this phenomenon.  
Therefore, in this study, we examined the regulation of endogenous AP by LPS in 
rat liver and explored whether cytokines might play a role in this process. AP 
regulation was examined in rat liver slices which were incubated with LPS. In 
these slices, also the levels of inflammatory cytokines like TNFα, IL-1β and IL-6 in 
response to LPS were studied. Subsequently, we checked whether cytokines might 
play a role in regulating AP activity in hepatocytes. Therefore, HepG2 and McA-
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Rh7777 cells were incubated with LPS and the AP expression was analyzed. 
Finally, effects of LPS on liver AP were studied in vivo in rats that received LPS 
intravenously. The present study indicates that the process of elevation of AP in 
hepatocytes by LPS is the result of an indirect process, which may be mediated by 
cytokines.  
 
Materials & Methods 
Animals 
Male Wistar rats (± 280-320 gram, Harlan, Zeist) were housed under standard 
laboratory conditions with a regular light/dark cycle with free access to laboratory 
chow and acidified water. All animal experiments were approved by the Local 
Committees on Animal Experimentation (DEC) of the University of Groningen.  
 
Enzymehistochemistry 
LPS-dephosphorylating enzyme activity in rat livers was examined by incubating 5 
µm cryostat sections with LPS (Escherichia Coli, serotype O55:B5 from Sigma) as a 
substrate as described previously (1). When the substrate LPS was omitted from 
the incubation medium, during histochemical staining, the reaction product was 
completely absent, indicating that this method detects enzyme activity. 
 
In vitro slice experiments 
For in vitro experiments, livers of male Wistar rats were used. Rats were sacrificed 
under O2/N2O/forene (Isoflurane, Abbott Laboratories Ltd, Queensborough, Kent, 
UK) anaesthesia and the liver was taken out and stored in University of Wisconsin 
organ preservation solution (UW) until slice preparation.  
Precision-cut liver slices were prepared from 8 mm liver cores using a Krumdieck 
tissue slicer (Alabama R&D, Alabama, USA), as described previously (18). The 
Krumdieck tissue slicer was cooled during the preparation of the tissue slices and 
was filled with ice-cold, oxygenated Krebs-Henseleit buffer. Slices were stored in 
UW on ice until incubation. 
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Slices were incubated in 6-well culture plates obtained from Greiner (Alphen a/d 
Rijn, The Netherlands). One slice per well was incubated in 3.2 ml Williams’ 
medium E (WME) supplemented with Glutamax I (Gibco BRL, Paisley, Scotland) 
and gentamicin, 50 mg/ml (Gibco BRL).  
Rat liver slices were incubated with or without 10 µg/ml LPS (Escherichia Coli, 
Serotype O55:B5, Sigma) during time intervals of 0, 2, 4, 6, 8, 16 and 24 hr. At each 
timepoint, three slices of each condition were pooled and stored at -80°C until 
RNA isolation. Medium of the slices was stored at -20°C until NOx measurement or 
at -80°C until TNFα measurement. 
 
Quantification of IL-1β, TNFα, IL-6 and AP mRNA levels in slices by real-time 
PCR 
RNA was isolated from liver slices using the QIAGEN RNeasy Mini Kit. After 
checking the quality of the RNA on a 2% agarose gel, the RNA concentration was 
determined by the Ribogreen assay. The Reverse Transcription System from 
Promega was used to convert 1.6 µg of RNA into complementary DNA (cDNA). In 
the reversed transcription reaction oligo-dT primers were used. The amplification 
of the cDNA was followed by real-time PCR using the following primers: GAPDH  
(forward primer 5’-CCATCACCATCTTCCAGGAG-3’; reverse 5’-
CCTGCTTCACCACCTTCT-TG-3’), AP (forward primer 5’-
GCAAGGACATCGCCTATCAG-3’; reverse 5’-AGTTCAGTGCGGTTCCAGAC-3’), 
IL-6 (forward primer 5’-CCGGAGAGGAGACTTCACAG-3’; reverse 5’-
ACAGTGCATCATCGCTGTTC-3’), TNFα (forward primer 5’-
ATGTGGAACTGGCAGAGGAG-3’ ; reverse 5’-GGCCATGGAACTGATGAGAG-
3’) and Il-1β (forward primer 5’-AGGCAGTGTCACTCATTGTG-3’; reverse 5’- 
GGAGAGCTTTCAGCTCACAT-3’). Real-time quantification was performed using 
the SYBR Green PCR Master Mix from Applied Biosystems. GAPDH was used as a 
housekeeping gene and levels of other genes were normalized to these GAPDH 
levels. Relative quantification was calculated using the comparative threshold 
cycle (CT) method as described earlier (1). 
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In vivo experiments with rats 
The rats were divided into two groups (n=9 per group). Control animals received 
saline i.v. at t = 0 whereas others received 1 mg/kg LPS i.v. at t = 0. In both groups, 
4 rats were killed after 2 hr and 5 rats after 24 hr. The rats were sacrificed under 
O2/N2O/forene (Isoflurane, Abbott Laboratories Ltd, Queensborough, Kent, UK) 
anaesthesia. Livers were taken out, partly frozen in isopentane and stored at –80°C 
for histochemical staining. Blood was collected to measure liver enzymes.  
 
Cell culture 
For in vitro cell culture experiments, 2 hepatoma cell lines were used: the human 
HepG2 and the rat McA-Rh7777 cell line. The cultured human hepatoma cell line 
HepG2 was kindly provided by the Department of Gastroenterology and 
Hepatology (University Medical Centre Groningen (UMCG), The Netherlands) 
and the McA-Rh7777 was a gift from Dr. A. Grefhorst (Department of Pediatrics, 
UMCG). The HepG2 cells were cultured in T75 cm2 flaks (Corning, NY, USA) in 
DMEM (BioWhitakker, Walkersville, MD, USA) supplemented with L-glutamine, 
(final conc. 2 mM), penicillin (final conc. 100 U/ml), streptomycin (final conc. 100 
µg/ml) and 10% fetal calf serum (FCS). McA-Rh7777 cells were cultured in T75 cm2 
flasks in DMEM supplemented with L-glutamine, (final conc. 2 mM), penicillin 
(final conc. 100 U/ml), streptomycin (final conc. 100 µg/ml) 5% fetal calf serum 
(FCS) and 20% horse serum (HS). Both cell lines were incubated at 37° C with 5% 
CO2. 
 
Measurement of alkaline phosphatase activity 
The AP activity was assayed at pH 9.8 with para-nitro-phenylphosphate (pNPP, 
Sigma) as a substrate according to standard procedures as described previously 
(15). 
 
Serum alkaline phosphatase activity 
Serum AP activity was measured according to routine procedures at the University 
Medical Centre Groningen (UMCG). 




Data are expressed as the mean ± the SD. The data were subjected to an unpaired 
two-tailed Student’s t-test, assuming similar variances. Differences were 
considered significant at p< 0.05. 
 
Results 
Serum AP activity upon LPS administration in rats 
 We first examined the serum AP activity in rats after LPS administration. It 
is known from literature that elevated systemic LPS levels are often accompanied 
by rises in serum AP levels (19-22). In the present study, LPS administration did 
not alter serum AP levels in normal rats, either after 2 or 24 hr.  In contrast, in a 
previous study we observed a significant rise in serum AP levels in bile duct 
ligated (BDL) rats already after 2 hr (1). This is likely due to the fact that BDL-rats 
generally exhibit an increased sensitivity for LPS (23; 24). 
 
Induction of enzyme-activity and mRNA levels of AP by LPS in rat liver slices 
Subsequently, in vitro experiments with liver slices were performed. Upon 
stimulation with LPS, enzyme-activity of AP and AP mRNA levels were 
determined.  
            
A B 
 
Figure 1: AP activity in cryostat sections of rat liver slices incubated for 24 hr with (A) and 
without (B) 10 µg/ml LPS. The dark staining indicates the locations were dephosphorylation 
occurs. Magnification: 400*.  
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It can be seen in figure 1A that 24 hr stimulation of liver slices with LPS results in a 
clear induction of AP activity. The activity is reflected by the dark staining around 
the hepatocytes. In control slices incubated in vehicle without LPS, no LPS- 
dephosphorylating activity was found (Fig. 1B). 
 
After detecting the enzyme-activity, we also measured the AP mRNA levels upon 
incubation with LPS after 2, 4, 6, 8, 16 and 24 hours of incubation. The control slices 
that were incubated without LPS, displayed rather constant AP mRNA levels at 
the different timepoints, whereas the slices incubated with LPS showed a clear 
increase in AP mRNA levels. A maximum incubation of around 40-fold compared 
to t = 0 was shown after 6 hr incubation with LPS (Fig. 2 upper left).  
AP

















































































Figure 2: AP, IL-1β, TNFα and IL-6 mRNA expression in rat liver slices at various 
timepoints after LPS stimulation. Representative graphs of 1 out of 3 independently 
performed experiments are shown. Each data point represents the response of 3 different 
slices, which were pooled together for analysis. 
 
At incubation times longer then 6 hr, the AP mRNA levels gradually decreased 
again, but remained significantly elevated until the end of the incubation period.  
Besides AP mRNA levels, we also examined the mRNA levels of the inflammatory 
cytokines TNFα, IL-1β and IL-6, which are known to be produced by macrophages 
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upon LPS stimulation. All inflammatory cytokines followed almost the same 
induction pattern as the AP mRNA levels. The TNFα mRNA level rose rapidly to a 
very high level, reaching a maximal induction of about 1000-fold already at t = 4 hr 
compared to t = 0 hr (Fig. 2, bottom left). Also the Il-1β mRNA levels showed a 
major induction after LPS-stimulation: mRNA levels rose to a maximum of 100-
fold induction at t = 4 hr (Fig. 2, upper right). Assessment of IL-6 mRNA levels also 
revealed a clear increase in mRNA levels. IL-6 levels displayed a maximum 
induction of approximately 50-fold at t = 4 and 6 hr (Fig 2, bottom right). 
 
AP activity upon LPS stimulation in HepG2 and McA-Rh7777 cell lines  
After showing that in rat liver slices AP mRNA levels (Fig. 2) and AP enzyme 
activity (Fig. 1) are clearly upregulated in parenchymal cells after LPS-stimulation, 
we wanted to examine whether this induction resulted from a direct or indirect 
effect of LPS on hepatocytes. Therefore, two liver hepatoma cell lines were 
incubated with LPS. As a positive control for AP-induction in cell lines, we used 
butyrate, a known inducer of AP-activity in HepG2 cells (25). After 48 hr 
incubation with butyrate, a concentration dependent increase of AP activity was 
found in HepG2 cells with a maximum induction of about threefold at 2 mM 














































Figure 3: AP activity in HepG2 (A) and McA-Rh7777 cells (B) stimulated with sodium 
butyrate. The AP activity is displayed as units per 109 cells. Each bar represents the mean ± 
SD of 11 (HepG2) and 3 (McA-Rh7777) experiments. * = p<0.005. 
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The rat hepatoma cell line McA-Rh7777, also showed a clear induction of AP 
activity, which was two times higher compared to that in the HepG2 cells (Fig. 3B 
versus 3A). AP activity in McA-Rh7777 cells was almost 25 times higher in cells 
incubated with 5.0 mM butyrate compared to control cells (p<0.005). In contrast, 
after incubation with LPS, no induction of AP activity was detected in neither 
HepG2 nor McA-Rh7777 cells (data not shown). 
 
AP activity in rat livers after LPS administration in vivo 
After examination of AP induction by LPS in liver slices and hepatoma cell lines, 
we studied AP induction in vivo in rat livers after intravenous injection of LPS. Rats 
were sacrificed either 2 or 24 hr after the LPS injection. A clear induction of AP 
mRNA levels was seen 2 hr after LPS injection, which is illustrated in figure 4, 
when LPS-treated rats were compared to untreated control rats. All livers were 
also examined for AP activity by enzymehistochemical methods, which use LPS as 
well as the traditional AP substrate, β-glycerophosphate, as a substrate. 
Surprisingly no difference in enzyme activity could be seen between LPS-treated 
and untreated control rats (data not shown).  
24 hr after LPS administration, no significant difference in AP mRNA levels was 
seen when LPS-treated rats and control rats, that only received saline, were 
compared. Also at the protein level, as qualitatively examined by 
enzymehistochemistry, we did not observe differences in enzyme activity. Thus, 
after an increase upon LPS administration, AP mRNA levels had returned to basal 






Figure 4: AP mRNA levels in 
rat livers at 2 and 24 hr after 
administration of 1 mg/kg LPS. 

























Lipopolysaccharide (LPS) is a component of the outer cell wall of Gramnegative 
bacteria and is highly toxic. LPS is the causative agent of sepsis, a systemic 
inflammatory process, and an important player in other diseases and conditions 
like inflammatory bowel disease, fibrosis, meningococcemia, burns and 
rheumatoid arthritis. In normal conditions, LPS is removed from the circulation by 
the liver. Predominantly macrophages within this organ and to a minor extent 
hepatocytes remove the LPS from the bloodstream (26). Diseases affecting the liver 
or the integrity of the intestinal wall both can lead to elevated LPS levels in serum. 
This is either due to a decreased capacity of the liver to remove LPS from the 
circulation or to LPS leakage from the intestinal lumen to the blood. Elevated LPS 
levels subsequently activate macrophages which produce high amounts of 
cytokines, reactive oxygen species and other inflammatory mediators. In turn, 
these cytokines may lead to enhanced vascular permeability in the intestinal wall 
(27; 28), and thus to further elevation of LPS levels. This might result in systemic 
inflammatory response syndrome (SIRS). 
In 1997, we discovered that the enzyme alkaline phosphatase (AP) is capable of 
dephosphorylating LPS, thereby detoxifying this bacterial product (15; 16). 
Moreover, pre-administration of exogenous AP was found to have beneficial 
effects in different sepsis models in mice, pigs and sheep (2-5).  
Although the enzyme is abundantly present in the body and although it is known 
that in many diseases AP levels in serum and tissue deviate from their normal 
values, little is known about the regulatory mechanisms that control endogenous 
AP expression. It is also unknown whether there is a relation between the LPS 
levels and the LPS-detoxifying enzyme AP. In many diseases in which LPS plays 
an important role, also the AP levels are abnormal (19; 21). In fact, serum AP levels 
are used as a marker for liver diseases.  
We recently found that LPS is capable of inducing AP mRNA levels in the rat liver 
(1). In addition, colocalisation of AP expression and CD14, a component of the 
LPS-signaling complex, was also found. Together these data suggest that there 
might be a close relation between AP and LPS. Unraveling the interaction between 
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the LPS-dephosphorylating activity and LPS levels may provide insight into this 
process and lead to new strategies to treat LPS-mediated diseases. 
We tried to examine this in vitro, using the human hepatoma cell line HepG2 and 
the rat hepatoma cell line McA-Rh7777. Cells were incubated with LPS and sodium 
butyrate. The latter has been reported to stimulate AP activity in HepG2 cells (25) 
and this bacterial product may serve as a positive control to show the capacity of 
the cells to enhance their AP activity. Butyrate indeed increased the AP activity of 
HepG2 cells and also that of McA-Rh7777 cells strongly. However, incubation of 
these cell lines with LPS did not result in any elevation of AP activity. An 
explanation for this may be that butyrate stimulates another isoenzyme of AP than 
LPS or that both products act via different pathways. AP can occur in the form of 
four isoenzymes; placental, intestinal, germ-cell (also called placental-like AP) and 
liver/bone/kidney AP of which the first three are tissue-specific isoenzymes. In 
literature, several studies report that butyrate stimulates the germ-cell isotype of 
AP (6; 29). We found in our in vivo experiments presented here and in a previous 
study (1) that LPS stimulates the liver/bone/kidney isoform of AP in the rat liver. 
Whether LPS is capable of inducing other isoenzymes of AP has not been 
examined yet. Another explanation might be that additional factors, for instance 
cytokines produced by other cells, are needed for the elevation of AP activity by 
LPS. In vivo, systemic administration of LPS activates Kupffer cells in the liver that 
will produce inflammatory cytokines like TNFα and IL-1β. However, in hepatoma 
cell lines, no cytokine-producing cells are present. This prompted us to the idea to 
use liver slices. In slices, all resident liver cells are present in their normal 
environment. Upon LPS stimulation, we found elevated mRNA levels of the pro-
inflammatory genes TNFα, IL-1β and IL-6 (Fig. 2). In contrast to the cell lines, we 
now found a clear increase of AP activity in hepatocytes (Fig. 1) and a concomitant 
elevation of AP mRNA (Fig. 2). These results support the hypothesis that cytokines 
may play a role in the regulation of AP activity. We subsequently tried to induce 
AP mRNA in the hepatoma cell lines using cytokines. Cytokine-rich medium from 
LPS-stimulated macrophages and cytokines alone were added to the cell lines, but 
so far none of these experiments resulted in an induction of AP activity (data not 
shown). Apparently, a complex mixture or unknown cytokines are required to 
induce this response in hepatocytes. 
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As AP is able to dephosphorylate and thereby detoxify LPS, the elevated AP levels 
both at the mRNA and the enzyme level, may represent a physiologic response to 
LPS. The AP elevations seen during liver diseases therefore may reflect a host 
defense response against gut-derived bacterial products rather than a signal of 
cellular damage. This idea is supported by the fact that enhanced activity is found 
along the hepatocyte plasma membrane in slices which occurs concomitantly with 
elevated mRNA levels for this enzyme. Whether this increase in AP activity is the 
result from de novo enzyme synthesis or re-allocation of AP from intra-cellular 
pools to the cell membrane remains to be elucidated, but the enhanced mRNA 
levels at least indicate de novo synthesis. 
From the present experimental data, we infer that more than one cell type is 
involved in the mechanism of AP regulation by LPS in hepatocytes. In the future, 
additional experiments with the various cytokines in slices, comprising all liver cell 
types, and further in vivo experiments might elucidate the exact mechanism of AP 
regulation.  
In conclusion, our studies indicate that AP activity in hepatocytes is enhanced by 
LPS and that cytokines from non-parenchymal cells are involved in the regulation 
of AP activity. This hypothesis is supported by the fact that slices, which are 
capable of cytokine production, displayed increased AP activity upon incubation 
with LPS and hepatoma cell lines did not. In addition, in vivo experiments also 
demonstrated an elevation of AP mRNA in the liver and in serum, very shortly 
after LPS administration. More detailed knowledge on the particular mechanism of 
AP regulation, might allow manipulation of AP expression. Since AP is an LPS-
detoxifying enzyme, modulation of its expression may serve as a new strategy to 
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Sepsis is induced by an excessive response of the immune system to micro-
organisms or their products. Lipopolysaccharide (LPS) is the pivotal initiator of 
Gramnegative sepsis and intervening with this initiator therefore seems rational. If 
LPS could be efficiently detoxified before reaching its receptors, inflammatory 
processes would no longer be initiated.  
In the present study, we confirm earlier studies, showing that alkaline phosphatase 
(AP) is able to dephosphorylate LPS in vitro, using a new fluorescent method to 
detect LPS. This new method uses pentamidine, a compound that fluoresces upon 
binding to diphosphoryl but not monophosphoryl lipid A.   
Having established the disappearance of LPS from samples by AP in vitro, we 
tested two isoenzymes in vivo, calf intestinal and placental AP. Despite their 
difference in plasma half-life, both ciAP and plAP strongly reduced TNFα plasma 
levels as compared with control mice in the LPS/galactosamine model. Also the 
number of pulmonary inflammatory cells was clearly attenuated in AP-treated 
mice.  
This study provides a new method to detect LPS and shows a significant 
therapeutic effect of exogenous AP in vivo. This novel approach, based on the 
detoxification of LPS itself, may provide new opportunities to remove this 
deleterious bacterial product from biological fluids.  
 
 




Sepsis or systemic inflammatory response syndrome (SIRS) is a complex 
pathological response against microbial particles, involving many cells and an 
array of mediators (1). In Gramnegative sepsis, lipopolysaccharide (LPS) or 
endotoxin, a constituent of the outer membrane of Gramnegative bacteria, is the 
major initiator of this response (2).  
LPS is a powerful activator of the innate immune system and interacts with 
macrophages, monocytes, neutrophils and endothelial cells, which results in the 
rapid release of many pro- and anti-inflammatory mediators such as tumour 
necrosis factor alpha (TNFα), nitric oxide (NO), interleukin-1β (IL-1β), IL-6 and IL-
8 (3-5). TNFα, the major cytokine in the early onset of sepsis, stimulates cells in an 
autocrine, paracrine and endocrine manner to produce other cytokines (6). LPS 
also activates the blood coagulation cascade and the complement system, which 
may lead to disseminated intravascular coagulation (DIC) (7). Simultaneously, a 
marked lowering of the blood pressure is induced by vasoactive mediators such as 
NO that may ultimately lead to multiple organ failure (MOF) and death (4; 8). 
Cytokines and other mediators exert multiple synergistic and sometimes opposing 
effects that may be both detrimental and beneficial to the patient, which hampers 
the design of an efficient therapy. This problem was encountered when anti-
cytokine antibodies such as anti-TNFα were used (9; 10). 
An alternative strategy may be to aim at the neutralization or detoxification of the 
LPS molecule itself. The molecular structure of LPS plays a major role in the 
induction of biological responses. LPS consists of a hydrophilic polysaccharide 
chain, containing many heptoses and anionic KDO (2-keto-3-deoxy-octonate) 
sugars. These are covalently linked to a hydrophobic lipid portion, lipid A, which 
anchors the LPS molecule into the bacterial outer membrane. The lipid A part is 
highly conserved among bioactive LPS molecules and in general contains two core 
phosphate groups (11). 
These two phosphate groups are of great importance for the biological activity of 
LPS (12; 13) and it is thought that they, together with the acyl chains, are 
responsible for the binding of LPS to myeloid differentiation-2-protein (MD-2), 
which is part of the LPS-signaling complex MD-2/TLR4 (14; 15). The phosphate 
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groups also strongly influence the conformation of the lipid A structure and 
thereby its ability to elicit the release of inflammatory mediators (16). Many studies 
have shown that phosphate-free synthetic lipid A 503 and monophosphoryl lipid A 
(with one phosphate group removed) are biologically completely inactive (17). 
Monophosphoryl lipid A was even found to antagonize LPS-induced responses 
(18).  
We have previously demonstrated a role for alkaline phosphatase (AP) in 
dephosphorylating LPS. We observed significant LPS dephosphorylating activity 
by AP at physiological pH levels (19; 20). From these findings we postulated that 
AP may be able to protect experimental animals from the deleterious effects of 
LPS.  
In this study, we first studied dephosphorylation of LPS by AP using a new 
method to measure LPS. Subsequently, we examined whether AP exerts protective 
effects in vivo after an LPS-challenge. Placental alkaline phosphatase (plAP) and 
calf intestinal alkaline phosphatase (ciAP), which differ considerably with respect 
to their plasma half-life, were administered to mice simultaneously with an LPS-
challenge. The effects on two crucial parameters for SIRS were examined: serum 
TNFα levels and leukocyte infiltration in different tissues. The present results 
support the idea that AP detoxifies LPS through dephosphorylation in vivo. This 
may provide a physiological role for AP and at the same time afford a new way to 
inactivate LPS in serum. 
 
Materials & Methods 
LPS  
For in vivo experiments, wild-type E.coli O55:B5 LPS (Sigma, St. Louis, USA) was 
dissolved in saline. Stock solutions (1 mg/ml) were stored at -20°C. For the 
pentamidine assay, LPS (Re chemotype) and lipid A of Salmonella Minnesota R595 
(List biological laboratories, Campbell, CA, USA) dissolved in water were used. 
Both the LPS and lipid A were dissolved according to standard procedure. Briefly, 
water was added to the vials and the vials were subsequently vortexed at 
approximately 1200 rpm. This resulted in a clear LPS solution and a somewhat 
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opalescent solution of lipid A. The LPS of the Re-chemotype contains only 
phosphate groups in the lipid A moiety, in contrast to wild-type LPS that may 




Placental alkaline phosphatase (plAP) 
plAP obtained from Sigma (Sigma, St. Louis, USA) was used for in vitro 
experiments (specific activity 14 U/mg protein). For in vivo experiments, this plAP 
was further purified. Briefly, hplAP was dissolved in 0.1% deoxycholic acid (DOC) 
to solubilise possible micellular structures and to remove lipid contaminations. 
Subsequently, the solution was ultrafiltrated using a Vivaspin filter with a cut-off 
of 100 kDa and the DOC portion was removed. The AP preparation (specific 
activity: 21 U/mg protein) was dissolved in PBS containing 1 mM MgCl2 and 0.1 
mM ZnCl2 and sealed in ampulles (final concentration 100 U/ml). The plAP dosage 
administered to the Balb/c mice (1.5 U) contained 71 µg protein. 
 
Calf intestinal alkaline phosphatase (ciAP) 
ciAP was obtained from AM-Pharma, Bunnik, The Netherlands. This batch had an 
activity of 38,970 U/ml and a protein content of 15.4 mg/ml with a purity of >>90% 
as determined with FPLC techniques. The dosage administered to Balb/c mice 
(1.5U) contained 0.60 µg protein. plAP and ciAP were routinely checked using 
SDS-PAGE gel and immunoblotting methods. 
 
Alkaline phosphatase (AP) assay 
AP activities were assayed at pH 9.8 with para-nitro-phenylphosphate (pNPP, 
Sigma) as a substrate according to standard procedures as described previously 
(19). Serum samples of 5 µl were used for the measurement of AP activity. 




The amount of LPS in samples was determined by the pentamidine assay. 100 µl of 
each sample was put in a white 96-wells plate (Costar, cat. no. 3912) and the 
fluorescence was first measured without pentamidine to correct for auto-
fluorescence of the samples. The fluorescence was measured at an excitation 
wavelength of 275 nm and an emission wavelength of 425 nm, using a Thermomax 
microplate reader (Molecular Devices, California, USA). Subsequently, 100 µl of 0.1 
mM pentamidine solution (ICN Biomedicals Inc., Ohio, USA) was added to each 
well and the fluorescence was measured again. A calibration curve of LPS R595 of 
S.minnesota (List) was prepared in 0.05 M ammediolbuffer of pH 7.8. 
 
In vivo experiments 
Balb/c mice (male, 20-22 gram) were obtained from Harlan, Zeist, The Netherlands. 
At t=0 hour the mice received 800 mg/kg galactosamine-D (GalN-D, Sigma) to 
enhance the sensitivity of mice for LPS. Simultaneously, 0.75 mg/kg of E.coli LPS 
serotype O55:B5 (Sigma) was administered intraperitoneally (i.p.). The mice were 
randomly divided in two groups (n=7 per group). One group received 1.5 U hplAP 
intravenously (i.v.) immediately after the LPS and GalN-D injections. Whereas the 
second group received 0.2 ml saline (=vehicle) i.v. after LPS and GalN-D (i.p.) 
administration. An additional group of control animals received only GalN-D i.p. 
and saline i.v.   
For the TNFα assay, blood samples were collected (in vials containing heparin) at 
t=2 hr after injection. 24 hr after injection the mice were sacrificed, blood samples 
were taken, and tissue samples from the liver, kidney, lungs, spleen and parts of 
intestine were frozen using isopentane and stored at -80°C until histochemical 
analysis. Timepoints of sampling and volumes of blood samples were carefully 
chosen and minimized to avoid influencing the condition of the mice. Blood 
samples were also analyzed for serum AP activity. 
In a second set of experiments with ciAP, mice were randomly divided in two 
groups (n=6 per group); one group was treated with ciAP (1.5 U, i.v.) immediately 
after the LPS (0.75 mg/kg, i.p.) and GalN-D (800 mg/kg, i.p.) injections, the second 
group received saline i.v. after LPS and GalN-D administration. For analysis of 
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serum AP, blood samples were taken at t=1 min after injection, since this 
isoenzyme of AP has a short half-life (21). 2 hours post-injection, the mice were 
sacrificed and organs were handled as described above for the experiments with 
plAP. Blood was collected for the measurement of TNFα-levels. 
 
TNFα assay  
TNFα production was determined using a TNFα-ELISA kit (BD PharMingen, San 
Diego, USA). ELISA plates (Corning, NY, USA) were coated overnight with a 
monoclonal anti-TNFα antibody, diluted 1/200 (PharMingen) in Na2HPO4 buffer 
0.1 M, pH 6.0. The plates were washed and blocked with 0.01 M PBS (pH 7.4) + 1% 
BSA (Sigma, St. Louis, USA). After washing, 100 µl of mouse plasma (1:5 diluted) 
was added and the plates were shaken for two hours at room temperature. Serial 
dilutions of mouse TNFα (PharMingen) were used as a quantitative standard. 
After washing, the second antibody (biotinylated rabbit anti-mouse-TNFα, 
PharMingen) was added and incubated for one hour followed by incubation with 
streptavidine-horseradish peroxidase (Amersham) and its substrate O-
phenylenediamine dichloride (Sigma). The reaction was stopped with (100 µl) 1 M 
H2SO4 and the absorbance was measured at 490 nm in a microplate reader. 
 
Histochemical analysis 
Detection of reactive oxygen species (ROS) producing cells 
Endogenous production of reactive oxygen species-production (ROS: superoxide 
anion and H2O2) was studied in various organs. Cryostat sections (4µm) were 
stained with 3,3-diamino benzidine (DAB) according to Poelstra et al (22). Briefly, 
sections were washed in 0.1 N Tris-HCL buffer (pH 7.6) and subsequently 
incubated in 0.1 N Tris-HCL containing 0.5 mg/ml DAB for 30 min at 60°C. In situ 
ROS-production by cells that express myeloperoxidase activity (MPO) will cause 
oxidation and subsequent polymerisation of DAB. Incubation of sections with 
catalase and superoxide dismutase confirmed involvement of O2- and H2O2.  




Data are expressed as the mean ± the SD. When two groups were compared, the 
data were subjected to an unpaired two-tailed Student’s t-test, assuming similar 




In this study, we first set up a method that allows discrimination between mono- 
and diphosphoryl lipid A. We used the observation of David et al that pentamidine 
binds to diphosphorylated LPS and emits a fluorescent signal at 425 nm (23), 
whereas no signal is emitted with monophosphoryl lipid A. 
Experiments showed a linear correlation between LPS concentrations and the 
fluorescence intensity. We used the Re chemotype of LPS (R595 S.minnesota). This 
truncated form consists of diphosphoryl lipid A plus a very short sugar chain 
without any additional Pi-groups. As can be seen in figure 1A, a strong linear 
correlation was found (R2=0.9996). This fluorescence signal was virtually absent 
when monophosphoryl lipid A of the same chemotype (S.minnesota R595) was 
used (Fig. 1B). We also incubated LPS at pH≈1 overnight to destroy its tertiary 
structure and to chemically remove at least one phosphate group from the lipid A 
moiety (24). Before the measurements, the pH was re-adjusted to pH 7.8. As 
illustrated in figure 1C, a very low signal was seen, indicating that an intact 
structure is required to induce fluorescence. Finally, we explored the specificity of 
the signal by adding serum to the LPS samples (0.1%). In the presence of serum, a 
linear correlation between LPS concentrations and fluorescence intensity was still 
notable, although some quenching was observed (Fig. 1D versus fig. 1A). 
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Figure 1: Detection of LPS by pentamidine. A Correlation between the LPS-concentration 
(R595, S.minnesota) and the Fluorescence Intensity at 425 nm (n=7). B Correlation between 
the monophosphoryl lipid A concentration and the Fluorescence Intensity (n=3) C 
Fluorescence of LPS Re 595 after overnight incubation at pH 1 (n=2). D Correlation between 
the LPS concentration and the Fluorescence Intensity in the presence of 0.1% serum (n=4). 
Values are expressed as means ± SD. 
 
Subsequently, we studied whether AP affected the measurements at 425 nm. 
Therefore, LPS was incubated with 0.5, 1.0 and 2.0 units of plAP for 2 hr at 37°C 
and 4°C at pH 7.8. Assays (final LPS conc. was 10 µg/ml) clearly showed a dose-
dependent decrease in LPS concentration at 37°C induced by plAP (Fig. 2). This 
effect was nearly absent at 4°C.  





















































Figure 2: LPS detection after incubation with plAP. LPS of S.minnesota Re595, at a 
concentration of 20 µg/ml, was incubated for 2 hr at 37°C and 4°C with 0.5, 1.0 and 2.0 units 
plAP at pH 7.8. The final LPS concentration in the samples at the time of measurement was 
10 µg/ml. Note the dose-dependent decrease of the LPS concentration at increasing plAP 
concentrations at 37°C whereas at 4°C nearly no decrease was measurable. Values represent 
means of six experiments ± SD. ** denotes significant differences between the incubations at 
37°C and 4°C (** = p<0.0005). * denotes significant difference between the incubation with 
and without plAP at 4°C (* = p<0.05).  
 
To investigate whether this AP-induced decline in LPS concentrations can also be 
induced by binding of LPS to proteins, the assay was also performed with HSA. 
Equimolar concentrations of HSA instead of plAP induced a similar decrease in 
LPS concentration compared to plAP (Fig. 3A). This may be explained by the fact 
that HSA is also able to bind LPS (25). Surprisingly, the HSA-induced decrease in 
LPS concentration also appeared to be temperature dependent. To our knowledge, 
this is the first time that this effect of HSA was observed. 
In addition, we also examined the influence of 0.1% serum on the effect of plAP 
and HSA. Serum contains many components that bind to the fatty acid binding site 
of HSA or that bind LPS and these components might therefore serve as 
competitive agonists. Our data show that serum components significantly reduced 
the effect of both plAP (p<0.01) and HSA (p<0.00001) on LPS levels as measured by 
pentamidine (Fig. 3B). Serum components attenuated the effect of HSA on LPS 
levels more than the effect of plAP on LPS levels. This difference between plAP 
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and HSA was significant at p<0.05. We also tested higher serum concentrations (up 









































































Figure 3: Influence of HSA and serum on the pentamidine assay. A Pentamidine assay at 37 
and 4°C with LPS plus HSA (equimolar to plAP). Assays were performed at 37 and 4°C. ** 
denotes significance between 37°C and 4°C (** = p<0.005). B Pentamidine assay at 37°C with 
plAP and HSA in equimolar concentrations with and without 0.1% serum. Incubations with 
LPS alone were set to 100%. Values represent means of six experiments ± SD (* = p<0.01 and 
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We conclude that both plAP and HSA bind to LPS and that this interaction is 
temperature dependent. The binding of LPS to plAP seems to have a higher 
affinity than the binding to HSA, because the latter is more strongly affected by 
competition with serum components. It is also shown that a strong reduction in 
serum LPS levels can be achieved by plAP (p<0.0005). 
 
Finally, we examined the specificity of the binding of LPS to plAP. In case of 
specific binding, it should be possible to inhibit this binding with other plAP 
substrates. We chose to use the well-known substrate for the enzyme AP, β-
glycerophosphate, as a competitor for LPS (26).  
 
β-glycerophosphate inhibits binding of LPS to AP






























Figure 4: Effect of the competitive substrate β-glycerophosphate on the binding of LPS to 
plAP. Assays were performed at 37°C. The LPS concentration in all incubations was 20 
µg/ml (final concentration at time of measurement 10 µg/ml). Incubation time was set at 10 
minutes. Values are expressed as average of at least 3 separate experiments. * = p<0.05 (10 
mM β-glycerophosphate versus no competitive substrate). 
 
Two concentrations of β-glycerophosphate were used, 5 and 10 mM, and as can be 
seen in figure 4, both concentrations inhibited the binding of LPS to plAP. 10 mM 
attenuated the effect of plAP more than 5 mM and the difference in LPS 
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concentrations with 10 mM competitive substrate was significant at AP 
concentrations of 10 U and higher (p<0.05).  
 
In vivo experiments with plAP 
As the enzyme AP is able to dephosphorylate LPS, shown in previous studies by 
the release of inorganic phosphate histochemically and biochemically (19; 20) and 
in the present study by the pentamidine assay in which plAP caused a decrease in 
the LPS signal (Fig. 2), we tested the effect of AP in vivo. To determine the effects of 
plAP on LPS-induced TNFα responses in an experimental model for sepsis, 1.5 U 
of plAP (71 µg protein) was administered to the mice immediately after an LPS + 
GalN-D injection. Assuming a plasma volume of 2 ml in mice, this would lead to a 
plasma level of 750 U/l. To avoid direct binding to LPS, plAP was administered 
intravenously and LPS intraperitoneally. In plAP-treated and untreated mice, 
serum AP levels were examined and blood samples were assayed for TNFα. In 
addition, the influx of inflammatory cells in various organs was examined. 
 
AP activity in serum  
The total AP activity in serum samples obtained at different timepoints was 
assayed. Serum AP activity of the mice that received plAP was markedly 
enhanced; 2 hours post-injection a 10-fold increase of the normal serum AP level 
(up to 700 U/L) was found (see Fig. 5). The AP activity in serum of mice that did 
not receive plAP remained at baseline levels throughout the experiment 
(approximately 70 U/L). The serum AP activity of the mice that received plAP was 
still significantly (p<0.0001) elevated at t=24 hours (Fig. 5). 

























Figure 5: Alkaline phosphatase in serum of Balb/c mice at different timepoints after injection 
of plAP. The mice (n=7 per group) received either LPS (i.p.) co-administered with D-
galactosamine (GalN-D), with or without 1.5 U plAP (i.v.). Control animals received GalN-D 
i.p. and saline i.v. The mice that received a plAP injection at t=0 show clearly elevated serum 
AP levels up to 24 hours post-injection. The results are expressed as the mean value ± S.D. * 
denotes significant difference between the plAP-treated and untreated group (p<0.0001). 
 
TNFα responses and detection of reactive oxygen species (ROS) producing cells 
The plasma samples obtained at 0, 2 and 4 hours post-injection of LPS and plAP 
were also analyzed for TNFα. At the timepoints t=0 and t=4 hours, TNFα levels 
were below detection limits (data not shown). However, at t=2 hours, high TNFα 
levels were found in all LPS-treated mice. These TNFα levels were significantly 
lower in the mice that received plAP after the LPS injection as compared to the 
mice that received saline after the LPS-challenge (Fig. 6A); plAP injection caused 













Figure 6: TNFα levels in plasma of Balb/c mice (A) and staining for ROS-producing cells in 
lungs of mice (B). The mice (n = 7 per group) received LPS (i.p.) co-administered with D-
galactosamine (GalN-D), either with or without 1.5 U plAP (i.v.). Control animals received 
GalN-D i.p. and saline i.v. A TNFα levels at two hours after injection using plAP. The LPS-
challenged mice that did not receive plAP showed elevated TNFα levels. plAP significantly 
reduced the TNFα levels. The result are expressed as the mean value ± S.D. * = p<0.001.  
B ROS-producing cells in lungs of mice 24 hours post-injection. Note the strong staining in 
the lungs of LPS-treated mice (B) compared to control mice (A) and the reduced amount of 
ROS-producing cells in the lungs of mice that received a treatment with plAP (C). (original 
magnification 200x). 
 
An important aspect of sepsis is the massive influx of inflammatory cells that 
produce reactive oxygen species (ROS) in tissues. The DAB staining allows the 
detection of ROS-producing cells in situ. The amount of ROS-producing cells was 
 
 A  C  B  
 















 Chapter 5  
 
104 
examined in various organs, 24 hours after injection of LPS. In particular ROS-
production in the lungs was very high, and profound differences between the LPS-
challenged and the control group were observed (Fig. 6B A and B). Within the 
lungs, the number of ROS-producing cells was markedly decreased in mice that 
received plAP after the LPS injection as compared to the LPS-mice receiving no 
treatment (Fig. 6B). This was observed in all mice that received plAP after the LPS 
injection (n=7). In the other organs that were examined (kidney, spleen, intestine, 
liver), the difference in ROS-producing activity between LPS-treated and control 
mice was less pronounced and hence no differences were observed between 
untreated and plAP-treated mice.  
 
In vivo experiments with ciAP 
In a second series of experiments, we tested the effects of calf intestinal AP (ciAP) 
on the LPS-challenged mice in vivo. Because of the short half-life of this isoenzyme 
(8.5 minutes (21)), only the short-term effects in our sepsis model were examined. 
We assessed the effects of ciAP on the LPS-induced TNFα response by 
administering 1.5 U (0.60 µg) of highly pure ciAP i.v. to the mice immediately after 
they had received an LPS + GalN-D injection (i.p.). Serum AP and TNFα levels in 
ciAP-treated and untreated mice were analyzed.  
 
ciAP activity  
Measurement of AP activity in serum samples obtained 1 min after injection of 
ciAP showed that AP activity rose to approximately 15-fold the normal level; 1087 
± 206.2 U/L. The AP activity in plasma of mice that did not receive ciAP remained 
at baseline levels (74.2 ± 11.3 U/L). In contrast to mice receiving plAP (Fig. 5), 2 
hours after injection of ciAP, no elevation of serum AP activity could be detected 
anymore (data not shown).  




As the optimal timepoint for measuring TNFα levels after an LPS challenge was 
already known from the experiments with plAP, TNFα levels in the experiments 
with ciAP were only assayed at 2 hours post-injection. Highly elevated TNFα 
levels were found in LPS-treated mice, whereas in control animals no TNFα could 
be detected in plasma. TNFα levels rose to 979 ± 270 pg/ml after the challenge with 
LPS, and treatment with ciAP reduced these TNFα levels to 225 ± 94.4 pg/ml (data 
not shown) (p<0.005). This reduction in TNFα levels by ciAP is similar to the data 
obtained with plAP (Fig. 6A).   
  
Discussion 
Despite many efforts, sepsis is still a major problem world-wide, especially in the 
intensive care units, although multiple clinical trials have been performed (27). 
Recombinant activated protein C was shown to be an important asset for the 
management of this disease (28). A large phase III trial, the PROWESS study, 
revealed a significant decrease in mortality. Activated protein C however proved 
to be only beneficial in patients with a high risk of death (high APACHE II score) 
and less beneficial or even harmful in patients with a low risk of dying from sepsis 
(29), which was confirmed in later studies (30; 31). The approach presented here is 
also based on the use of an endogenous plasma enzyme. However, the major 
difference with previous strategies is that this therapy is directed at LPS, the 
initiator of the sepsis cascade rather than to secondary mediators. 
LPS is the triggering molecule in the pathogenesis of Gramnegative sepsis, and the 
involvement of different receptors in this process has been demonstrated in 
various studies (32; 33). If LPS is detoxified or neutralized, it should no longer 
recognize or activate the receptors that switch on the cascade of events during 
sepsis. In the past, many studies have been conducted in which antibodies against 
LPS or LPS-binding substances such as HDL and BPI (34; 35) were tested. 
However, the success in clinical trials of these anti-sepsis preparations has been 
limited. 
 Chapter 5  
 
106 
It is known that lipid A harbours the toxicity of the LPS molecule, and that the 
dephosphorylated form of lipid A, monophosphoryl lipid A (MPLA), is no longer 
harmful. In fact, dephosphorylated LPS may even antagonize the effect of native 
LPS (18; 36) and successful attempts to use this monophosphoryl lipid A as a 
prophylactic treatment have been reported (36). 
In previous studies we showed the ability of alkaline phosphatase (AP) to 
dephosphorylate LPS in vitro, a phenomenon that was associated with reduced 
toxicity of this molecule (19; 20). By demonstrating that AP is able to 
dephosphorylate LPS at physiological pH levels, we established a potential 
physiological role for this ubiquitous enzyme whose role in vivo has been 
completely obscure.  
The aim of the present study was to demonstrate that AP is capable of removing 
diphosphorylated lipid A from samples, using a new method to measure LPS in 
vitro and to show that this activity of AP has beneficial effects in vivo during LPS-
induced sepsis. In this study, we show therapeutic effects of 2 isoenzymes of AP, 
plAP and ciAP. AP has been the subject of numerous studies ever since its 
discovery. Although this enzyme is present in macrophages and in neutrophils in 
the same granules where LPS accumulates (37), only recently attempts have been 
undertaken to elucidate its role during LPS-induced inflammation (38-44).  
In vitro studies were performed to demonstrate the LPS-dephosphorylating activity 
of AP using a truncated, well-characterized form of LPS (S. Minnesota R595). 
Previously, dephosphorylation of LPS was shown by measuring the free inorganic 
phosphate (Pi) that is released from the LPS by AP and by histochemical detection 
of in situ release of Pi from LPS (19; 20). Now we show that the binding of 
pentamidine to the phosphate groups of LPS is affected by plAP in a dose-
dependent and temperature-dependent manner. Whether this AP-induced 
decrease in pentamidine-detectable LPS is caused by binding or by 
dephosphorylation cannot be directly established using this assay. Yet, previous 
studies showed dephosphorylation of LPS by AP. The effect of HSA on the 
pentamidine-detectable LPS concentration probably reflects binding and shielding 
of the lipid A moiety (25). Unexpectedly, this HSA-effect appeared to be also 
temperature-dependent. The effects of plAP and HSA were similar when both 
were applied in equimolar concentrations but serum attenuated the effect of HSA 
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more strongly than the effect of plAP (p< 0.005), indicating that the affinity of LPS 
for plAP is higher than for HSA. Serum itself quenched the signal from LPS (Fig. 
1D), which may be related to the fact that serum contains both AP and HSA. So, 
our studies with truncated LPS and the studies of David (23) show that 
pentamidine binds to the lipid A part of LPS and we now also show with our 
inhibition studies with β-glycerophosphate, as a competitive substrate which 
specifically binds to the active site of AP,  that pentamidine-recognizable LPS is 
bound to the active site of AP. It can therefore be concluded that AP binds to the 
lipid A part of LPS. 
We subsequently performed in vivo experiments to examine a potential protective 
effect of plAP. The placental isoform of AP (a sialylated glycoprotein) has a long 
circulating half-life in serum (approximately 13 hours). Other isoforms of AP such 
as intestinal and liver-bone-kidney AP have a short half-life in serum, due to 
recognition of terminal galactose groups by endocytotic receptors on hepatocytes 
(21). Using plAP, we were able to attain high serum AP levels for a prolonged 
period of time (>24 hours). This allowed us to study both short-term (≤4 hours) and 
long-term (24 hours) effects after a single injection of plAP. 
In these in vivo experiments, we used wild-type LPS to mimic the clinical situation 
more closely. The mice received plAP immediately after the LPS challenge via 
another route of administration to avoid direct binding. We measured TNFα levels 
because these are high in the acute phase of the disease and this cytokine is of 
major importance in initiating the systemic effects during SIRS. Several studies also 
have shown a good correlation between TNFα levels and survival in sepsis (45). 
Administration of plAP prevented the elevation of TNFα profoundly; 75% 
reduction was obtained (Fig. 6A).               
We examined the inflammatory cell influx in the liver, kidney, spleen and lung, at 
the end of the experiment to assess the final outcome of the systemic inflammatory 
response. We only found marked differences between the different experimental 
groups within the lung. This organ appeared to be the primary site for 
accumulation of neutrophils after a LPS-challenge (46). LPS markedly enhanced 
the amount of ROS-producing cells in this organ, and treatment with plAP reduced 
this influx significantly (Fig. 6B).  
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To study whether the protective effect of plAP is isoenzyme dependant, we also 
tested calf intestinal AP. Using ciAP in vivo, serum AP levels up to 1000 U/L were 
reached for a short period of time. In contrast to plAP, intestinal AP is rapidly 
taken up by asialoglycoprotein receptors on hepatocytes (21). ciAP also reduced 
TNFα levels by 75% as compared to untreated LPS-challenged mice. So, despite the 
differences in pharmacokinetic profile between plAP and ciAP, both isoenzymes 
were shown to be therapeutically effective. The long serum half-life of plAP 
compared to ciAP apparently did not favour the effectivity of treatment. One 
explanation for this is that LPS has a relatively short half-life in serum and is 
dephosphorylated or bound rapidly after injection of both forms of AP. 
We conclude that a single injection of AP reduces the inflammatory response in 
mice challenged with LPS. The simultaneous presence of AP and LPS during the 
first phase of the disease appears to be essential. This study confirms and extends 
our previous study showing a therapeutic effect of AP during E.coli induced 
inflammation (39) and studies of others (42). These observations may provide a 
new strategy to attenuate the effects of LPS in vivo. Whether enzymatic 
dephosphorylation of LPS can lead to an effective anti-sepsis treatment is currently 
evaluated in a phase 2 clinical study. Our studies may also provide more insight 
into a possible physiological role of AP that is present in many organs and 
inflammatory cells. We postulate that apart from those therapeutics that aim at 
antagonizing the mediators of inflammation, therapeutic enzymes like AP that 
either neutralize or detoxify the main causative agent LPS in sepsis should be 
included in anti-sepsis research. Not surprisingly, most inflammatory cells are 
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Background & Aims: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic 
multifactorial inflammatory bowel diseases with unknown etiology, but a 
dysregulated mucosal immune response to gut-derived bacterial antigens is 
thought to be involved. Toll-like receptor ligands, especially lipopolysaccharide 
(LPS), seem to contribute in the maintenance of the disease. Previously, we showed 
that the enzyme alkaline phosphatase (AP) is able to detoxify LPS and the aim of 
this study was therefore to examine its role in inflammatory bowel diseases. 
Methods: We examined intestinal AP (iAP) mRNA expression and LPS-
dephosphorylation in intestinal biopsies of control persons and IBD patients, and 
we studied the effect of orally administered acid-protected enteric coated iAP-
tablets on the progression of dextran sodium sulphate-induced colitis in rats. 
Results: In healthy persons, iAP mRNA and protein expression was high in the 
ileum relative to the colon. iAP mRNA expression was not altered in CD patients, 
but it was markedly reduced in UC patients when inflamed tissue was compared 
to non-inflamed tissue. Oral administration of iAP-tablets to colitic rats resulted in 
a significant attenuation of colonic inflammation as reflected by reduced mRNA 
levels for TNFα, IL-1β, IL-6 and iNOS, a reduced iNOS-staining and inflammatory 
cell influx, and a significantly improved morphology of the intestinal wall.  
Conclusions: The present study shows that epithelial iAP mRNA expression is 
clearly reduced in UC patients. The rat colitis model showed that oral 
administration of iAP can not only replenish the intestinal tract with active AP-
enzymes, but also results in a significant reduction of gut inflammation. This may 
provide new opportunities for the treatment of IBD.  
 




Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases 
(IBD) of the digestive tract that are thought to result from inappropriate and 
ongoing activation of the mucosal immune system driven by the presence of the 
normal luminal flora (1). The exact causes of IBD are still unclear but 
environmental factors, genetic predisposition and immunologic disorders are 
suggested to be involved. Mutations in several genes, like NOD2/CARD15 during 
CD (2) and TLR4 during CD and UC (3; 4), seem to predispose for IBD. The 
intracellular protein encoded by the NOD2 gene is thought to interact with 
bacterial products like peptidoglycans (5; 6) and TLR4 is the signaling receptor for 
lipopolysaccharide (LPS). Deficiencies in response mechanisms against bacterial 
products, including LPS, thus seem to be an important factor in IBD.  
Alkaline phosphatase (AP) has been found to dephosphorylate LPS (7-10), which 
results in the formation of a non-toxic lipid A group within the LPS molecule. In 
general, the lipid A group of LPS harbours 2 phosphate groups that are responsible 
for the toxicity of LPS and AP was shown to remove at least one of these 
phosphate groups. This enzyme is abundantly present along the microvilli in the 
small intestine of all species (11), indicating a possible role in the protection of the 
host against endotoxins. 
As AP is able to detoxify LPS and response mechanisms against LPS are changed 
during IBD, we wondered whether the levels of AP are changed in the intestines of 
IBD patients. Therefore, iAP mRNA expression and LPS-dephosphorylation in 
intestinal biopsies of control persons and IBD patients were determined. 
Furthermore, we studied the efficacy of orally administrated acid-resistant iAP-
tablets on dextran sodium sulphate-induced colitis in rats. In this study, we show 
that epithelial iAP expression is decreased in UC patients and that oral iAP 
administration ameliorates LPS-mediated symptoms in colitic rats. In colon 
biopsies of IBD patients, a response to LPS was only observed when the epithelial 
layer was affected by ulcerations. These observations provide novel insights and a 
rationale for new therapeutic strategies against IBD through augmentation of LPS 
detoxification in the intestinal lumen. 
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Materials & Methods 
Patient characteristics / specimen collection  
Intestinal mucosal biopsy specimens were obtained during endoscopy following 
informed consent (approved by the Ethics Committee of the University Medical 
Centre Groningen) from patients with Crohn’s disease (CD), ulcerative colitis (UC) 
and control subjects. Patient characteristics are described in table 1.  Diagnosis of 
IBD was established by endoscopic and histopathological examination. The group 
control subjects were referred to our endoscopy centre because of polyp 
surveillance or changed stool frequency. In control subjects, biopsies were obtained 
from 4 different intestinal areas (ileum, ascending colon, transverse colon, and 
rectum). Biopsies from IBD patients were obtained from the rim of ulceration’s or 
aphtoid lesions if present and from macroscopic non-inflamed areas using a 
standard biopsy forceps. Intestinal specimens were immediately snap-frozen in 
liquid nitrogen for mRNA and protein analysis or liquid nitrogen-cooled 
isopentane for immunohistochemical staining, and stored at –80°C until further 
processing. For LPS incubation experiments, biopsies from the transverse colon 
were immediately incubated after endoscopy. 
 
Table 1: Patient’s characteristics 







CD 10(1/9) 37 (20-80) 7/3 Azathioprine (2), corticosteroids (2) 
5-aminosalicylic acid (1) 
UC 10(7/3) 37 (27-59) 4/6 Azathioprine (1), corticosteroids (3) 
5-aminosalicylic acid (5) 
Healthy controls 8(4/4) 56 (36-77) 8/0 Polyps (2) 
  
Enzymehistochemical detection of AP activity 
LPS-dephosphorylation by human iAP was examined in cryostat sections (5 µm) of 
biopsies of human ileum and colon (ascendens, descendens and rectum) with LPS 
as a substrate as described previously (12). The specificity of this staining has been 
demonstrated before using the iAP-inhibitor L-phenylalanine (13). LPS was 
omitted in control incubations.  
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Incubation of human intestinal biopsies 
Per patient, 8 biopsies were collected and immediately put in 6-well plates 
containing 2 ml William’s medium E supplemented with glucose (final conc. 25 
mM), gentamicin (final conc. 50 µg/ml), amphotericin B (final conc. 2.5 µg/ml) and 
1% human serum. Of the 8 biopsies, 2 were incubated in medium only (controls), 2 
in medium plus 500U AP, 2 in medium plus 10 µg/ml LPS and 2 in medium plus 
500U AP and 10 µg/ml LPS. After 4 hr incubation in a CO2-incubator, biopsies were 
snap-frozen in liquid nitrogen and stored at –80°C until RNA isolation. 
 
RNA isolation and real-time PCR  
RNA was isolated from incubated human intestinal biopsies using the QIAGEN 
RNeasy Mini Kit and subsequently converted to cDNA with the Promega Reverse 
Transcription System. The cDNA was amplified with appropriate primers (Table 2) 
by quantitative real-time PCR using SYBR Green (Applied Biosystems) and 
products were detected using the ABI PRISM 7900HT Detection System. Relative 
quantification of the genes was calculated using the comparative threshold cycle 
(CT) method as described by Van de Bovenkamp, using GAPDH as a 
housekeeping gene (14). 
 
Table 2: Primers used for amplification of the listed genes in human cDNA. 
Gene Forward primer Reversed primer 
GAPDH CCATCACCATCTTCCAGGAG CCTGCTTCACCACCTTCTTG 
iAP ACGCGGCAATGAGGTCATCT CCGCCAAGGATCACGTCAAT 
IL-1β GGGCCTCAAGGAAAAGAATC TTCTGCTTGAGAGGTGCTGA 
TNFα CGTCTCCTACCAGACCAAGG CCAAAGTAGACCTGCCCAGA 
Villin TGACCCTGAGACCCCATC TCAGCAGTGATCTGGCTCCA 
CD14 CGCAACACAGGAATGGAGAC CCAGCGAACGACAGATTGAG 
TLR4 GGCTTGTCCAGTCTCGAAGT GAGGTCCAGGAAGGTCAAGT 
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In vivo experiments 
To examine whether exogenous iAP affects experimental colitis, a colonic 
inflammation was induced in male Sprague-Dawley rats by dextran sodium 
sulphate (DSS). The rats were divided in four groups; 1: normal drinking water 
and placebo-tablets (n=5), 2: normal drinking water and iAP-tablets (n=5), 3: 5% 
DSS in drinking water and placebo-tablets (n=10) and 4: 5% DSS in drinking water 
and iAP-tablets (n=10). Both the iAP- and placebo-tablets had a diameter of 5.3 mm 
and an enteric coating, consisting of eudragit L, triethylcitraat and talc, to prevent 
dissolution in the stomach, which would destroy the activity of acid-sensitive AP 
enzymes. The pH at which the tablets dissoluted was determined at 5.5. The AP-
tablets contained 1250 glycine units iAP (specific activity: 1035 units/mg protein), 
as determined by a standard enzyme activity assay.  
 
Table 3: Primers used for the amplification of the listed genes in rat cDNA.  
Gene Forward primer Reversed primer 
GAPDH CCATCACCATCTTCCAGGAG CCTGCTTCACCACCTTCTTG 
TNFα ATGTGGAACTGGCAGAGGAG GGCCATGGAACTGATGAGAG 
IL-1β AGGCAGTGTCACTCATTGTG GGAGAGCTTTCAGCTCACAT 
IL-6 CCGGAGAGGAGACTTCACAG ACAGTGCATCATCGCTGTTC 
iNOS CGTTCGATGTTCAAAGCAAA CCCTGGACTTCTCACTCTGC 
IL-10R GCCCAGAGACTCTCGATGAC AAGACCCTTCCTTTCCCAGA 
villin TGTGGAACTGGCAGGGAG GGGGTGGGTCTTGAGGTATT 
  
Oral treatment consisted of daily administration of a tablet, under 
isofluran/O2/N2O anaesthesia, from day 1 to 7 after start of the DSS administration. 
From day 1 to 8, the rats were daily weighed, their consumption of drinking water 
was measured and their condition was scored using a standard scoring-procedure.   
At day 8, the rats were anaesthetized with isofluran/O2/N2O and sacrificed by heart 
puncture. Faeces were collected for measurement of AP activity. The colon was 
harvested and scored macroscopically by examining whether there was distension 
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(score 1), partial distension (score 0.5) or no distension (score 0) and whether the 
serosa was thickened (score 1), partially thickened (score 0.5) or not thickened at all 
(score 0). The proximal, middle and distal part of the colon were scored separately 
and all scores were summed. Thereafter, the colon was weighed, the length was 
measured and tissues samples of the distal part were stored for RNA isolation and 
real-time PCR analysis, as described above, for several genes (Table 3).  
The rest of the colon was filled with Tissue-Tek, rolled up and frozen in 
isopentane for histochemical analysis.  
 
AP activity in faeces 
Homogenates of approximately 1 gram/ml rat faeces in water were centrifuged at 
2000 rpm to spin down insoluble materials. The supernatant was removed and 
centrifuged at 13000 rpm to completely remove insoluble materials. Samples were 
diluted 0, 2, 4, 8, 16, 32, 64 and 128 times in a 96-wells plate in 0.05 M ammediol 
buffer containing 2 mM MgCl2. After addition of 10 µl of 10 mg/ml 4-nitrophenyl 
phosphate disodium salt, the plate was incubated for 30 min at 37°C. The reaction 
was stopped by adding 105 µl 1N NaOH. The ODs were measured at 405 nm on a 
Thermomax microplate reader.  
 
Immunohistochemistry 
The H&E staining was performed according to standard procedures. 
Myeloperoxidase (MPO) activity in activated neutrophils was visualized according 
to Poelstra (15). This staining was inhibitable by catalase. The staining for iNOS 
was done according to standard indirect immunoperoxidase techniques with a 
rabbit polyclonal antibody directed against iNOS and GARPO (DAKO) as the 
secondary antibody. The iNOS antibody was developed in the laboratory of dr. H. 
Moshage (University of Groningen, The Netherlands) and has been described 
previously (16). Peroxidase activity was visualized with 3-amino-9-ethylcarbazole. 
The staining for villin was performed like the iNOS-staining using a goat 
polyclonal antibody against villin (sc-7672, Santa Cruz) and RAGPO and GARPO 
as a secondary respectively third antibody (both from DAKO).  
 




Statistical analysis of patient data was done by an unpaired two-tailed Student’s t-
test, assuming similar variances, and expressed as the mean ± the S.D. The data of 
the animal experiment were subjected to a non-parametric one-sided Mann-
Whitney U test, because these data were not normally distributed. Differences 
were considered significant at p< 0.05. 
 
Results 
LPS-dephosphorylation and iAP mRNA levels in healthy human intestinal 
biopsies 
To investigate whether the human small intestine and colon have LPS-
dephosphorylating activity, cryostat sections of biopsies of human terminal ileum, 
colon ascendens, colon transversum and rectum of healthy persons were 
examined. Results from the enzymehistochemical analysis showed that the cells in 
sections of human ileum have a high LPS-dephosphorylating activity as 
demonstrated by a brown lead sulphate precipitate along the apical side of the 
microvilli of the enterocyte (Fig. 1A). In contrast, LPS-dephosphorylation was 
absent in human colon sections; colon ascendens, colon transversum and rectum 
(Fig. 1B, C and D). These reactions were also negative when a conventional 
substrate for AP (β-glycerophosphate) was used. Occasional cells stained positive, 
which probably reflects AP activity in macrophages and endothelial cells of small 
blood vessels. When LPS was omitted from the incubation medium, no staining 
was detected (Fig. 1E). 
 
In addition to LPS-dephosphorylation, the biopsies were inspected for their 
intestinal AP mRNA levels. As previous studies have shown that AP can 
dephosphorylate LPS (7; 8), AP expression levels may be indicative for the LPS-
detoxifying capacity of the intestine. iAP mRNA levels in the human ileum were 
found to be about 30 times higher than those in the human colon (Fig. 2).  
 
  





Figure 1: LPS dephosphorylation by sections of the intestine of a normal healthy person (a 
full color version of this figure is depicted on page 172). A brown staining was clearly visible 
along the apical side of the microvilli of the enterocyte in the terminal ileum (A). In contrast, 
biopsies from the colon ascendens (B), colon transversum (C) and rectum (D), showed 
hardly any LPS-dephosphorylating activity along the enterocytes. Occasional cells stained 






































Figure 2: Intestinal iAP expression throughout the human colon and in the ileum. Biopsies 
were taken from healthy subjects (n=6) and analyzed for iAP mRNA levels by real time RT-
PCR. Expression levels of iAP mRNA were related to the average expression level in the 
colon transversum. Values are expressed as mean ± SD, * = p< 0.005 versus ileum. 
 
LPS-dephosphorylation and iAP mRNA levels in colon biopsies of UC and CD 
patients 
After assessing LPS-dephosphorylation and AP-activity in the small intestine and 
colon of healthy persons, we examined whether these activities had changed 
during IBD. Similar to normal colon biopsies, no LPS-dephosphorylation could be 
detected in colon biopsies from CD or UC patients (data not shown).  
 
We subsequently examined mRNA levels of iAP. Real-time PCR revealed clear 
differences in mRNA levels between inflamed and non-inflamed tissue. A decline 
in mRNA levels was found in UC patients; a 5-fold decrease of iAP mRNA levels 
was observed when inflamed and non-inflamed tissue of the same patient were 
compared (Fig. 3A). To examine whether this decline in mRNA levels was due to 
the destruction of colonic epithelial cells by ulceration, we measured the amount of 
villin mRNA (Fig. 3B), which is a marker for intestinal epithelial cells (17; 18). 
Inflamed mucosa from UC patients displayed a clear decrease in villin expression 
(p<0.005). In contrast, Crohn patients displayed no significant differences in iAP 
and villin mRNA levels between inflamed and non-inflamed tissue, but a clear 
correlation was found between iAP and villin mRNA levels in the ileum of Crohn 
* * * 
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Figure 3: iAP (A) and villin (B) mRNA expression in non-inflamed and inflamed intestinal 
tissue of UC patients (n=7). Total RNA was isolated from biopsies of non-inflamed and 
inflamed intestinal tissue. A decreased iAP expression strongly correlated with a decreased 
expression of the epithelial marker villin. * =  p<0.005. 
 
Responsiveness of human colon biopsies to LPS  
Human colonic biopsies from healthy persons and IBD patients were tested for 
their responsiveness upon exposure to LPS. Biopsies from healthy volunteers 
showed at best only a very low induction of inflammation-related genes after 
incubation with LPS.  
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It is known that during CD and UC, the LPS receptor TLR4 is upregulated on colon 
epithelium (3; 19) and therefore it could be envisioned that biopsies of CD and UC 
patients would react more vigorously upon incubation with LPS. However, also in 
the biopsies of patients, hardly any inflammatory response was observed. mRNA 
levels of the inflammatory genes TNFα and IL-1β upon LPS incubation in three UC 
patients were not significantly induced compared to biopsies incubated without 
LPS. In two of the three tested CD patients an induction of inflammatory genes 
after incubation with LPS was observed. However, no effects of iAP could be 
determined. The two patients that reacted upon LPS had a reduced villin 
expression and higher expression levels of the LPS receptors TLR4 and CD14. 
These data indicate that only when the intestinal barrier is damaged due to 
ulceration, LPS is able to induce an inflammatory response. 
 
Effect of oral administration of enteric-coated iAP-tablets on DSS-induced colitis 
in rats 
To examine whether oral administration of iAP affects experimental colitis, 
inflammation was induced in the colon in male Sprague-Dawley rats by oral intake 
of dextran sodium sulphate (DSS).   
 
Oral administration of AP in tablets resulted in a higher AP activity within the 
intestine. AP activity in faeces at 24 hr after treatment had risen from 0.13 
units/gram faeces in rats that received normal drinking water plus placebo-tablets 
to 7.08 units/gram faeces in rats that received normal drinking water plus AP-
tablets. The total recovery of AP activity from acid-resistant AP-tablets in the 
intestine is approximately 30% as determined previously (20).  
 
The daily consumption of drinking water by the rats showed no significant 
differences, confirming that both treated and untreated rats received the same 
amount of DSS. 
In this study also no difference in weight loss between the different groups that 
received DSS in their drinking water was found. The rats in the AP-treated and 
placebo-treated group lost 11.0% and 11.9% of their initial body weight, 
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respectively. The control groups, i.e. the groups that received normal drinking 
water plus either placebo- or AP-tablets, showed an average increase of body 
weight of 4.5% respectively 4.6%.  
Macroscopic evaluation of the colons revealed that the colon morphology of AP-
treated DSS rats was better than the colon morphology of placebo-treated DSS rats, 
as illustrated by a significantly lower macroscopical score (Fig. 4, p<0.05). 
Measurement of the colon length revealed a significant difference between DSS-
treated rats receiving placebo-tablets and DSS-treated rats receiving AP-tablets; 8.1 
± 0.8 cm in the placebo-treated group versus 9.5 ± 1.3 cm in the AP-treated group 
(p<0.05). The shortening of the colon in DSS-treated rats was associated with a 
clearly visible thickening of the intestinal wall, as reflected by a significant increase 
in weight per length in DSS-treated rats. AP treatment reduced this thickening 
(p<0.01).  
 



















Figure 4: Effects of acid-resistant iAP or placebo-tablets on the macroscopic score of the 
colons in male Sprague-Dawley rats with (n=10 per group) or without (n=5 per group) DSS-
induced colitis after 8 days of treatment. Horizontal bars represent the median of each 
group. The difference between untreated and AP-treated DSS-rats was significant at p<0.05. 
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In the distal part of the colon, relative mRNA expression levels of the following 
genes were determined: TNFα, IL-1β, IL-6, iNOS, IL-10R and villin. The mRNA 
levels of the inflammatory genes, TNFα, IL-1β, IL-6, iNOS and IL-10R were all 
strongly upregulated in DSS-treated rats. Expression levels of all these genes were 
significantly lower in DSS-rats that received AP-tablets compared to DSS-rats that 
received placebo-tablets (p<0.05). Only two out of ten rats treated with AP still had 
elevated levels of TNFα, IL-1β, IL-6, iNOS and IL-10R. In contrast, mRNA levels 
for the epithelial marker villin, which were profoundly reduced in placebo-treated 
DSS-rats, were significantly increased in colitic rats receiving AP-tablets (p<0.05). 
Interestingly, the two rats that displayed aberrant cytokine, iNOS and IL-10R 
levels, also had reduced villin levels. In other words, the outliners were the same 
rats for all parameters. These data indicate that the epithelial layer in the colon of 
rats receiving DSS plus placebo-tablets is severely damaged whereas the epithelial 












Figure 5: Effects of oral treatment with acid-resistant iAP or placebo-tablets on mRNA 
expression of several genes in male Sprague-Dawley rats with (n=10 per group) or without 
(n=5 per group) DSS-induced colitis after 7 days of treatment (Figure on page 127). Dot plots 
show the expression levels of TNFα, IL-1β, IL-6, iNOS, IL-10R and villin mRNA in the distal 
part of the rat colons. Horizontal bars represent the median of each group. Expression levels 
were normalized to GAPDH. For each parameter, the difference between untreated and AP-
treated DSS-rats was significant at p<0.05. 
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The colon was also histochemically evaluated by H&E, iNOS, MPO and villin 
staining. The colons of DSS rats receiving AP-tablets were clearly less damaged 
than those of DSS rats that received placebo-tablets (Fig. 6C versus fig. 6B). The 
epithelial lining of the colon was more intact, confirming the PCR results for villin 
mRNA levels, and in line with the macroscopical data (Fig. 4), the serosa was less 
thickened in AP-treated rats. In both groups of rats that received normal drinking 
water, no staining for the inflammation marker iNOS was observed (Fig. 6D). 
However, in placebo-treated DSS-rats, all colon segments displayed a profound 
iNOS staining (Fig. 6E). In contrast, colons from AP-treated DSS-rats showed no or 
only minor iNOS staining (Fig. 6F). The amount of MPO-positive cells in the colon 
was highly increased in DSS-treated rats receiving placebo-tablets (Fig. 6H) 
compared to normal rats (Fig. 6G). Administration of AP-tablets to DSS-treated 
rats markedly reduced this influx of MPO-positive cells (Fig. 6I). The epithelial 
marker villin was abundantly present along the epithelial lining of the mucosa in 
control rats (Fig. 6J), but completely absent in colons of DSS-rats that received 
placebo-tablets (Fig. 6K). In contrast, DSS-rats that received AP-tablets displayed a 
clear villin-staining along the epithelial cells which was comparable to control rats 
(Fig. 6L), which is in line with the PCR data for villin mRNA. 
Taken together, all data indicate that the inflammation of the colon and the 
structural damage after DSS exposure is significantly reduced upon AP treatment. 
 
 
Figure 6: H&E staining (A, B, C), histochemical staining for iNOS (D, E, F) and activated 
neutrophils (G, H, I) and villin (J, K, L) in male Sprague-Dawley rats with DSS-induced 
colitis after 7 days of treatment with placebo (mid-panel) or acid-resistant iAP-tablets (right-
hand column). Normal rats are depicted in the left-hand column. Note the mucosal 
ulceration and thickening of the serosa in placebo-treated colitic rats (B) compared to oral 
iAP-treated colitic rats (C). The inflammation marker iNOS was absent in non-colitic rats 
(D), enhanced in placebo-treated colitic rats (E), and strongly decreased in oral iAP-treated 
colitic rats (F). The amount of activated neutrophils was low in non-colitic rats (G), high in 
placebo-treated colitic rats (H) and clearly reduced in iAP-treated colitic rats (I). The red 
staining for the epithelial marker villin was visible along the epithelial lining in non-colitic 
rats (J), absent in placebo-treated colitic rats (K) and retained in iAP-treated DSS rats (L). 
Magnification of all figures is 100*. A full color version of this article can be found on page 
173) 
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Inflammatory bowel disease (IBD) is one of the major chronic inflammatory 
diseases, affecting several millions of people world-wide. It is believed that the 
inflammation of the damaged gut is the result of an inappropriate ongoing 
activation of the mucosal immune system triggered by components of the normal 
luminal flora (1). When the sub-epithelial layers of the intestinal wall are exposed 
to LPS due to damage, macrophages residing in these layers start to produce 
cytokines and chemoattractants (21), leading to the migration of high amounts of 
neutrophils to the site of damage and local activation. Production of high amounts 
of ROS by accumulated neutrophils will cause local damage and further enhance 
inflammation. A damaged intestinal barrier sometimes also leads to elevated LPS 
levels in the blood caused by translocation of luminal LPS and/or bacterial 
translocation, which in turn may induce elevated levels of circulating cytokines 
like TNFα, IL-1β, IL-6 and IL-17 (22; 23). This may increase the intestinal 
permeability even further. Several reports have shown that the enzyme alkaline 
phosphatase (AP) is able to dephosphorylate and detoxify LPS (7-10). The resulting 
product, LPS with a monophosphoryl lipid A moiety, is non-toxic (24) and may 
even antagonize LPS (25). Because inflammatory bowel diseases are associated 
with a perpetuating inflammatory response towards intestinal bacterial products, 
in particular LPS, administration of LPS-detoxifying molecules might attenuate the 
inflammatory response during periods of severe inflammation. 
We first studied intestinal AP expression in normal healthy persons with 
enzymehistochemistry and real-time PCR techniques. The results obtained with 
both techniques corresponded with each other and showed a strong LPS-
dephosphorylation in the human ileum along the lining of the villi whereas the 
human colon showed almost no LPS-dephosphorylation. This difference was 
confirmed by real-time PCR; the human ileum showed much higher iAP mRNA 
levels than the human colon. Previous studies have demonstrated that this LPS-
dephosphorylation was caused by AP activity (7; 8) and the localization of this 
activity here is also in agreement with the reported localization of iAP in the small 
intestine (11; 26). The reason for the lack of LPS-dephosphorylation in the colon is 
unknown. Because bacterial titers in the colon are high, the barrier function may be 
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sufficiently strong under physiological circumstances and LPS receptors are not 
expressed in the colon epithelium in the normal situation (19; 27; 28), leading to a 
hyporesponsiveness to LPS within the colon. So, LPS detoxification may not be 
required in the colon. AP activity within the colon might also be blocked by 
dephosphorylated LPS, which is a known inhibitor of AP activity (9). In the ileum, 
where intestinal nutrient uptake is high, LPS-dephosphorylation mechanisms may 
be more relevant. 
Although LPS-dephosphorylation in the colon in the healthy control group was 
low, we observed decreased mRNA iAP levels in the colon of UC patients. These 
decreases were paralleled by decreases in the expression levels of the epithelial 
marker villin, suggesting that the decrease in iAP expression is most likely due to 
loss of the epithelial cell layer.  
LPS-dephosphorylation was shown to be associated with reduced toxicity of this 
bacterial product (7-10; 29) and this may be relevant in view of the role of LPS in 
the pathology of IBD. We therefore explored whether administration of calf 
intestinal AP (ciAP) might affect DSS-induced colitis, a model for human UC in 
rats (30). The DSS-model is characterized by colonic epithelial damage, diarrhea, 
bloody faeces, decrease of body weight, colon shortening and neutrophilic 
infiltration in the intestinal wall (31). Treatment with AP will not affect DSS-
induced damage but only the secondary damage caused after destruction of the 
epithelial layer (32). Intestinal AP appeared to display a profound effect on the 
colon. All parameters reflecting the colon condition at the macroscopical level 
showed that the colon was significantly improved in diseased rats receiving AP-
tablets.  
Measurement of drinking water consumption showed that both treated and 
untreated groups received equal amounts of DSS, leading to a decreased water-
resorption capacity of the colon and diarrhea, and subsequently weight loss in both 
groups. Nevertheless, significant effects were found on mRNA levels of all genes 
examined; mRNA levels of inflammatory genes were strongly decreased, 
indicating a reduced inflammation within the colon wall, and villin mRNA levels 
were strongly enhanced in the colons of AP-treated rats, reflecting a more intact 
epithelial cell layer. Also intestinal wall thickness and integrity were nearly normal 
in all AP-treated colitic rats, and the patchy staining for iNOS found in all DSS-rats 
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treated with placebo-tablets was completely absent in all rats treated with AP. So, 
these data demonstrate a significant therapeutic effect of oral administration of 
iAP-tablets. Although AP activity in the colon is normally low or absent, 
administration of exogenous iAP seems therefore beneficial. Apparently, during 
disease, when damage to the colon wall occurs and infiltration of CD14 / TLR4 
receptor-positive cells has taken place, shielding mechanisms are affected and LPS-
hyperresponsive cells infiltrate in the tissue. So only when the normal barrier is 
affected, a high concentration of AP may exert a clinical relevant function.  
The role of the barrier and the effect of LPS-responsive cells that subsequently 
infiltrate in the tissue became also clear in human biopsies. Biopsies of normal 
healthy persons appeared to be quite insensitive to stimulation with LPS. This 
apparent hyporesponsiveness might be due to the absence of TLR4 in human 
intestinal epithelial cells (27; 33). After examining the response upon LPS in 
biopsies from 3 CD and 3 UC patients, we only found induction of mRNA for 
inflammatory genes in biopsies of 2 CD patients. Biopsies of these two patients also 
displayed low villin mRNA levels indicating that in these patients the epithelial 
layer was affected. It has been described that IBD patients have higher expression 
levels of the LPS receptor TLR4 (3; 19), but in contrast to these reports, we could 
not detect such differences. Since there was no response upon LPS in most cases, 
no significant effect of AP on the LPS-response was noted either.  
In summary, this study shows for the first time that epithelial iAP expression is 
decreased in UC patients and that the iAP-mediated endogenous LPS-detoxifying 
activity is therefore challenged in these patients. Importantly, oral iAP 
administration was found to reduce LPS-mediated inflammatory effects in colitic 
rats. These data provide new insights into the role of iAP during IBD and support 
the notion that oral administration of iAP to UC patients may be therapeutically 
effective. This prompted us to a phase II proof of concept study in patients with 
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Summary, General Discussion 















Diseases in which LPS plays an important role are a major healthcare problem. 
World-wide, millions of people suffer from diseases like sepsis, inflammatory 
bowel disease (IBD) or liver fibrosis.  
Angus et al reported that in a large study the incidence of sepsis in the US is about 
3 cases per 1000 population (3). With a present US population of 300 million people 
and a European population of 800 million people, this results in an estimate of 
about 3.3 million cases of sepsis in the US and Europe together.  
In contrast to sepsis, the incidence of IBD world-wide is more difficult to estimate 
because of the geographic variation of its incidence. The incidence of IBD is higher 
in industrialized areas like Western and Northern Europe and North America and 
lower in regions like central and southern Europe, Asia, Japan, Africa and South 
America (19). According to the Annual Report of the Crohn’s and Colitis 
Foundation of America, in America 1.4 million people suffer from either Crohn’s 
disease (CD) or ulcerative colitis (UC) 
(www.ccfa.org/media/pdf/AR2006/ar2006fullfinalfinal.pdf). This means that IBD 
affects at least several millions of people world-wide. 
The condition though, which affects most people globally, is undoubtedly liver 
fibrosis. Liver fibrosis can have many underlying causes e.g. hepatitis B and C, 
schistomiasis and alcohol abuse. World-wide, it was estimated by the World 
Health Organization that respectively 350, 150 and 200 million people suffer from 
hepatitis B, C and schistomiasis. A considerable amount of these patients will 
develop fibrosis and ultimately cirrhosis. The most common cause of cirrhosis in 
Western society though, is alcohol abuse, accounting for several other millions of 
cases of liver fibrosis.  
In the National Vital Statistics Reports number 54 of the National Center for Health 
Statistics, about causes of death in the US, septicemia and chronic liver diseases 
and cirrhosis represent the 10th and 12th cause of death among people in the U.S. 
(4). 
 
Taken together, sepsis, IBD and liver fibrosis affect tens of millions of people 
world-wide and represent a tremendous burden on the healthcare system. 
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A common problem of these diseases in which LPS is an important player is their 
complexity and multi-factorial character, which hampers adequate treatment. A 
major cause of disease complexity is the fact that LPS initiates a cascade of events, 
resulting in the activation of numerous pathways (Fig. 1). Amongst others, LPS is 
known to induce massive production of inflammatory cytokines (TNFα, IL-1β and 
IL-6), lipid mediators, chemokines and oxygen radicals (12). In addition, LPS also 





Figure 1: Scheme of initiated cascades and produced mediators during Gramnegative sepsis. 
Picture from David (13).  
 
Most therapies so far are designed to eliminate one mediator or shutdown one 
pathway, but as so many pathways are involved, this is often not sufficient. 
In the field of sepsis, much progress has been made in understanding the 
pathology of sepsis. Despite this progress, the development of anti-sepsis 
therapeutics has not been very successful. There have been many clinical trials 
using e.g. antibiotics, volume resuscitation, vasoactive agents, anti-TNFα 
antibodies, IL-1 receptor antagonists, anti-LPS anti-bodies, lipid A analogs, 
glucocorticoids, NO-synthesis inhibitors, antithrombine III, tissue factor pathway 
inhibitor and activated protein C ((15; 40) for an overview of clinical trials, which 
use a variety of anti-sepsis strategies, see Riedemann et al (36)).  
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Of all these therapeutics, only activated protein C (APC) did show a small but 
significant reduction in mortality in septic patients (7; 8; 46). In the large PROWESS 
trial, APC resulted in a significant reduction of 6.1 % in absolute mortality (8). 
However, patients which had an increased risk of bleeding upon administration of 
the natural anticoagulant APC, e.g. patients with renal failure or recent surgery, 
were excluded from the study (8). In addition, the effectiveness of APC appeared 
to be related to the risk of mortality. Post-hoc analysis of the data generated from 
the PROWESS trial revealed that APC was beneficial in patients with a high risk of 
death, i.e. APACHE scores above 25, and that an absolute reduction in mortality of 
13% could be achieved in this subset of patients (41). In contrast, APC appeared to 
be potentially harmful in patients with a low risk of death (18). For this reason, the 
U.S. Food and Drug Administration (FDA) approved APC only for the use in 
severe septic patients and asked for additional clinical trials for assessing the 
effects of APC on severe septic patients with a lower risk of death. A recent study 
of Abraham et al in which only severe septic patients were included with a low risk 
of death, i.e. APACHE scores less than 25, confirmed the lack of efficacy of APC in 
this group of severe septic patients (1).  
So, the restricted use of APC for a subset of severe septic patients and the fact that 
sepsis is still the 10th cause of death in the US emphasizes that there is obviously 
still a need for the development of better and more effective anti-sepsis therapies. 
After the approval of APC though, no other effective therapeutic compounds have 
been approved by the FDA so far. 
 
Regarding inflammatory bowel disease, treatment is dependent on the severity, 
activity and etiology (Crohn’s disease or ulcerative colitis) of the disease. A nice 
overview of the current treatment options is given in a review of Domenèch (17). 
Briefly, the therapeutic compounds currently in use to treat IBD are: therapeutics 
which have 5-aminosalycilyc acid (5-ASA) as their active compound (sulfalazine 
and mesalazine), corticosteroids and other non-steroid immunosuppressive drugs 
(cyclosporine A, thiopurines, methotrexate and since recently infliximab) and 
antibiotics. The chimeric anti-TNFα antibody (infliximab) has shown to be very 
successful in the treatment of severe to moderately severe UC (26). In severe cases, 
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when treatment yields insufficient results, surgery in which part of the intestine is 
removed, may be necessary.  
Despite the array of available therapeutics, quite a number of people experience 
drawbacks of the treatments mentioned above. Corticosteroids for example 
occasionally have numerous side effects. These may be “mild”, e.g. acne, obesity 
and fluid retention or more severe in patients, e.g. bone loss (osteoporosis), 
metabolic complications (hyperglycemia or hyperlipaemia), hypertension, 
psychosis, ocular effects and immunosuppression, leading to other infectious 
diseases (17; 38). In addition, quite a number of people do not respond to steroids 
and are steroid-resistant, also called steroid-refractory. Besides corticosteroids, also 
compounds having 5-ASA as their active compound and immunosuppressives are 
known to have side-effects. In particular side-effects of immunosuppressives can 
be quite serious when they are used for a longer period. As LPS is thought to play 
an important role in the perpetuation of chronic inflammatory bowel diseases (2; 
11; 21; 28) and as the current treatment options are almost all accompanied by side 
effects, ranging from mild to severe, exploration of anti-LPS therapies in IBD might 
be worthwhile, especially for patients for which the current therapies are not an 
option. 
 
When looking at all therapies that are currently available for the treatment of 
diseases in which LPS has an important role (17; 35; 36), it is striking that of all 
these therapies, only few are directed at the LPS molecule itself.  
After Poelstra et al discovered in 1997 that the enzyme alkaline phosphatase (AP) 
was able to dephosphorylate and thereby detoxify AP; a possible new anti-LPS 
therapeutic protein was discovered. This research was extended by Bentala, 
Verweij and Beumer, who demonstrated beneficial effects of AP in several animal 
models of sepsis (6; 9; 45). 
 
The research described in this thesis further extends the research on the effects of 
AP in sepsis, but we also explored the possibility of AP as a new therapeutic 
compound in another LPS-associated disease; inflammatory bowel disease. 
Whereas LPS is the causative agent in sepsis, the role of LPS in IBD is not that of 
the causative agent, but LPS is thought to play a role in the perpetuation of the 
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inflammatory process once the disease has started. In addition, we tried to 
elucidate the mechanism by which endogenous AP activity is regulated. As 
outlined in chapter 2, endogenous AP levels are often elevated or downregulated 
during LPS-mediated diseases. If AP is important in these diseases, insight in the 
mechanism of AP up- or downregulation may be used to design new therapies. 
 
The liver is the major LPS-removing organ in the body, and it is also an organ that 
expresses endogenous AP. As AP is able to detoxify LPS, we wanted to explore 
whether the liver itself is capable of LPS-detoxification and whether there is a 
relation between LPS and endogenous AP levels in the liver (chapter 3). In 
addition, we also explored the efficacy of calf intestinal AP (ciAP) in LPS-induced 
sepsis in rats. Staining of liver sections of normal and fibrotic rats showed that the 
liver itself is not only capable of removing LPS from the circulation (37; 44), but is 
also capable of dephosphorylating several LPS-serotypes. Moreover, LPS proved to 
be an inducer of AP mRNA in the livers of normal as well as fibrotic rats. This 
induction was seen in vivo and in vitro in freshly prepared liver slices. Induction of 
AP by LPS has not been reported before and indicates a close relation between LPS 
and AP, which was even more emphasized when we demonstrated a co-
localization between the LPS receptor CD14 and AP at sites were possible 
pathogens, e.g. Gramnegative bacteria, may enter the body (e.g. lung epithelium, 
intestine) or where LPS may accumulate (liver, kidney). Finally, we demonstrated 
a therapeutic effect of intestinal AP (derived from calf: ciAP). Placental AP, which 
has a long half-life in serum, had already been proven successful in septic mice (6) 
and we now wanted to see if ciAP, which has a short half-life in serum, is also 
capable of influencing sepsis parameters. We first demonstrated in vitro and in vivo 
that the short-half life of ciAP is due to its rapid uptake by hepatocytes via the 
asialoglycoprotein receptor. Despite this rapid uptake, ciAP caused a significant 
reduction in TNFα and NO production by LPS-stimulated liver slices. In addition, 
in vivo, preservation of hepatic glycogen could be demonstrated when rats with 
LPS-induced sepsis were treated with ciAP. From the studies described in this 
chapter, we concluded that there is a close relation between LPS and AP and that 
ciAP, despite its short half-life in plasma, is also capable of reducing levels of 
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important sepsis mediators in vitro and in vivo. The latter was confirmed by a study 
of Beumer et al and ciAP is currently evaluated in clinical trials (9). 
 
As we found in chapter 3 that liver AP could be induced by LPS, we wanted to 
study the mechanism of AP regulation in more detail. Chapter 4 therefore focused 
on the mechanism of AP-induction. In HepG2 cells and McA-Rh7777 cells, we tried 
to induce AP activity with the compounds butyrate, a fermentation product of 
anaerobic bacteria in the colon (49), and retinoic acid. Reports have been published 
that these compounds increase AP activity (22; 23; 27). Butyrate indeed induced AP 
activity in both cell lines whereas retinoic acid did not. We subsequently tried to 
induce AP mRNA levels by incubating the cells with LPS. In contrast to our in vivo 
experiments described in chapter 3, we did not find any induction of AP mRNA by 
LPS. This led us to the hypothesis that perhaps cytokines are needed to induce AP 
activity. We therefore incubated rat liver slices and measured the mRNA levels of 
TNFα, IL-1β, IL-6 and AP, and found that peak levels of TNFα and IL-1β mRNA 
were reached several hours before the peak level of AP mRNA. This might be an 
indication that AP mRNA induction occurs via cytokines. The fact that Kupffer 
cells, which produce high amounts of cytokines upon LPS stimulation, are present 
in liver slices but absent in cultured cell lines, might serve as an explanation for the 
different results obtained in cell lines and slices after LPS stimulation. In vivo, LPS 
induced elevated AP mRNA levels already 2 hr after LPS administration, but 24 hr 
after LPS administration, levels had gone back to basic levels.  
Despite our results obtained with freshly prepared liver slices, which suggested 
that cytokines are involved in the mechanism of AP induction, other in vitro 
studies did not provide further evidence for this hypothesis. Besides butyrate and 
retinoic acid, we also added cytokines and cytokine-rich medium from 
macrophages that were stimulated with LPS to the cell lines. Unfortunately, none 
of these resulted in a significant induction of AP activity in the cells. So, no 
conclusion can be drawn yet on the mechanism of AP-induction in the liver by 
LPS. We think it is likely that induction of AP by LPS in vivo is the result of a 
complex of factors which is difficult to mimic in vitro. Because we saw AP 
induction in slices and because we think cytokines are involved in the mechanism 
of AP induction, experiments with slices in which the Kupffer cells are silenced 
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might be the next step to provide further evidence for our hypothesis. An option 
could be the compound gadolinium chloride (GdCl3), which inhibits the Kupffer 
cell response upon LPS, and has even been shown to protect rats from sepsis-
induced hepatic injury (25; 47). Caution should be taken though when using GdCl3, 
as conflicting results have been published about the inhibition of cytokine 
production by Kupffer cells after GdCl3 administration. 
 
In chapter 5 we examined the effect of plAP and ciAP on LPS-induced sepsis in 
mice. In addition, we introduced a new assay for LPS measurement. Our new 
assay for the detection of LPS uses the compound pentamidine. This compound 
fluoresces upon binding to LPS, but not upon binding to monophosphoryl lipid A. 
If one of the 2 core phosphate groups is removed from the LPS, pentamidine is not 
able to bind anymore (14). This assay therefore allows us to discriminate between 
LPS and dephosphorylated LPS. The assay is currently used to measure LPS 
concentrations in buffer solutions, but in the future we hope to optimize the assay 
for LPS measurements in serum. The second part of this chapter describes an in 
vivo study in which effects of plAP and ciAP on LPS-induced mice are studied. It 
appeared that both plAP and ciAP induced a significant effect on TNFα levels in 
serum, 2 hr after LPS administration. Serum TNFα is an early parameter for 
systemic inflammatory response syndrome (SIRS). Despite the fact that ciAP levels 
in serum decreased much faster than plAP levels, the net effect on the reduction of 
TNFα levels was almost exactly the same. This indicates that AP probably has its 
effect shortly after its administration. Besides exploring the effect of AP on an early 
sepsis parameter, we also evaluated the effect of plAP on a late sepsis parameter, 
i.e. the influx of neutrophils in the lungs. plAP clearly attenuated the influx of 
intrapulmonary neutrophils.  
 
In chapter 6, we investigated the possibility to use AP as a therapeutic protein in 
IBD and we explored the expression of AP in the human intestine in normal and 
IBD patients. AP mRNA levels in the human small intestine appeared to be much 
higher than in the human colon. Despite the lower levels in the colon, these levels 
could decrease to even lower levels during ulcerative colitis (UC). In contrast, 
Crohn’s disease did not significantly influence AP levels in the intestine. 
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As AP has already been proven effective in sepsis, we now wanted to examine its 
effects in a disease with a completely different etiology, but in which LPS also 
exerts an important role, colitis. To examine whether AP could have a beneficial 
effect in this disease, we induced colitis in rats and studied the effect of daily oral 
administration of AP-tablets. Oral administration of AP had very significant effects 
on several inflammatory parameters and parameters reflecting colon integrity. AP-
treatment of colitic rats resulted in amongst others a better morphology of the 
colon, less influx of neutrophils and lower mRNA levels of inflammatory cytokines 
in the colon. We concluded from this experiment that AP strongly reduced the 
inflammatory effects of colitis. Moreover, at this moment, effects of ciAP 
administration on the progression and severity of UC in humans are examined. 
 
Discussion and Future perspectives 
The research described in this thesis has resulted in a more clear view on the 
relation between alkaline phosphatase (AP) and LPS. Furthermore, we provided 
evidence that AP might have the potency to become a therapeutic protein in 
patients with IBD. Significant effects of AP administration in a rat model of colitis 
were obtained. This, and other preclinical work has been taken forward and as 
mentioned above, currently, 2 clinical trials using calf intestinal AP (ciAP) are 
ongoing. The first trial is a phase II clinical trial in which ciAP is administered to 
septic patients. The second trial is a phase I clinical trial in which UC patients that 
do not respond to other treatment, receive ciAP via an oral probe, which passes the 
stomach and delivers the AP directly in the intestine. The latter is necessary 
because the low pH in the stomach would destroy the enzyme activity of AP.  
 
Most of the research presented in this thesis was done on sepsis and IBD. In 
addition, pilot studies were performed to study the role of AP and LPS in rats with 
liver fibrosis (not described in this thesis). In this study, we modified the enzyme 
AP with a cyclic peptide that binds to the PDGF receptor (5). These studies were 
conducted to examine whether the active enzyme can be delivered to specific 
designated receptors. Secondly, recent evidence shows that hepatic stellate cells 
(HSC) are activated directly by LPS (33) and activated HSC play a crucial role in 
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the progress of fibrosis leading to liver cirrhosis. During liver fibrosis, the 
expression of the PDGF receptor on the cell membrane of activated HSC is highly 
upregulated (34). These receptors might therefore serve as a target to deliver active 
enzymes. Our studies resulted in the coupling of several cyclic peptides to AP, 
after which the enzyme still had enzymatic activity, although the specific activity 
was lower than before the synthesis procedure. We could also demonstrate 
binding of the construct, AP-PDGF, to 3T3 fibroblasts (Fig. 2), that is, cells that 
express the PDGF receptor.  
 
   
 
Figure 2: Binding of plAP conjugated with cyclic peptides recognizing the PDGF receptor 
(left) and control plAP (right) to 3T3 fibroblasts (a full color version of this picture can be 
viewed on page 171). The brown staining in the left picture reflects AP activity of the AP-
PDGF construct that is bound to the cells.  
 
The specific delivery of AP at sites were it is needed may open new possibilities for 
the use of AP as a therapeutic protein. It is now possible to deliver AP in a specific 
cell type that plays a crucial role in liver fibrosis. The enzyme can be directed to 
cells that are sensitive to LPS, in other words, it is possible to let AP and LPS 
“meet” and thereby enable AP to dephosphorylate and thus detoxify LPS. 
Stimulation of LPS-sensitive cells might thereby be avoided. These studies will be 
pursued in the coming years. 
 
Direction of AP to LPS-sensitive cells, though, should be done early in the disease 
process of diseases in which LPS has a central role. The half-life of LPS in serum is 
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quite short (44) and LPS is quickly removed from the circulation by predominantly 
Kupffer cells and to a minor extent by hepatocytes (37; 44). Hereafter, cytokines, 
which are the important mediators of the inflammatory process, are already 
present in serum and the inflammatory process will have been initiated. Early 
administration of AP thus is of crucial importance. 
 
At first sight, this seems unfavorable for the use of AP as a therapeutic protein. 
Most patients, for example septic patients, that are admitted to the hospital are 
already very ill and the LPS that caused the systemic inflammation will have been 
removed from the blood by the time of admission. The cytokines and other 
inflammatory mediators that have been produced in response to LPS levels are still 
present in serum and they induce many effects. Amongst others, these mediators 
may induce an enhanced vascular permeability, also in the intestinal wall. In this 
way, cytokines may cause a “second” elevation of systemic LPS levels. High levels 
of circulating cytokines and other inflammatory mediators and locally produced 
gut-derived cytokines, especially IFNγ and TNFα, can cause an increased 
permeability of the intestinal wall (16; 20; 43; 48; 50), and hence an increase in 
bacterial translocation from the intestinal lumen to the blood and/or lymph. This 
may lead to the “second” elevation of systemic LPS levels, and this in turn results 
again in the production of high amounts of cytokines and other mediators, which 
may increase the intestinal permeability even further; this may lead to a vicious 
circle. Although AP might often not be present at the very start of this circle, it can 
be administered later to break this vicious process. Many people suffering from 
elevated LPS levels due to a disease often do not die from the initial LPS overload, 
but from the vicious process in which their condition gradually worsens.  
 
Therefore, AP can very well be beneficial for septic patients in whom the 
inflammatory process has already started but it could also be beneficial in a chronic 
inflammatory disease like inflammatory bowel disease in which the role of AP is 
then the interruption of the chronic inflammatory process. This is currently 
investigated in clinical trials.  
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Next to sepsis and IBD, applicability of AP in other diseases might be an 
interesting issue for research in the near future. The general concept of AP being 
able to detoxify LPS might be beneficial in many other LPS-associated diseases. 
Diseases or conditions one could think of are for instance rheumatoid arthritis, 
burns, meningococcal disease (24; 32), ischemia/reperfusion after intestinal surgery 
(30) and liver fibrosis (42).  
Regarding rheumatoid arthritis, a very recent study has pointed out LPS as an 
important causative agent in rheumatoid arthritis in moist buildings (29). If further 
research indeed identifies LPS as the main causative agent, AP administration 
might decrease the inflammatory symptoms. 
Also burn patients could profit from AP administration. Obviously, the skin as a 
barrier for infectious agents is damaged, but it is also known that shortly after 
burns, the intestinal permeability is increased due to ischemia/reperfusion injury, 
leading to bacterial translocation (31; 39). If AP is administered before the increase 
in intestinal permeability, and hence before bacterial translocation occurs, a 
systemic inflammatory reaction upon gut-derived LPS may be avoided. 
In case of fibrosis, AP could also have beneficial results because fibrosis is almost 
always accompanied with liver inflammation. In liver fibrosis, the targeting of 
modified AP to “LPS-sensitive cells” like HSC (10; 33), the ECM-producing cells in 
the fibrotic process, is of importance. For an optimal LPS-detoxifying effect of AP, 
it is essential to bring AP and LPS together at crucial sites. Another important 
aspect in fibrosis is that the fibrosis state can have many underlying etiologies. 
Eradication of the fibrosis is only possible if also the underlying cause is treated. 
So, in the case of hepatitis B and C, combination therapies of targeted AP with 
antiviral compounds might be an option in the future. 
 
In summary, clinical trials using AP as a therapeutic protein in sepsis and IBD are 
already ongoing and hopefully in the future, the use of AP as a therapeutic 
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Endotoxine is een stofje dat voorkomt aan de buitenkant van bepaalde soorten 
bacteriën, zogenaamde Gramnegatieve bacteriën. Deze categorie bacteriën komt in 
grote hoeveelheden voor in de dikke darm, maar ze bevinden zich ook op de huid 
en de slijmvliezen van bijvoorbeeld de neus. Endotoxine is voor mensen erg giftig 
en veroorzaakt hevige ontstekingsreacties als het in grote hoeveelheden in het 
bloed terecht komt.  
 
Als endotoxine in het bloed terecht komt, wordt het normaal gesproken uit het 
bloed gehaald door de lever. In de lever zijn 2 soorten cellen betrokken bij het 
verwijderen van endotoxine uit het bloed, de “gewone levercellen”, ook wel 
hepatocyten genoemd, en de levermacrofagen, ook wel Kupffer cellen genoemd. 
Macrofagen zijn de “vuilnismannen” van het immuunsysteem. Ongewenste 
indringers, bacteriën, virussen en vreemde stofjes, worden door macrofagen 
opgenomen en afgebroken tot kleine brokstukken. Deze worden vervolgens 
aangeboden aan cellen van het immuunsysteem zodat het immuunsysteem de 
binnendringers kan opruimen. Er treedt dan een zogenaamde ontstekingsreactie 
op. Als dit plaatselijk is, is dit goed. Als bijvoorbeeld een splinter met vuil en 
bacteriën eraan in een vinger zit, wordt het rond de splinter vaak wat warm en 
rood. Dit zijn de tekenen van een plaatselijke ontstekingsreactie waarbij 
binnengedrongen vuil en bacteriën door het immuunsysteem worden opgeruimd.  
Echter, als er grote hoeveelheden endotoxine in de bloedbaan terecht komen, kan 
het immuunsysteem hier soms zo hevig op reageren dat er een “over-reactie” 
ontstaat met als resultaat een ontstekingsreactie door het hele lichaam. Er is dan 
sprake van bloedvergiftiging, ook wel sepsis genoemd. Sepsis veroorzaakt door 
endotoxine wordt ook wel Gramnegatieve sepsis genoemd, genaamd naar de 
categorie bacteriën die de oorzaak is van de sepsis, maar sepsis kan ook 
veroorzaakt worden door virussen, parasieten, schimmels en gisten. Sepsis gaat 
gepaard met een aantal symptomen, onder andere koorts (hoger dan 38°C) of een 
te lage lichaamstemperatuur (lager dan 36°C), een vertraagde of verhoogde 
hartslag, een versnelde ademhaling, bloedruk daling en bloedstolling in kleine 
bloedvaatjes. Dit laatste kan er voor zorgen dat bloedvaten verstoppen en dat 
organen geen zuurstof meer krijgen. Organen kunnen dan afsterven en als het 
vitale organen betreft kan dit uiteindelijk leiden tot de dood. Sepsis kan zich erg 
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snel ontwikkelen en de toestand van een sepsis-patiënt kan binnen enkele uren tot 
dagen levensbedreigend worden.  
 
Er zijn een aantal oorzaken waardoor er verhoogde endotoxine concentraties in het 
bloed kunnen optreden. Het kan zijn dat de lever niet meer goed werkt. De lever is 
zoals genoemd het belangrijkste orgaan in het lichaam dat endotoxine uit de 
bloedbaan verwijdert. Als de lever niet meer goed werkt, bijvoorbeeld doordat 
mensen lijden aan leverontsteking (hepatitis type B of type C) of leverfibrose, 
bijvoorbeeld door alcoholmisbruik, dan wordt er minder endotoxine uit het bloed 
verwijderd en stijgt de concentratie in het bloed. Leverfibrose is een ziekte waarbij 
gezonde levercellen, hepatocyten, vervangen worden door bindweefsel. Hierdoor 
gaat de werking van de lever geleidelijk achteruit. Een tweede reden waardoor 
endotoxine concentraties in het bloed verhoogd kunnen zijn, is doordat de 
darmwand beschadigd is. Normaal gesproken is de darmwand een goede barrière 
die zorgt dat de grote hoeveelheden bacteriën die in de darm zitten, niet in het 
bloed terecht kunnen komen. Nu kunnen darmen beschadigd raken, waardoor 
bacteriën de darmwand kunnen passeren en in het bloed terecht kunnen komen. 
Darmen kunnen bijvoorbeeld beschadigd raken door zuurstofgebrek bij 
darmoperaties of door chronische ontstekingen zoals die voorkomen bij de ziekte 
van Crohn en colitis ulcerosa. Een derde oorzaak van verhoogde endotoxine 
concentraties in het bloed kunnen grote open wonden zijn. Hiervan is bijvoorbeeld 
sprake bij brandwonden en bij grote buikoperaties. Ook dan zijn de natuurlijke 
barrières tegen indringers, huid en darmwand, aangetast. Tot slot kunnen het 
gebruik van antibiotica en corticosteroïden ook leiden tot meer endotoxine in het 
bloed. Antibiotica zorgen ervoor dat bacteriën dood gaan. Als bacteriën dan 
uiteenvallen, kan het endotoxine dat aan de buitenkant van de bacterie zit loslaten, 
in het bloed terecht komen en zich zo door het lichaam verspreiden. 
Corticosteroïden daarentegen zorgen er voor dat het immuunsysteem wordt 
onderdrukt. Hierdoor worden ongewenste bacteriën en stoffen die in het lichaam 
terecht komen minder goed opgeruimd wat ook kan leiden tot verhoogde 
endtoxine gehaltes. 
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In 1997 hebben wij ontdekt dat een eiwit, het enzym alkalisch fosfatase (AF), 
endotoxine kan ontgiften. Het toxisch (giftig) zijn van endotoxine wordt voor een 
groot deel bepaald door 2 fosfaatgroepen in een bepaald gedeelte van het 
endotoxine, het zogenaamde lipid A gedeelte. Als 1 van deze 2 fosfaatgroepen 
wordt verwijderd, is het endotoxine niet langer toxisch. Het enzym AF is in staat 
een fosfaatgroep van het endotoxine af te splitsen en het zo te ontgiften. Dit is 
schematisch weergegeven in figuur 1. Als de fosfaatgroep verwijderd is, is het 




















Figuur 1: Het ontgiften van endotoxine door het enzym alkalisch fosfatase. Alkalisch 
fosfatase is in staat om een fosfaatgroep van endotoxine te verwijderen. Hierna is het 
endotoxine niet meer toxisch en veroorzaakte het geen sepsis meer. 
 
 Nederlandse Samenvatting  
 
159 
Het enzym AF komt van nature ook in het lichaam voor. Er zijn een aantal organen 
waarin AF aanwezig is, de dunne darm, de longen, de nieren, de lever, maar ook in 
de placenta en in neutrofielen. Neutrofielen zijn cellen van het immuunsysteem. 
 
Nadat we ontdekten dat AF er voor kan zorgen dat endotoxine onschadelijk 
gemaakt wordt, hadden we het idee om te kijken of AF misschien geschikt zou zijn 
als nieuwe therapie voor sepsis. Er is vervolgens eerst in een aantal diermodellen 
gekeken of AF gunstige effecten had op het verloop van de ziekte. In deze 
diermodellen kregen de dieren sepsis door het in de ader inspuiten van endotoxine 
of door hele bacteriën in de buikholte in te spuiten. In muizen, schapen en varkens 
bleek vervolgens dat AF er voor zorgde dat de ontstekingsreactie in het lichaam 
sterk verminderd was en dat de sterfte van dieren als gevolg van sepsis afgenomen 
was. Na deze goede resultaten in dierproeven, is de werking van AF getest in 
mensen met sepsis. 
 
Het doel van het onderzoek beschreven in dit proefschrift, was het verder 
ophelderen wat precies de rol is van het enzym AF tijdens sepsis. Verder hebben 
we ook gekeken of AF misschien ook als therapie zou kunnen worden toegepast bij 
andere ziekten waarbij endotoxine een belangrijke rol speelt. In ons onderzoek 
hebben we gekeken naar de mogelijke toepassing van AF bij chronische 
darmziekten als de ziekte van Crohn en colitis ulcerosa. Endotoxine speelt bij deze 
ziekten een belangrijke rol in het in stand houden van de voortdurende 
ontstekingen in de darmen. 
 
In hoofdstuk 1 worden het doel van het onderzoek en de opbouw van het 
proefschrift beschreven. In de inleiding, hoofdstuk 2, wordt beschreven welke 
stoffen en welke processen een rol spelen bij het ontstaan van sepsis en welke 
ziekten hiervan de oorzaak kunnen zijn. De rol van endotoxine in sepsis, 
ontstekingsziekten van de darmziekten en leverfibrose wordt hierbij wat 
uitgebreider bekeken. Ook wordt in dit hoofdstuk bekeken welke therapieën 
momenteel gebruikt worden voor de bestrijding van de genoemde aandoeningen 
en de mogelijke toepassing van AF tijdens deze ziekten 
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In hoofdstuk 3 hebben we bestudeerd of de lever, welke zoals gezegd endotoxine 
uit de bloedbaan kan verwijderen, ook endotoxine kan ontgiften door middel van 
het van nature in de lever aanwezige enzym AF. Daarnaast hebben we gekeken of 
er misschien een relatie bestaat tussen de aanwezigheid van endotoxine in het 
bloed en de hoeveelheid enzym in de lever. Indien de hoeveelheid AF omhoog 
gaat als er meer endotoxine in het bloed is, kan dat een aanwijzing zijn dat AF deel 
uitmaakt van de natuurlijke afweer tegen Gramnegatieve bacteriën. Tot slot 
hebben we bekeken wat het effect is van het toedienen van AF dat gezuiverd is uit 
kalverdarmen (de dunne darm bevat veel AF) aan ratten met sepsis.  
Uit ons onderzoek bleek dat het AF dat van nature in de lever aanwezig is, 
inderdaad endotoxine kan ontgiften. Het lever-AF was in staat om verschillende 
soorten endotoxine van verschillende soorten bacteriën onschadelijk te maken. De 
lever kan dus op 2 manieren de endotoxine concentratie in het bloed verlagen; 
endotoxine kan door levermacrofagen en hepatocyten worden opgenomen en 
vervolgens afgevoerd via de gal of het endotoxine kan door AF wat in de lever 
aanwezig is ontgift worden. Uit ons onderzoek bleek verder dat er inderdaad een 
mogelijke relatie is tussen de hoeveelheid endotoxine in het bloed en de 
hoeveelheid AF enzym in de lever. In een dierstudie met ratten tot slot, bleek een 
duidelijk positief effect waarneembaar te zijn als AF werd toegediend aan ratten 
met sepsis. De therapeutische effecten van AF die wij vonden in ratten geïnjecteerd 
met endotoxine ondersteunen onze eerdere resultaten en ons idee dat AF een 
mogelijke rol speelt als beschermingsmechanisme tegen dit schadelijke bacteriële 
product. 
 
Omdat we in hoofdstuk 3 hadden ontdekt dat de het lichaamseigen (ook wel 
endogeen genoemd) AF in levercellen in korte tijd verhoogd werd door 
endotoxine, wilden we het mechanisme hierachter in meer detail bestuderen. In 
hoofdstuk 4 hebben we ons daarom gericht op het mechanisme achter de 
verhoging van AF in levercellen. In hepatoma cellijnen (cellen afkomstig van 
levertumoren die je buiten het lichaam heel lang in leven kan houden) afkomstig 
van zowel mens als rat, hebben we geprobeerd de activiteit van het enzym AF te 
verhogen. In tegenstelling tot onze experimenten beschreven in hoofdstuk 3, 
waarbij we korte tijd na toediening van endotoxine een sterk verhoogde AF 
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activiteit in de levercellen (hepatocyten) van ratten vonden, konden we geen 
enkele verhoging van AF activiteit vinden in de hepatoma cellijnen na incubatie 
met endotoxine. Butyraat, een stofje geproduceerd door bepaalde soorten 
bacteriën, zorgde wel voor een sterke verhoging van AF in deze levercellen. Dit 
effect was eerder beschreven en toonde aan dat de door ons gebruikte cellijnen wel 
degelijk de capaciteit hadden om hun AF activiteit te verhogen, maar dat 
endotoxine niet direct het signaal hiervoor was. Dit bracht ons tot de hypothese, 
dat er wellicht ontstekings-eiwitten (cytokines) nodig waren voor de verhoging 
van AF activiteit. Deze worden in het lichaam vooral geproduceerd door 
macrofagen als er endotoxine aanwezig is. Maar omdat de levercellijnen maar uit 1 
soort cellen bestaan, welke geen macrofagen zijn en dus geen cytokines 
produceren, is het mogelijk dat deze verhoging van AF spiegels nooit in dit 
systeem kan optreden. In het lichaam zijn deze cellen die veel cytokines kunnen 
produceren wel aanwezig en dit kan derhalve een verklaring vormen voor het 
verschil in resultaten gevonden in cellijnen en in het lichaam. Concluderend kan 
gesteld worden dat nader onderzoek moet worden verricht om definitieve 
conclusies te kunnen trekken over het mechanisme achter de regulatie van AF in 
levercellen. 
 
In hoofdstuk 5 hebben we het effect van AF gezuiverd uit placenta’s (plAF) en AF 
afkomstig van kalverdarmen op de respons op endotoxine onderzocht in muizen. 
Tevens hebben we in dit hoofdstuk een nieuwe methode voor het meten van 
endotoxine geïntroduceerd. Deze nieuwe methode maakt gebruik van het stofje 
pentamidine.  
Dit molecuul fluoresceert (zendt een lichtsignaal uit) als het bindt aan endotoxine, 
maar niet aan ontgift endotoxine waar een fosfaatgroep van verwijderd is. Deze 
methode stelt ons dus in staat onderscheid te maken tussen giftig endotoxine en 
ontgift endotoxine waarvan een fosfaatgroep is verwijderd. De methode is tot nu 
toe alleen bruikbaar om endotoxine in waterige oplossingen te meten, maar we 
hopen dit in de toekomst te verbeteren zodat we ook endotoxine in bloed kunnen 
meten.  
In het tweede gedeelte van dit hoofdstuk beschrijven we een studie in muizen 
waarin de effecten van het toedienen van plAF en AF uit kalverdarmen aan 
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muizen met sepsis (veroorzaakt door het inspuiten van endotoxine in het bloed) 
worden onderzocht. Het bleek dat zowel plAF als AF uit kalverdarmen zorgden 
voor een duidelijke verlaging van de hoeveelheid van het ontstekings-eiwit 
(cytokine) TNFα 2 uur na de toediening van endotoxine. De hoeveelheid TNFα is 
een belangrijke graadmeter in een vroeg stadium van ontsteking door het hele 
lichaam. TNFα wordt door macrofagen geproduceerd als reactie op endotoxine en 
het is een cytokine dat een hevige ontstekingsreactie opwekt. Behalve naar een 
vroege graadmeter voor sepsis, hebben we ook gekeken naar graadmeter voor een 
later stadium van sepsis, in dit geval het binnendringen van neutrofielen 
(ontstekingscellen van het immuunsysteem) in de longen. Toediening van plAF 
aan muizen met sepsis zorgde ervoor dat het aantal neutrofielen dat ophoopte in 
de longen duidelijk verminderde. 
 
In hoofdstuk 6 beschrijven we een studie naar de mogelijkheid om AF te 
gebruiken als een therapeutisch eiwit tijdens ontstekingsziekten van de darmen. In 
deze studie onderzochten we tevens de expressie van AF in de menselijke darm in 
gezonde mensen en in patiënten met een chronische ontstekingsziekte aan de 
darmen. De activiteit van het AF enzym bleek in de gezonde menselijke dunne 
darm veel hoger te zijn dan in de gezonde menselijke dikke darm (colon).  
Aangezien al in diverse diermodellen was aangetoond dat toediening van AF 
effectief is tijdens sepsis, wilden we nu de effecten van AF onderzoeken in een 
ziekte met een totaal andere achtergrond, maar waarin endotoxine wel een 
belangrijke rol speelt, namelijk colitis ulcerosa. Om te onderzoeken of AF positieve 
effecten zou kunnen hebben op het verloop van deze ziekte, veroorzaakten we een 
ontsteking aan de dikke darm (colitis) in ratten en bestudeerden we het effect van 
het oraal (de AF tabletten werden door de ratten doorgeslikt) toedienen van 
tabletten die AF bevatten. Orale toediening van AF had zeer significante effecten 
op verschillende ontstekingsparameters en parameters die een graadmeter zijn 
voor de colon integriteit. Behandeling van ratten die colitis hadden met AF 
resulteerde onder andere in een colon waarvan het weefsel minder aangetast was 
en er bleek ook minder ophoping te zijn van ontstekingscellen (neutrofielen) in het 
colon. Uit dit experiment konden we de conclusie trekken dat AF de 
ontstekingseffecten tijdens colitis drastisch reduceerde. Momenteel wordt het effect 
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van AF uit kalverdarmen op de progressie en ernst van colitis ulcerosa in mensen 
onderzocht. 
 
In het laatste hoofdstuk van dit proefschrift, hoofdstuk 7, worden de resultaten 
van dit proefschrift samengevat en bediscussieerd. De belangrijkste conclusie uit 
het in dit proefschrift beschreven onderzoek is dat AF zeer veelbelovend is als 
therapeuticum voor bloedvergiftiging (sepsis) en chronische ontstekingsziekten 
van de darmen. Inmiddels lopen er 2 verschillende klinische trials met AF, 1 met 
sepsis patiënten en 1 met colitis ulcerosa patiënten. We veronderstellen dat AF ook 
een mogelijke toepassing heeft als therapeutisch enzym bij andere ziekten waarbij 
endotoxine een belangrijke rol speelt. 
 
Verklaring van termen en afkortingen 
Colon = dikke darm 
Cytokines = ontstekings-eiwitten 
Sepsis = ontstekingsreactie in het hele lichaam veroorzaakte door endotoxine 
AF = alkalisch fosfatase 
Endogeen = lichaamseigen 
Neutrofielen = ontstekingscellen 
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List of abbreviations 
 
γ-GT gamma-glutamyl transferase  
5-ASA 5-aminosalycilyc acid  
AEC 3-amino-9-ethylcarbazole  
AP  alkaline phosphatase 
AP-1 activating protein-1 
APACHE  Acute Physiology and Chronic 
Health Evaluation 
APC activated protein C  
AsF asialofetuin 
ASGP-R  asialoglycoprotein receptor  
AT-III antithrombin III  
BDL3 3 week after bile duct ligation 
BPI bactericidal/permeability-
increasing protein 
CARD15 caspase recruitment domain 15 
CD Crohn’s Disease  
CD14r CD 14 receptor 
ciAP calf intestinal alkaline 
phosphatase 
DIC disseminated intravascular 
coagulation 
DOC deoxycholic acid  
DSS dextran sodium sulphate  
ECM extra-cellular matrix  
FDA Food and Drug 
Administration  
Fig. figure 
GalN-D galactosamine-D  
GAPDH glyceraldehyde-3-phosphate 
dehydrogenase  
GARPO  goat anti-rabbit IgG 






HDL high-density lipoproteins 
HSA human serum albumin 
HSC hepatic stellate cells  
i.p. intraperitoneal 
i.v. intravenous 
iAP intestinal alkaline phosphatase 
IBD inflammatory bowel disease 
IFNγ interferon gamma 
IkappaB inhibitory kappa B protein 
IL interleukin 
IL-10R interleukin-10 receptor 
iNOS inducible NO-synthase 
IRAK IL-1 receptor-associated kinase 
IRF3/5 interferon regulatory factor 3/5 
KDO  2-keto-3-deoxy-octonate 
LBK-AP liver-bone-kidney alkaline 
phosphatase 
LBP LPS-binding protein  
LDH lactate dehydrogenase  
LDL low-density lipoproteins 
LPS lipopolysaccharide 
LRR leucine rich repeat 
MD muramyl dipeptide 
MD-2 myeloid differentiation 
protein-2 
MOF multiple organ failure  
MPLA monophosphoryl lipid A 
MPO myeloperoxidase activity  




NFκB nucleair factor-kappa B 
NO nitric oxide 
NOD2 nucleotide-binding 
oligomerization domain 2 
p38 MAPK p38 mitogen-activated protein 
kinase 
PAF platelet activating factor 
PAS periodic acid Schiff 
PBS phosphate-buffered saline 
PDGF platelet derived growth factor 
PG peptidoglycan 
Pi phosphate group 
plAP placental alkaline phosphatase 
pNPP para-nitrophenyl-phosphate  
PROWESS The Recombinant Human 
Activated Protein C World-
wide Evaluation in Severe 
Sepsis 
RA retinoic acid  
RAGPO  rabbit anti-goat IgG 
conjugated with horseradish 
peroxidase 
RES reticuloendothelial system  
ROS reactive oxygen species 
SB sodium butyrate 
sCD14 soluble CD14 
SD standard deviation 
SIRS systemic inflammatory 
response syndrome 
TIR toll/IL-1 receptor homology 
domain 
TLR toll-like receptor 
TNFα tumour necrosis factor-alpha 
TRAF TNF receptor-associated factor 
U unit(s) 
UC ulcerative colitis 
UW University of Wisconsin 
preservation solution 
VLDL very low density lipoproteins 
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Figure 1: Structure of the enzyme alkaline phosphatase. The two monomers are shown in 
blue (left) and green (right). The two metal binding domains are shown in yellow, the crown 













Figure 2: CD14r expression and AP 
activity in rat liver (A, B), kidney 
(C, D), lung (E, F) and small 
intestine (G, H). Figures A, C, E and 
G show the localisation of the 
CD14r, indicated by the red 
staining, whereas figures B, D, F 
and H show AP activity, reflected 
by brown staining. Pictures show 
occasional staining for CD14r in all 
organs examined. Staining for AP 
activity is also seen in every organ. 
AP staining is frequently localized 
in the same areas as the CD14r 
staining (details see text). Figures I 
and J are negative controls 
(omission of the first antibody) of 
the two organs in which the CD14r 
staining was most intense, that is, 
the liver (I) and the kidney (J). Fig. 



















Figure 6: Glycogen staining in hepatocytes as detected by a PAS staining on rat liver 
cryostat sections. Rats received saline (A, n = 9), LPS (B, 1 mg/kg, n = 9) or LPS (1 mg/kg) 
plus ciAP (1000 U) i.v. (C, n = 6). Note the reduced PAS-staining in LPS-treated rats (B) as 
compared to control (A), whereas PAS-staining was higher in rats that received LPS plus 





   
 
Figure 2: Binding of plAP conjugated with cyclic peptides recognizing the PDGF receptor 
(left) and control plAP (right) to 3T3 fibroblasts. The brown staining in the left picture 
reflects AP activity of the AP-PDGF construct that is bound to the cells.  














Figure 1: LPS dephosphorylation by sections of the intestine of a normal healthy person. A 
brown staining was clearly visible along the apical side of the microvilli of the enterocyte in 
the terminal ileum (A). In contrast, biopsies from the colon ascendens (B), colon 
transversum (C) and rectum (D), showed hardly any LPS-dephosphorylating activity along 
the enterocytes. Occasional cells stained positive (arrows). Control sections (without LPS) 
were completely negative (E). Magnification 200*. 







         




















Figure 6: H&E staining (A, B, C), histochemical staining for iNOS (D, E, F) and activated 
neutrophils (G, H, I) and villin (J, K, L) in male Sprague-Dawley rats with DSS-induced 
colitis after 8 days of treatment with placebo (mid-panel) or acid-resistant iAP-tablets (right-
hand column). Normal rats are depicted in the left-hand column. Note the mucosal 
ulceration and thickening of the serosa in placebo-treated colitic rats (B) compared to oral 
iAP-treated colitic rats (C). The inflammation marker iNOS was absent in non-colitic rats (F), 
enhanced in placebo-treated colitic rats (D), and strongly decreased in oral iAP-treated 
colitic rats (E). The amount of activated neutrophils was low in non-colitic rats (G), high in 
placebo-treated colitic rats (H) and clearly reduced in iAP-treated colitic rats (I). The red 
staining for the epithelial marker villin was visible along the epithelial lining in non-colitic 
rats (J), absent in placebo-treated colitic rats (K) and retained in iAP-treated DSS rats (L). 
Magnification of all figures is 100*. 
















Annemarie Tuin werd op 2 mei 1978 geboren te Veendam. In 1996 behaalde zij het 
VWO diploma aan het Dollard College te Winschoten. In hetzelfde jaar verhuisde 
zij naar Wageningen alwaar gestart werd met de opleiding Moleculaire 
Wetenschappen aan de Wageningen Universiteit, destijds nog Landbouw-
universiteit geheten. 
 
In 2001 behaalde zij haar doctoraalexamen met lof. Tijdens de opleiding werden 3 
stages doorlopen. De eerste stage werd uitgevoerd bij de vakgroepen Biochemie en 
Toxicologie aan de Universiteit Wageningen onder begeleiding van prof. dr. ir. 
Ivonne Rietjens. Het onderwerp van deze stage was het metabolisme van luteoline. 
De tweede stage werd gelopen bij de vakgroep Farmacokinetiek & Drug Delivery 
van de Rijksuniversiteit Groningen. Tijdens deze stage werd onder leiding van dr. 
Ruben de Kanter en prof. dr. Geny Groothuis een nieuw model om darmweefsel te 
incuberen opgezet. De laatste stage tot slot, vond plaats bij Organon NV. Onder 
leiding van ing. Johan Rijss en dr. Rob Hanssen werden chimere LH/FSH 
receptoren geconstrueerd en getest. 
 
Na haar afstuderen in 2001 startte zij als promovendus bij de vakgroep 
Farmacokinetiek & Drug Delivery. Haar promotoren waren prof. dr. Klaas Poelstra 
en prof. dr. Dick Meijer. Het onderzoek heeft geresulteerd in dit proefschrift 
getiteld “Detoxification of LPS by alkaline phosphatase: application of a new 
concept in sepsis and inflammatory bowel disease”. 
 
Thans is zij werkzaam als postdoc bij de onderzoeksgroep Stam Cellen & Tissue 
Engineering van het Universitair Medisch Centrum Groningen. 
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And finally……. the masterpiece is finished!! Ja, net als je denkt, “komt het nog 
af?”, dan is het toch af. Raar maar waar. 
 
En dan is het tijd om iedereen te bedanken. Hierbij wilde ik maar gelijk een lekkere 
open deur in trappen; promoveren doe je niet alleen. En dat zou ik ook niet gewild 
hebben. Werken in een team is zoveel efficiënter, gezelliger en, en … zo kan ik nog 
wel even doorgaan. De afgelopen 5 jaar heb ik met erg veel plezier gewerkt aan 
mijn promotieonderzoek bij de Farmacokinetiek. In die tijd heb ik met veel mensen 
samen gewerkt die hebben bijgedragen aan het tot stand komen van dit 
proefschrift en die wil ik daar graag voor bedanken. 
 
Om te beginnen mijn eerste promotor en dagelijks begeleider Klaas. Onder jou 
leiding ben ik van student via AIO geworden tot post-doc. Met je enthousiaste kijk 
op onderzoek en je creativiteit in het bedenken van nieuwe onderzoeksideeën heb 
je een belangrijke bijdrage geleverd aan mijn ontwikkeling als onderzoeker. Ik 
hoop dat ik ooit nog eens net zo creatief kan worden in het bedenken van 
onderzoeksideeën als jij. Ik heb veel van je geleerd de afgelopen jaren en één van 
de belangrijkste is wel een positieve kijk op je resultaten houden. Ik heb me er wel 
eens over verbaasd hoe binnen een paar minuten overleggen met jou mijn 
negatieve resultaten toch niet negatief waren?! Ook de discussies over resultaten, 
maar ook over “de wetenschap” waren erg leerzaam. Na dit promotietraject zal 
onderzoek naar AF en LPS altijd mijn belangstelling houden en wie weet werken 
we in de toekomst nog wel eens samen, Nederland is een klein landje after all. 
 
Ook wil ik mijn tweede promotor Dick hartelijk bedanken. De eerste 2 jaar was je 
nauwer betrokken bij het onderzoek dan na je emeritaat, maar ook na je emeritaat 
heb je je goed op de hoogte laten houden van het onderzoek door regelmatig even 
langs te komen. Manuscripten had je snel gelezen en gecorrigeerd en bovenal 
regelmatig verfraaid met mooie volzinnen. 
 
Dan “mijn analisten” Ali en Alie (in chronolgische volgorde). Beide bedankt voor 
het vele werk dat jullie gedaan hebben. Ali in de eerste 2 jaar van mijn promotie-
onderzoek was jij “mijn analist”. Het was prettig met je samen te werken en vooral 
je lach, hahaaa, is heel aanstekelijk. Ik vond het erg jammer dat je weg ging 
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destijds, maar in dit geval geldt dat je elkaar toch gauw weer tegen komt. Ik vind 
het erg leuk dat we nu opnieuw collega’s zijn. Dan Alie nummer 2. Tsja, het was 
even wennen toen Ali weg ging. Maar al gauw kwam er een nieuwe analist en 
warempel, weer een Alie, maar nu met ie! Beste Alie, ik heb het heel leuk en 
gezellig gevonden (je bent altijd zo’n heerlijk opgewekte persoon) dat jij de laatste 
jaren van mijn promotie-onderzoek “mijn analist” was en ben erg blij dat je mijn 
paranimf wil zijn! En hoewel we niet meer op dezelfde afdeling zitten, hoop ik dat 
we onze Coach-spel perikelen samen met Catharina en onze “Wilfredden” gewoon 
voort kunnen zetten volgend seizoen ☺. Ook is een bedankje op zijn plaats voor de 
andere 2 analisten van de “fibrose-groep”, Catharina en Hester, bedankt voor de 
praktische tips & tricks bij het uitvoeren van allerlei experimenten. 
 
Wat betreft de dierproeven ben ik Anne-miek veel dank verschuldigd. Ik ben 
ontzettend blij geweest met je hulp de laatste 5 jaar bij de diverse dierproeven die 
we gedaan hebben op het gebied van sepsis en IBD onderzoek. Zeker de laatste 
dierproef was geen sinecure; in totaal hebben we in een week tijd 210 AF-tabletten 
aan 30 ratten toegediend. Bedankt voor je inzet en je flexibiliteit wat betreft 
werktijden! En natuurlijk bedankt voor je gezelligheid als kamergenoot. 
 
Daarnaast wil ik mijn andere kamergenoten, Marja, Esther (veel succes met jou 
laatste loodjes) en Ansar bedanken voor de gezellige tijd. Marja, het was fijn dat we 
het laatste wel en wee van onze AIO tijd samen konden bepraten. Je met z’n 
tweeën ergens aan ergeren of over opwinden is minder erg dan in je eentje. Verder 
wil ik de andere collega-AIO’s: Heni, Rick, Werner, Teresa, Jai, Kai, Asia, Ansar en 
Janja, bedanken voor de gezellige tijd op en om het lab. Misschien moet er toch 
maar eens een Kolonisten-reunie komen in de toekomst?! Gillian, bedankt voor het 
helpen met het vinden van de weg naar de juiste mensen als ik weer eens lost was 
in de bureaucratie van de RuG. Ook alle andere (ex)-“Kinetiekers” bedankt voor de 
gezelligheid (lab-dagjes, Kerstbrunches) en hulp met van-alles-en-nog-wat de 
afgelopen jaren. En bij deze Willem bedankt voor al je PC hulp (en ook je andere 
hulp hoor de eerste 2 jaar van mijn promotietraject).  
En wie ik ook nog speciaal wil noemen is “Ome” Jan (Visser). Net als ik een echte 
Groninger en dat schept een band! Ome Jan is van veel verschillende probleem-
markten thuis: lab-problemen, bureaucratie-problemen, bestel-problemen, kortom, 
problemen in het algemeen ☺. Af en toe vloog er wel eens een opruim-mopper 
over het lab, maar door af en toe een moppertje bleef alles wel lekker opgeruimd. 
En ik weet wat er in de kast op jullie kamer bewaard wordt Jan en Frits…  
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De bijdragen van de studenten Erik, Marieke en Helma aan het onderzoek werden 
uiteraard ook zeer gewaardeerd. Ik hoop dat jullie het doen van onderzoek leuk 
hebben vonden.  
 
Naast de collega’s van het eigen lab waren ook een aantal mensen van andere 
onderzoeks-afdelingen betrokken bij mijn onderzoek. Allereerst wil ik Gerard 
Dijkstra bedanken voor de samenwerking de laatste 2 jaar op het gebied van IBD. 
Je enthousiasme voor onderzoek is erg aanstekelijk en tijdens onze samenwerking 
is mijn belangstelling voor onderzoek naar IBD definitief gewekt. Daarnaast is een 
bedankje op zijn plaats voor Lisette Bok voor het isoleren van RNA uit 
darmbiopten en voor het uitzoeken van biopten uit de grote database. In het kader 
van dit onderzoek is ook samen gewerkt met het bedrijf AM-Pharma. Van AM-
Pharma wil ik Markwin Velders en Willem Raaben bedanken voor hun 
samenwerking bij de studie waarin AF-tabletten aan ratten met colitis werden 
toegediend. Willem, bij deze heel hartelijk bedankt voor het snelle regelen van AF-
tabletten toen bleek dat het granulaat niet oraal toe te dienen was. De planning van 
deze dierproef was heel krap, woensdag om 9 uur werden de tabletten geleverd en 
een uurtje later hadden we de eerste serie al toegediend! Door deze strakke 
planning kon de dierproef nog net in mijn verlenging afgemaakt worden, pfieuw. 
 
Ook de nieuwe collega’s van Stam Cellen & Tissue Engineering bedankt voor het 
aanhoren van de laatste promotieperikelen van zoals Barry het noemt, “een 
terminale AIO”. En dank Barry dat je fotograaf wilt zijn bij mijn promotie! 
 
Naast het werk zijn er gelukkig vele andere dingen te doen en zijn er ook vele 
mensen die met je meeleven.  
 
Allereerst wil ik de overige 6 leden van de club van 7 uit Wageningen bedanken 
voor medeleven, steun en de gezelligheid. Uit ervaring weten jullie precies welke 
“stadia” je als promovendus doorloopt. Hester, Josefien Mark, Wendy, Louis en 
Petra, bedankt hiervoor en dat we in de toekomst nog maar veel gezelligheid en 
leuke events mogen beleven. Josefien, na mijn promotie gaat het er echt van komen 
hoor, samen op pad met onze beide paardjes! Nog een ding op mijn to-do-list; een 
bezoek aan Petra, Henk en de kleine Rebecca. Petra, na mijn promotie moet het er 
toch echt van komen hoor, dan vlieg ik richting Bristol. En Hester, onze 
Groningen-shopping moeten we eindelijk ook maar eens doen denk ik! Mark en 
Wendy, ook jullie hoop ik straks weer vaker te zien als we allemaal weer tijd 
hebben. 
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Wie ook niet vergeten mogen worden zijn al mijn paardrij-kenissen. Naast werken 
moet er ook tijd zijn voor ontspanning, en wat is nu meer relaxt dan in de zon 
buiten rijden op de rug van een paard ☺. Iedereen bedankt voor de leuke en 
gezellige ritjes en dat er nog maar vele mogen volgen. En Ingrid, naast het feit dat 
we eerst collega’s op het werk waren, zijn we nu nog steeds paardrij-collega’s. Erg 
gezellig, en ik hoop dat we van de zomer weer eens een ritje buiten kunnen maken.  
 
En last but not least, de onmisbare steun van “the family”. En gelukkig heb ik 
nogal wat family. Ook al is het soms niet altijd te begrijpen wat ik nou precies doe, 
het maakte de belangstelling voor mijn werk er niet minder om. Pap en mam, 
bedankt voor alle steun en support, bij werkelijk allerlei uiteenlopende 
beslissingen waarover je (of beter gezegd ik) kan dubben. Wat ook niet onvermeld 
mag blijven is jullie onmisbare hulp bij mijn talloze verhuizingen. Het zijn er geloof 
ik 6 (!!) geweest sinds de start van mijn studie in Wageningen. En mam, 
Moleculaire Wetenschappen bleek  achteraf een goed idee van jou. 
 Ook de sissies, Astrid, Marion en Janneke bedankt voor de support en 
gezelligheid. Astrid, gelukkig lijkt het door MSN alsof je soms niet “helemaal” in 
Amerika zit, maar gewoon om de hoek. Echt super dat je er bij kunt zijn op 11 mei 
en te gek dat je dan ook nog paranimf wil zijn! Marion, ook jij bedankt voor je 
belangstelling voor mijn onderzoek. Veel succes met je opleiding tot tandarts en 
met “blik trekken” bij het roeien. Misschien haal jij Peking 2008 ook nog…??!! En 
dan de jongste, Janneke, de laatste van de 4 musketiers die over een poosje gaat 
studeren. Jou gaat het net als je 3 grote zussen ongetwijfeld ook lukken! Leuk om 
straks nog een zus te hebben die om de hoek studeert!  
Natuurlijk wil ik ook mijn schoonfamilie Albert, Wennie, Jos en Josine bedanken 
voor de interesse in mijn onderzoek. Als ik straks gepromoveerd ben komen we 
“de Beetse” en Maastricht weer vaker onveilig maken. 
 
En als allerlaatste en lest best, Wilfred. Lieve Wilfred, zo langzamerhand moet jij 
wel heel bedreven zijn in het kalmeren van mensen….  at least, in het kalmeren van 
mij als het weer eens niet meezat (of ik me te druk maakte). Anyway, het is voor 
mij onmogelijk je genoeg te bedanken voor alle steun en support, daarom zeg ik: Ik 









En dit is waar ik nu hopelijk weer meer tijd voor heb!! Heb er nog even over 
gedacht om haar ook te bedanken in mijn dankwoord. Doch aangezien het 
merendeel van de mensen denkt dat ik dan echt doorsla, toch maar niet gedaan. 
Maar omdat ik het niet helemaal kan laten…. Nisko bij deze bedankt voor de vele 























Dutch Biopharmaceutical Company AM-Pharma announces 
positive results in its double-blind, placebo controlled Phase IIa 
Sepsis trial with Alkaline Phosphatase 
 
Bunnik, the Netherlands, October 20, 2006. AM-Pharma B.V., a biopharmaceutical 
company engaged in the pre-clinical and early clinical development of novel 
compounds to treat infectious and inflammatory diseases, announces first 
positive results observed in its multi-center double blind, placebo-controlled 
pilot study in the treatment of sepsis with its patented Alkaline Phosphatase 
(AP) drug. The study was conceived as a first pilot clinical study to assess safety 
of a single treatment with 200 U Alkaline Phosphatase i.v./kg in patients 
suffering from severe sepsis. At the same time also efficacy parameters were 
recorded as secondary variables. 
 
AM-Pharma is developing a unique therapy against sepsis, based on detoxification 
of the bacterial endotoxin LPS. This is an early mediator in the sepsis cascade, and 
one of the highest possible upstream targets, and therefore a promising approach 
for the development of a successful therapy.  
 
Dr. Bruno Giannetti, President & Chief Executive of AM-Pharma: “These are very 
promising data, although obtained in relatively small patient numbers, particularly 
when considering the fact that the dose and the treatment schedule still needs to be 
optimized. We are now in the process of planning a dose finding pivotal trial to 
optimize the dosing regime and demonstrate the efficacy of the drug.”  
 
A total of 36 patients admitted to intensive care units with the diagnosis of severe 
sepsis were included in the study (25 Verum/11 Placebo, 2:1 randomization 
scheme). The treatment consisted in a bolus of 67.5 U/kg infused in the first 10 
minutes followed by a 23 hour and 50 minutes infusion of a total of 132.5 U/kg. The 
primary aim of the study was to assess safety of the treatment. Next to (serious) 
adverse events (S)AEs also 28 and 90 days survival rates were recorded.  
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The treatment was well tolerated. No drug-related SAEs were reported in the 
Verum group. The 28 days survival rates were 19/25 in the Verum and 7/11 in the 
Placebo group. The 90 days survival rates were 18/25 in the Verum and 6/11 in the 
Placebo group. The reduction of the mortality risk due to sepsis is represented by 
the calculated absolute and relative risk reduction. After 28 days, the Verum group 
showed 12.4% absolute risk reduction and 34% relative risk reduction. After 90 
days absolute risk reduction was 17.5% and relative risk reduction was 38.4%. 
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‘t Is de lucht achter Oethoezen, 
‘t Is ‘t torentje van Spiek, 
‘t Is de weg van Lains noar Klooster, 
En deur Westpolder langs de diek. 
 
‘t Binnen de meulens en de moaren, 
‘t Binnen de kerken en de börgen, 
‘t Is ‘t laand woar ik as kind, 
Nog niks begreep van pien of zörgen. 
Dat is mien laand, mien Hogelaand... 
 
‘t Is ‘n doevetil, ‘n dörpsstroat, 
‘t Is ‘n olde bakkerij 
‘t Binnen de grote boerenploatsen, 
Van Waarvum Oskerd, zo noar Mij. 
 
‘t Is de waait, t is de hoaver, 
‘t Is t koolzoad in de blui, 
‘t Is de horizon bie Roanum, 
Vlak noa ‘n dunderbui 
Dat is mien laand, mien Hogelaand... 
 
‘t Is ‘n mooie oavend in maai, 
‘n Kou houst doeknekt in ‘t gruinlaand, 
Ik heb veur d'eerste moal verkeren, 
En vuil de vonken van dien haand. 
 
De wilde plannen dij ik haar, 
Komt sikkom niks meer van terecht, 
Totdat de nacht van ‘t Hogelaand, 
‘n Donker klaid over ons legt, 
Dat is mien laand, mien Hogelaand... 
 
Songteks van ’t Hogelaand van Ede Staal  
